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ABSTRACT 
 
Rebecca Jo Loomis: The Role of RhoA Signaling Pathways in Regulating  
HIV-1 Replication 
(Under the direction of Dr. Lishan Su) 
 
RhoGTPases are involved in regulating important cellular processes including 
cytoskeletal organization, gene transcription and membrane vesicle transport – poising 
RhoGTPases to link these pathways to HIV-1 replication.  However, RhoGTPase function in 
HIV-1 replication is essentially unknown.   
RhoA activation can be modulated by the cytoplasmic tail of the HIV-1 
transmembrane envelope glycoprotein through its interaction with p115RhoGEF, a RhoA 
specific activator.  Furthermore, activation of the RhoA signaling pathway inhibits HIV-1 
gene expression.   
To investigate how RhoA pathways modulate HIV-1 replication, I tested individual 
RhoA effectors.  Rho-associated kinase (ROCK) specifically inhibits HIV-1 gene expression 
in T cells.  A ROCK specific inhibitor counteracts RhoA inhibition of HIV-1 gene 
expression, indicating that RhoA signals via ROCK to inhibit HIV-1.  HIV-1 LTR mutations 
in either the NF-κB or Sp1 binding sites abrogate ROCK-mediated inhibition.  ROCK may 
disrupt the cooperative interaction between NF-κB and Sp1 or modulate epigenetic 
regulation to inhibit HIV-1 gene expression. 
Additionally, I identified a disparate role for the RhoA effector, citron kinase.  Citron 
kinase preferentially enhances HIV-1 virion production by promoting exocytosis.  This 
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activity depends on the leucine zipper, Rho-binding and zinc-finger domains, but not the 
kinase activity, of citron kinase.  Although citron kinase-mediated enhancement of HIV-1 
replication is late domain independent, an intact late endosomal sorting pathway is required.  
Citron kinase may act as a scaffold, linking host proteins to the endosomal sorting and 
exosomal pathways.  I also found a functional interaction between citron kinase and the 
ESCRT-I component, Tsg101.  Ectopic expression of either citron kinase or Tsg101 
enhances HIV-1 virion production, however, coexpression of citron kinase and Tsg101 
inhibits HIV-1 replication.  This functional interaction is mediated by the kinase activity of 
citron and the PTAP-binding region of Tsg101.  The two activities of citron kinase involved 
in HIV-1 regulation are distinct and independent of one another. 
 In summary, I identified two RhoA effectors, ROCK and citron kinase to regulate 
HIV-1 replication.  ROCK specifically inhibits HIV-1 gene expression while citron kinase 
demonstrates a disparate role.  These RhoA effectors may provide novel targets for 
developing antiviral therapeutics and further our understanding of the role of RhoA signaling 
pathways in HIV-1 replication. 
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CHAPTER ONE: 
INTRODUCTION 
 
 Human immunodeficiency virus (HIV-1) is the causative agent of AIDS.  The AIDS 
pandemic, with over 40 million HIV-1 infected individuals, is one of the worst tragedies of 
modern times.  As of December 2005, UNAIDS and WHO estimated that 37-45 million 
people live with HIV-1 (Figure 1A), 4.9-6.6 million people were newly infected in 2005 and 
2.8-3.6 million people died with AIDS (Figure 1B).  Sub-Saharan Africa is the worse-
affected area with 23.8-28.9 million people currently living with HIV-1.  Two thirds (64%) 
of all HIV-1 infected people are living in Sub-Saharan Africa [1].  South and South East Asia 
are the second most affected regions with 18% of all HIV-1 infected people [1].  In 2005, the 
steepest increases in HIV-1 infection (25% increase) occurred in Eastern Europe, Central 
Asia and East Asia [1]. 
 HIV-1 was first reported in North America, Western Europe and parts of Sub-Saharan 
Africa.  The pandemic is now worldwide and has become primarily a heterosexually 
transmitted disease, disproportionately affecting socially and economically underprivileged 
populations.  The spread of HIV-1 in developed countries appears to be slowing [1], but in 
developing nations, particularly Africa, Latin America and Asia, is rapid and has been 
characterized as “out of control”. 
 HIV-1 is transmitted in blood, semen and vaginal secretions and occurs most 
commonly via sexual intercourse, sharing of HIV-1 contaminated needles and vertical 
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transmission from mother-to-child during pregnancy and childbirth [2].  Individual 
susceptibility to HIV-1 is variable, may change over time and is influenced by genetics, 
relative levels of different cell types, patterns of cytokine secretion and cellular activation 
and the expression of cell surface cytokine receptors which act as coreceptors required by the 
virus for cellular entry [3-7]. 
 
Progression of HIV-1 Infection 
The major cause for AIDS progression in HIV-1 infected individuals is the decline of 
CD4+ T cells which are the primary target for HIV-1.  CD4+ T cells elicit specific humoral 
and cell-mediated immune responses necessary to fight infections.  Approximately 50% of 
cases in primary HIV-1 infection remain asymptomatic, whereas the other half of patients 
develop flu-like symptoms within the first few weeks following infection.  During primary 
infection, viral titers are extremely high in the peripheral blood and the number of CD4+ T 
cells decreases significantly [8].   
The pathogenesis of HIV-1/AIDS is best described as the result of two sequentially 
distinct phases with different pathogenic mechanisms (Figure 2).  The first phase; acute viral 
infection is characterized by a rapid and massive, directly HIV-1 mediated, loss of memory 
CD4+ T cells found in the mucosal tissues and have a profound effect on immune system 
function [9-12].  The second phase; chronic infection, typically lasts for several years and is 
characterized by the immune system’s struggle to recover from the earlier assault.  Chronic 
HIV-1 infection results in a slow decline of CD4+ T cells in the peripheral blood, a low 
fraction of infected CD4+ T cells and increased death rates of both CD4+ and CD8+ T cells.  
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Once there is sufficient depletion of CD4+ and CD8+ T cells, the host is unable to adequately 
fight opportunistic infections and viral titers increase, leading to death. 
 HIV-1 infection requires the engagement of both a receptor and coreceptor on the 
cell’s surface by the HIV-1 envelope glycoprotein for entry of the viral genome into the 
cytoplasm to occur (Figure 3, 4).  CCR5 is the coreceptor most commonly used by primary 
isolates at the onset of HIV-1 infection and is present on macrophages and a subset of CD4+ 
T cells [13].  Individuals with a 32-base pair deletion in the CCR5 gene (Δ32) are highly 
resistant to infection by primary HIV-1 isolates [14].  As the virus continues to replicate, 
evolutionary pressures result in mutations in gp120 allowing the virus to utilize CXCR4, a 
receptor present on the majority of CD4+ T cells. 
 One of the most striking observations about HIV-1 is the extensive genetic variation 
that the virus can exhibit within a single individual, most notably the hypervariable region of 
the env gene [15].  HIV-1 is one of the fastest evolving organisms.  The rapid evolution of 
HIV-1 is the result of a myriad of factors.  First, the virus experiences a high rate of mutation 
with the viral reverse transcriptase making ~0.2 errors per genome during each replication 
cycle [16] with further errors occurring during transcription from DNA by RNA Pol II 
polymerase [17].  Second, HIV-1 has remarkable replication dynamics with its viral 
generation time being ~2.5 days and producing ~1010-1012 new virions per day [18]. 
Many factors contribute to the detrimental effect of HIV-1 on an individual.  
Understanding how the virus has evolved to usurp necessary cellular mechanisms to facilitate 
its replicative capacity and how it evades the immune system are key factors in developing 
effective control strategies.  
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HIV-1 Life Cycle 
In addition to the four major proteins, Gag, Pro, Pol and Env, encoded by all 
retroviruses, HIV-1 is a retrovirus that also encodes six accessory proteins that help regulate 
and control viral replication (Figure 5) [19, 20].  Gag encodes the major structural proteins, 
Pro and Pol encode the major enzymatic activities such as the viral protease, reverse 
transcriptase and integrase, and Env encodes the envelope glycoproteins required for 
recognition and binding of the cellular receptors and viral entry.  HIV-1 also encodes Tat 
which is critical for HIV-1 LTR transcription, Rev which plays a role in transport of viral 
RNAs from the nucleus to the cytoplasm.  Additionally, HIV-1 contains the accessory 
proteins, Vpu, Vif, Vpr and Nef which are not uniformly required for viral replication. The 
HIV-1 life cycle can be considered as a sequence of steps which are regulated by both viral 
and cellular proteins, although many steps are likely to occur in concert (Figure 6).   
The HIV-1 glycoprotein consists of two noncovalently associated subunits, gp120 
and gp41, that are generated by proteolytic cleavage of a precursor polypeptide, gp160 [21, 
22].  Gp120 directs target-cell recognition and viral tropism through interaction with the cell-
surface receptor, CD4 and one of several coreceptors, most commonly CCR5 or CXCR4 [23-
28].  The CD4 glycoprotein is expressed on the surface of T lymphocytes, monocytes and 
dendritic cells, the main target cells for HIV-1 infection in vivo.  The primary function of 
CD4 binding is to induce conformational changes in the V1/V2 hypervariable region of 
gp120 glycoprotein, allowing exposure of the secondary chemokine receptor binding site in 
the V3 hypervariable region (Figure 3, 4). 
The membrane-spanning gp41 subunit promotes fusion of the viral and cellular 
membranes, a process resulting in the release of the viral contents into the host cell.  In 
 5
addition, gp41c has been implicated in replication and cytopathogenicity of HIV-1.  Gp41c 
has been found to have a role in maintaining stability of the envelope glycoprotein in its 
oligomerized form [29, 30] and mediating envelope viral protein incorporation into mature 
virion in a cell-type dependent manner [31-34].  SIV gp41c isolated from human cells 
contained a premature stop codon, truncating the cytoplasmic domain of gp41, and this 
truncation was found to be an adaptation of a non-human primate lentivirus to growth in 
human cell lines because when the SIV-isolated from human cells was put back into simian 
primary cells, the gp41c reverted to full-length [35, 36].  HIV-1 or SIV mutants with 
defective gp41c have cell-type and species-dependent phenotypes suggesting host factors 
potentially mediate functions of gp41c.   
Upon viral entry into the host cell, viral uncoating occurs, involving cellular factors 
and the viral proteins Gag matrix, Nef and Vif.  The viral RNA genome is reverse transcribed 
into a full-length double-stranded DNA copy by the viral reverse transcriptase [37, 38].  This 
preintegration complex [39], directed by HIV-1 Vpr, docks to the nuclear membrane [40], 
enters the nucleus through the nuclear pore [41, 42] and is inserted into the host chromosome 
by the viral integrase [43-45].  Once the proviral DNA is integrated, the first rounds of 
proviral transcription and translation occur [46].  The newly synthesized viral RNAs are 
transported to the cytoplasm.  The env gene is translated into the precursor protein gp160, 
which is glycosylated within the endoplasmic reticulum.  After translation, the env proteins 
migrate and insert into the plasma membrane.   
The Gag-Pro-Pol polyprotein precursor is synthesized to produce the Gag and Gag-
Pro-Pol polyproteins (Figure 7).  Gag polyprotein is a 55 kDa precursor that is proteolytically 
processed during the maturation of the virus into six structural proteins (matrix, capsid, 
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nucleocapsid, late domain and 2 spacer proteins, p2 and p1) which rearrange and produce the 
mature virion.  A regularly occurring ribosomal -1 frameshift, which occurs 5% of the time 
during translation, leads to the expression of the Gag-Pro-Pol polyprotein that additionally 
encodes the enzymatic proteins; protease, reverse transcriptase and integrase [47].  Gag and 
Gag-Pro-Pol polyproteins move to the cellular membrane and start to assemble, a process 
directed by the Gag polyprotein [48-50].  Additionally, viral enzymes, genomic RNA and 
cellular components associate with the immature core [51-53].  Later on, this complex buds 
through the plasma membrane producing an immature virion [19, 54-57].  Budding triggers 
the activation of the viral protease that autocatalytically cleaves the Gag and Gag-Pro-Pol 
polyprotein precursors releasing the structural proteins and enzymes.  The individual proteins 
undergo further interactions, with capsid and nucleocapsid forming the conic nucleocapsid, 
matrix remains associated to the viral envelope [48, 58-60] and the late domain mediates the 
final step of viral release [47, 61, 62] with these interactions resulting in the formation of a 
mature, infectious virion. 
Mature HIV-1 virions are spheres of 100-120 nm in diameter, with a lipid bilayer 
membrane surrounding a dense truncated cone-shaped nucleocapsid core that contains the 
genomic RNA molecules, the viral protease, reverse transcriptase, integrase, Vpu, Vif, Vpr 
and Nef [38, 63] (Figure 8).  The HIV-1 genome consists of two identical 9.2 kb single 
stranded RNA molecules within the virion. 
 
HIV-1 LTR and Transcription 
HIV-1 requires specific and fine-tuned levels of transcription and the strength of the 
LTR promoter represents an evolutionary optimum in terms of viral fitness.  HIV-1 gene 
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expression is controlled by the interplay of viral factors (Tat, Rev, Nef) and host regulatory 
proteins (NF-κB), that bind the LTR in a cell-specific and cell activation-dependent manner 
[64-70].  Too high transcription rates may disturb this well balanced process and over-
activation of HIV-1 transcription may exhaust one or more factors present in limiting 
amounts, resulting in a decrease in infectivity [71].  Tat transactivation may be influenced by 
Sp1 elements in the HIV-1 core promoter regions since loss of Sp1 elements in LTR 
dramatically reduces Tat-mediated LTR activity [72].   
The core viral promoter is comprised of TATAA box and three Sp1 binding sites – 
this is the region necessary for efficient HIV-1 proviral DNA-mediated basal transcription 
[73, 74] (Figure 9).  Immediately upstream of the three Sp1 sites is an enhancer region with 
two inducible NF-κB binding sites and although they are not absolutely necessary for viral 
replication, they respond to cellular activation signals by stimulating LTR activity and 
increasing the rate of viral production [73, 75].  Further upstream is the modulatory region 
with numerous transcription factor binding sites that may increase or decrease transcription 
[73].  The modulatory region contains binding sites for NFAT, C/EBP, LEF-1 and 
ATF/CREB [76]. 
In contrast to the genetic variation found in HIV-1 envelope, the enhancer/proximal 
region of the HIV-1 LTR is relatively invariant [77-80].  The HIV-1 enhancer/proximal 
region in most clades of HIV-1 is composed of two NF-κB sites [75] and three Sp1 sites [74].  
These sites are highly conserved among divergent isolates suggesting an important regulatory 
function and non-random association [81].  NF-κB and Sp1 sites function well in both 
macrophages and T cells, the cell-types most commonly infected by HIV-1 [82, 83].   
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NF-κB/Rel family members are involved in transcriptional regulation of a number of 
cellular and viral genes.  These family members form hetero- and homodimers between five 
mammalian subunits p50, p52, p65, c-Rel and RelB, binding with different affinities to a 
group of related NF-κB DNA binding sites with a consensus sequence of GGGTNNYYCC 
[84, 85].  Dimerized NF-κB factors are blocked from nuclear translocation by cytoplasmic 
IκBs until signaling processes lead to induced IκB degradation and nuclear translocation of 
NF-κB [86-90].   NF-κB/Rel dimers exert specific functions through non-identical DNA 
binding site preferences, as well as through individual interactions with other promoter-
bound gene-specific or basal factors [91, 92].  The ubiquitous transcription factor Sp1 
contains three zinc finger DNA binding domains and four transactivation domains [93-95] 
and binds to GC-rich sites [96, 97]. 
To induce HIV-1 gene expression, a specific interaction between NF-κB and Sp1 
bound to adjacent sites occurs, binding DNA cooperatively and activating transcription 
synergistically [81].  Transcriptional synergy depends on orientation and spacing of the NF-
κB/Sp1 binding sites although transcriptional activation domains are required for functional 
activation, specific interaction between Sp1 and NF-κB requires the zinc finger region of Sp1 
and an N-terminal portion of the Rel homology domain of p65, the DNA binding domains of 
each protein [98].  Sp1 elements are often found adjacently to NF-κB sites in 
enhancers/promoters, including those for HIV-1 [74] intracellular adhesion molecule 1 [99], 
vascular adhesion molecule 1 [100] and granulocyte-macrophage colony-stimulating factor 
[101], suggesting a precedent for transcriptional cooperativity.   
 Nuclear factor of activated T cells (NFAT) activity has been defined as a complex 
family of transcriptional regulators distantly related to NF-κB through the Rel homology 
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domain [102-104].  Resting T cells express inactive NFAT molecules in their cytoplasm 
which upon T cell activation translocate to the nucleus [104-107].   NFAT is an immediate 
early activation factor that plays a role in the process of T cell activation through control of 
IL-2 gene activation [108].  Ironically, T cell activation itself contributes to virus replication 
and the progressive immune dysfunction that is associated with HIV-1 infection, inducing 
events within cells to enhance HIV-1 transcription [109, 110].  Initially, it was thought that 
NFAT played no role in HIV-1 enhancer transactivation [111] because deletion of the 
putative NFAT binding site (position -255 to -217) in the HIV-1 LTR had no effect on HIV-1 
gene expression in Jurkat T cells [112].  However, NFAT serves as a positive activator of 
HIV-1 transcription and replication when NFAT is bound to the HIV-1 NF-κB enhancer 
motifs (nucleotides -104 to -81) [113].   Ca2+-dependent signaling can be activated through 
the NF-κB enhancer regions and is a hallmark of NFAT activation in T cells [102, 108, 114-
118].   
A multitude of gene-specific transcription factors which can activate or repress 
transcription of their target genes in a combinatorial fashion through their individual binding 
sites have been identified in modulating HIV-1 LTR promoter activity.  The synergistic 
protein-protein or protein-DNA interactions lead to a functional cross-coupling that allows a 
high degree of complexity. 
 
RhoGTPases and Transcription 
The small GTPase family of Rho proteins (Rho, Rac, Cdc42, RhoD, RhoG, RhoE and 
TC10) are members of the Ras superfamily of monomeric GTP-binding proteins.  They 
regulate a variety of important cellular processes by cycling between an inactive GDP-bound 
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form and an active GTP-bound form [119-121].  Activation of the GTPase, through GDP-
exchange is promoted by guanine nucleotide exchange factors (GEFs) [121], whereas 
inactivation by an intrinsic GTPase activity, is stimulated by GTPase-activating proteins 
(GAPs).  Rho guanine nucleotide dissociation inhibitors (Rho-GDIs) stabilize the inactive, 
GDP-bound form of the protein (Figure 10).   
RhoGTPases are involved in numerous intracellular signaling pathways including 
actin cytoskeletal reorganization [122-124], activation of transcription factors such as serum-
response factor [125] or NF-κB [126] and cell cycle progression [127, 128].  Rho mediates 
the integrin-dependent cell adhesion of a variety of cells in the substratum, which are found 
to form focal adhesions and stress fibers in fibroblasts [120].  Rho is also required for 
cytokinesis [129-131], inducing and maintaining the contractile ring [130, 132], the 
actinomyosin-based contractility as it increases calcium sensitivity in smooth muscles [133] 
and mediates stimulus-evoked neurite retraction in N1E-115 neuroblastoma cells [134].  Rac 
induces the assembly of small focal complexes at the periphery of cells and controls the 
production of lamellipodia and membrane ruffles [123, 124, 135, 136].  Cdc42 triggers actin 
polymerization to form filopodia or microspikes [122-124, 137, 138].   
The JNK/stress-activated protein kinase and p38 MAP kinase cascades control gene 
transcription in response to cellular stresses [139] and these two MAP kinase pathways can 
be activated by Rac and Cdc42 [140, 141].  Overexpression of constitutively active Rac or 
Cdc42 lead to a modest activation of JNK reporter plasmids, making the exact role of 
GTPases in MAP kinase activation unclear [142].  However, in the S. cerevisiae pheromone 
response pathway, where both Cdc42 and a JNK-like MAP kinase pathway are required, the 
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GTPase is not required for activation of the kinase cascade, but is required for the correct 
cellular localization of the MAP kinase containing signaling complex [143].  
Additionally, Rho, Rac and Cdc42 have each been reported to activate serum 
response factor (SRF)-dependent transcription and the transcription factor, NF-κB [125, 126, 
144].  The c-fos serum response element (SRE) forms a ternary complex with the 
transcription factors SRF and TCF (ternary complex factor).  By itself, SRF can mediate 
transcriptional activation induced by serum, LPA or intracellular activation of heterotrimeric 
G proteins.  Activated forms of the GTPases RhoA, Rac1 and Cdc42Hs also activate 
transcription via SRF and act synergistically at the SRE with signals that activate TCF [125].  
RhoA, Cdc42, and Rac-1 proteins efficiently induce the transcriptional activity of NF-κB by 
a mechanism involving phosphorylation of IκBα and translocation of p50/p50 and p50/p65 
dimers to the nucleus in a variety of cell-types [145], but independently of the Ras GTPase 
and the Raf-1 kinase [126].   Overexpression of either normal or constitutively active forms 
of RhoA, Rac1, and Cdc42Hs induced the transactivation of the HIV-1 promoter, which is 
partly mediated by the presence of two NF- B binding sites in its enhancer region [75, 145]. 
Rho, Rac and Cdc42 activities are required during G1 cell cycle progression, but it is 
unclear if this is because of their effects on actin cytoskeleton and integrin adhesion 
complexes or if it is because of more direct effects on gene transcription [128, 146-151].  
RhoA has been suggested to regulate cell cycle progression by modulating the protein 
stability of cell cycle regulators such as p27KIP1 [152] and transcription of specific genes such 
as cyclin D1 [148], c-fos [125], or p21WAF [153]. 
Activation of GTPases is temporally and spatially controlled with GEFs playing an 
essential role.  A large family of GEFs (>40) have been identified, each of which shares two 
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common motifs.  The Dbl homology domain has been shown to encode the catalytic 
nucleotide exchange activity [154, 155] and the pleckstrin homology domain whose function 
is less clear but may determine subcellular localization [121, 156-158].  Experimentally, it 
appears that some GEFs are specific for an individual GTPase, whereas others are more 
promiscuous [159-161].   
G proteins transduce signals from a large number of cell surface heptahelical 
receptors to various intracellular effectors including adenylyl cyclases, phospholipases and 
ion channels.  Each heterotrimeric G protein is composed of a guanine nucleotide-binding α-
subunit and a high affinity dimer of β and γ subunits.  Gα subunits are commonly grouped 
into four subfamilies (Gs, Gi, Gq and G12) on the basis of their amino acid sequence and 
function [162, 163].  The G12 subfamily only has two members, Gα12 and Gα13 [164].  
Members of the RGS family of proteins, which includes at least 19 members, negatively 
regulate G protein signaling [165-168]. 
A RhoA-specific exchange factor, p115RhoGEF, directly links Gα13 to regulation of 
RhoA (Figure 11).  p115RhoGEF was initially isolated as a protein that bound tightly to the 
nucleotide-free form of RhoA and increased the nucleotide exchange rate of RhoA [169].  
p115RhoGEF contains both a regulator of G protein signaling (RGS) domain which allows 
specific binding to either Gα12 or Gα13,  resulting in the activation of their GTPase activity 
(negative regulator) and a Dbl homology (DH) domain which acts as a guanine exchange 
factor to specifically activate the small GTPase RhoA (positive regulator) [170-172].   
Furthermore, the activated form of Gα13, in vitro, stimulates the ability of p115RhoGEF to 
catalyze dissociation of GDP from RhoA by 3-4 fold [173].  Overexpression of either Gα13 
or p115RhoGEF potentiated transcription of a reporter gene regulated by the modified SRE 
 13
which drives transcription of SRF when activated by Rho-dependent mechanisms [125, 174], 
demonstrating a link between Gα13, p115RhoGEF and RhoA in mediating cellular processes.  
Once GEFs have catalyzed the replacement of bound GDP for GTP, Rho proteins can 
specifically interact with their effectors or targets and transmit signals to downstream 
molecules.    
The small GTP-binding protein Rho functions as a molecular switch in the formation 
of focal adhesions and stress fibers, cytokinesis and transcriptional activation.  RhoA’s 
diverse functions are mediated by its association with downstream RhoA effector proteins 
when in its active GTP-bound form [175].  These include three families of Ser/Thr kinases; 
(1) Rho kinase (ROCK) and other ROCK family kinases, (2) protein kinase N and its related 
kinases and (3) citron kinase.  The conformational changes between the GTP and GDP-
bound forms of RhoA are restricted primarily to two surface loops, named switch regions I 
and II [176, 177].  Effector proteins must utilize these differences to discriminate between 
GTP- and GDP-bound forms, though they can also interact with other regions of the GTPase.  
Using RhoA effector domain mutants, with point mutations introduced into the switch I 
region, it was demonstrated that distinct effectors are involved in RhoA-mediated 
transformation of NIH3T3 cells, SRF activation and actin stress fiber formation [178, 179].   
 
RhoGTPases, T cell Activation and HIV-1 
T cell development within the thymus involves an ordered sequence of differentiation 
and proliferation events.  Hematopoietic stem cells from the bone marrow enter the thymus 
undergoing phases of proliferative expansion, T cell antigen receptor (TCR) rearrangements 
and positive and negative selection processes to mature into peripheral T cells.  In a normal 
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thymus, double positive (DP, CD4+CD8+) thymocytes are the most abundant.  DP 
thymocytes undergo positive selection where the TCRα chain rearranges and only T cells 
producing a TCR capable of recognizing either MHC I or MHC II and transducing a signal 
are able to survive.  The surviving thymocytes undergo negative selection to eliminate cells 
responding too strongly to self-antigen presentation [180, 181].  These thymic developmental 
events ensure only cells with the appropriate immune repertoire exit to the periphery [182].  
Lymphocyte development in the thymus is dependent on signaling pathways generated by a 
complex array of extracellular stimuli involving antigen receptor- and cytokine receptor-
derived signals [183].   
G protein coupled receptors (GPCRs) play critical roles in facilitating T cells to react 
to external signals by controlling thymocyte survival, differentiation and proliferation [184-
186].  Both p115RhoGEF and RhoA have been shown to affect T cell function.  Gα13 
knockout embryos die at day nine due to defects in angiogenesis [187, 188] and in G2A 
knockout mice, a GPCR known to work specifically through the Gα13 pathway, develop a 
late onset autoimmune disorder [189, 190].   Additionally, blocking Gα13 signaling by using 
a dominant-negative mutant of p115RhoGEF (p115ΔDH) blocked Gα12 and Gα13 signaling 
in T cell progenitors leading to impaired thymopoiesis, reduced proliferation and increased 
cell death [191].  Peripheral T cells in p115RhoGEF knockout mice hyperproliferate even in 
the absence of antigenic stimulation [192].  A transgenic lck C3 transferase mouse, which 
expresses the RhoA inhibitor C3 transferase under the control of the lck promoter, showed a 
specific requirement for RhoA at the CD4-CD8- stage for survival [193].  Inactivation of Rho 
function in the thymus demonstrates that differentiation of progenitor cells to mature T cells 
can occur with both positive and negative selection of T cells remaining intact [182].  
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However, these transgenic mice show maturational, proliferative and cell survival defects 
during T cell development that severely impair the generation of normal numbers of 
thymocytes and mature peripheral T cells [182].   An additional study demonstrated that 
processes of proliferation and survival are independently regulated during thymopoiesis and 
establish two different functions for Rho in the development of early thymic progenitors.  In 
pre-T cells, Rho function was required for survival but not G1/S phase cell cycle progression 
and in late pre-T cells, Rho regulates cell cycle progression but not survival [193].  
Collectively, these studies indicate that the function of the GTPase Rho is essential for 
normal thymic development and define Rho as a critical intracellular signaling molecule in T 
lymphocytes. 
Although RhoGTPases have been implicated in various steps of T cell activation 
[182, 191, 193], little is known about how RhoGTPases affect HIV-1 replication.   The 
transmembrane envelope glycoprotein (gp41c) of HIV-1 contains a highly conserved long 
cytoplasmic domain that has been implicated in regulating HIV-1 replication and 
cytopathogenicity [194].  We have previously shown that gp41c interacts directly with the 
carboxy-terminal regulatory domain of p115RhoGEF [195], the upstream activator of RhoA.  
Ectopic expression of p115RhoGEF or Gα13, which activates p115RhoGEF activity, leads to 
inhibition of HIV-1 replication via a RhoA-dependent mechanism (Figure 11).  The RhoA 
effector activity inhibiting HIV-1 replication is genetically separable from its activities in 
activation of SRF and actin stress fiber formation, suggesting RhoA inhibits HIV-1 
regulation via a novel effector activity (Figure 11) [196]. 
To investigate how RhoA signaling pathways modulate HIV-1 replication, we tested 
several RhoA effectors in human T cells.  We discovered that Rho-associated kinase 
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(ROCK), a RhoA effector, specifically inhibits HIV-1 gene expression in T cells.  Ectopic 
expression of wild-type ROCK inhibited viral gene expression in a dose-dependent manner.  
At very low levels of ROCK overexpression, we saw a significant inhibitive effect on viral 
production (i.e. assembly/release) with a minimal effect on viral gene expression, whereas 
high levels of ROCK efficiently inhibited HIV-1 gene expression.  A ROCK specific 
inhibitor, Y27632, counteracted RhoA inhibition of HIV-1 gene expression.  Coexpression of 
ROCK with constitutively active RhoA further inhibited viral gene expression than when 
either ROCK or constitutively active RhoA were expressed alone.  Mutations in the second 
NF-κB and/or the first two Sp1 binding sites of the HIV-1 LTR abrogated ROCK-mediated 
inhibition of HIV-1 gene expression.  Further experiments need to be completed to elucidate 
the mechanism used by ROCK to mediate inhibition of HIV-1 transcription. 
 
HIV-1 Viral Assembly and Release 
HIV-1 assembly and release occur in a series of essential steps driven by the viral 
Gag precursor protein, Pr55Gag [20, 47].  In the absence of all other viral proteins, HIV-1 Gag 
can still promote the release of virus-like particles [197].  HIV-1 Gag is organized into four 
distinct regions; matrix, capsid, nucleocapsid and late domain (Figure 7).  The N-terminal 
matrix domain harbors a myristoylation signal essential for transport of Gag from within the 
cell to the plasma membrane [198, 199].  Additionally, a basic patch on the surface of the 
globular core of matrix contributes to the selective association of Pr55Gag with the plasma 
membrane by interacting with acidic phospholipids [200].  Capsid, which follows matrix in 
the context of Pr55Gag, can by itself assemble into hollow cylindrical particles reminiscent of 
viral cores in vitro but requires relatively high protein concentrations [201-203].  Cleavage at 
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the matrix/capsid junction results in the conformational rearrangement of capsid into a 
conical structure during virus maturation [201, 203, 204].  The nucleocapsid domain contains 
two copies of a conserved zinc finger-like motif which are required for the encapsidation of 
the genomic viral RNA [47].  The late (L) domain catalyzes the pinching off and detachment 
of virus particles from the cell surface and from each other [47].  In the case of HIV-1, the L 
domain is encoded by PTAP in the C-terminal, p6 domain of Pr55Gag.  HIV-1 Gagp6 is also 
required for the incorporation of the accessory protein, Vpr [205-207], the viral Pol and 
envelope proteins [208, 209] and to control particle size [210, 211].  The L domain has two 
highly conserved domains; one located near the C terminus which is essential for Vpr 
incorporation [205, 206, 212] and the second, located at the N terminus of p6, is critical for 
late domain’s role in viral release [61, 62].    Point mutations in the PTAP motif of p6 or 
deletion of the entire p6 domain produces a striking defect in the production of virus particles 
[61, 62].  Mutant virus remains attached to the cell surface via a thin tether rather than 
budding off from the plasma membrane, identifying the p6 domain as crucial for HIV-1 
budding (Figure 12). 
The late domain is a highly conserved Pro-rich motif found in most enveloped 
viruses, including rhabdoviruses [213, 214], filoviruses [215] and Epstein-Barr virus [216], 
in addition to retroviruses.  L domains map to three classes of tetrapeptide motifs with 
sequence PT/SAP [61, 62], PPXY [217-219] or YPXL [220].   PPXY motifs appear to be the 
most common sequence associated with L domain function, stimulating budding of Rous 
sarcoma virus [217, 221], Mason-Pfizer monkey virus [218], murine leukemia virus [219, 
222], human T-cell leukemia virus type I [223], bovine leukemia virus [224], the 
rhabdoviruses [213, 214, 225] and the filoviruses [215].  Equine infectious anemia virus 
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(EIAV) L domain activity is encoded by a YPDL motif [220].  In addition, a number of 
retroviruses and the Ebola filovirus, contain adjacent or overlapping PTAP and PPXY 
sequences [218, 223, 226].  The presence of both PTAP and PPXY motifs may provide 
functional redundancy or enable sequential association of L domains with multiple host 
factors (Table 1).   
L domains interact with the cellular ubiquitination and endosomal sorting machinery 
[197, 227], but the role of ubiquitination is unclear.  Evidence suggests there is a positive 
correlation between late domain function and ubiquitination; (1) L domain containing 
proteins of several retroviruses (i.e. HIV-1, HIV-2, MLV and EIAV) are ubiquitinated [228-
230], (2) proteasome inhibitors disrupt budding of rhabdoviruses and some but not all 
retroviruses [230-236], (3) L domains of Rous sarcoma virus [237], Mason-Pfizer monkey 
virus [238], the rhabdoviruses [231] and Ebola virus [215] appear to functionally interact 
with proteins related to Nedd4, a ubiquitin E3 ligase, (4) the EIAV L domain bind and 
colocalize with the AP-50 subunit of the AP-2 complex which is involved in endocytosis 
[239] and (5) the host protein Tsg101, a ubiquitin enzyme 2 variant protein, was identified in 
S. cerevisiae yeast two-hybrid screens as a HIV-1 Gagp6-interacting protein [204, 240, 241].  
In HIV-1, Gagp6 ubiquitination enhances the binding of Tsg101 and Gagp6 but is not required 
for that binding to occur [240].  In HIV-1, the PPEY motif from Ebola’s VP40 late domain 
was unable to replace the L domain function normally provided by the PTAP motif and all 
PPXY motifs examined stimulated Gag ubiquitination.  These findings suggest that 
ubiquitination of HIV-1 Gag is not sufficient to promote viral egress and that active L 
domains may recruit deubiquitinating enzymes as a consequence of class E Vps factor 
recruitment [242]. 
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Despite retroviral L domains differing in amino acid sequence and location within 
their respective viral structural proteins, they tend to be functionally exchangeable, 
suggesting commonality of function, perhaps as docking sites for host proteins [222, 234, 
243].  The YPXL-type L domain of EIAV recruits the AP-2 clathrin adaptor complex [244] 
and has been shown to interact with host protein, AIP1, a central component of the 
multivesicular body (MVB) pathway [245-247].  The PPXY-type L domains of 
rhabdoviruses, retroviruses and Ebola virus have been shown to bind to WW domain-
containing proteins [197, 215, 231].  Among these, Nedd4 family ubiquitin E3 ligases are of 
particular interest because cellular ubiquitin pools are critical for the release of several 
retroviruses [227].  Additionally, PTAP-type L domain viruses, like HIV-1, bind the UEV-
like protein, Tsg101 [204, 240, 248], a component of the endosomal sorting complex 
required for transport-I (ESCRT-I).   
Host factor requirements can be altered by exchanging L-domain usage, yet all 
retroviruses are dependent on the VPS pathway for efficient release [240, 249, 250].  
Retroviruses use different host factors to complete viral release suggesting that retroviruses 
utilize different sites in cellular processing pathways to accomplish a common assembly step 
in viral replication in their respective host cells.  EIAV YPXL L domain has been shown to 
be critical for the release of assembling virions and to interact in vitro with AP-50 subunit of 
the AP-2 complex [244].  However, it was found that the functionally interchangeable late 
domains of RSV Gagp2b protein and HIV-1 Gagp6 protein, which utilize PPPY and PTAP L 
domains, respectively, do not bind AP-50 in vitro, but are still able to facilitate EIAV release.  
A role for the AP-2 complex in viral assembly is supported by specific colocalization of the 
α-adaptin subunit of AP-2 with the EIAV Gagp9 protein at sites of viral budding on the 
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plasma membrane [244].  EIAV Gag release is blocked by inhibition of the VPS pathway 
using dominant-negative Vps4, an ESCRT recycling factor, but is insensitive to Tsg101 
depletion [250].  An N terminal truncation of Tsg101, TSG3’ impairs budding of PPPY- and 
PTAP-containing viruses [251] but not YPDL-dependent EIAV [252].  In addition, fusing a 
mutant EIAV Gag directly to another cellular component of the ESCRT-I complex, Vps28, 
restored efficient viral release of the EIAV Gag late domain mutant suggesting that EIAV 
normally enters the Vps pathway downstream of ESCRT-I [250].  AIP1/Alix recognizes 
proteins bearing the YPXL sequence [252] directly interacts with ESCRT-III component 
CHMP4 [253] suggesting EIAV Gag may be recruited to ESCRT-III/Vps pathway by 
interaction with AIP1/Alix [246, 252].   
The L domain of RSV is located near the N-terminus of Gag in the p2b region and 
has the core sequence PPPPY [217, 221] and the deltaretroviruses, which include bovine 
leukemia virus (BLV) and human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2, have 
a conserved PPPY motif in the C-terminal region of the matrix domain of Gag, while HTLV-
1 also encodes a PTAP motif in the matrix domain [254].  The PY motifs, like those found in 
RSV Gag, resemble ligands for WW domains, which are approximately 38 amino acid 
modules containing two widely spaced, conserved tryptophans that are found in a wide 
variety of signaling, regulatory and cytoskeletal proteins [255, 256].  For RSV, vesicular 
stomatitis virus and Ebola virus, the L domains have been shown to interact in vitro with 
WW domains from Yes-associated protein (Yap), a signal-transducing molecule and Nedd4, 
an E3 ubiquitin ligase [214, 215, 237, 257].  A dominant-negative form of Vps4, an AAA 
ATPase interferes with RSV Gag release, indicating that RSV uses the endocytic trafficking 
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machinery [249].  Retroviruses can interact with the Vps machinery in several different ways 
to accomplish particle release. 
Several viruses, including HTLV-1, MPMV and Ebola, carry closely spaced PPPY 
and PT/SAP motifs.  In HTLV-1, mutation of either motif reduced budding efficiencies, 
switching the locations of the two late domains eliminated particle release, replacement of 
the PTAP motif with either PPPY or YPDL motifs had no effect on particle release but 
replacement of the PPPY motif with either PTAP or YPDL eliminated particle release 
indicating that the PPPY motif plays an essential role in HTLV-1 viral budding [254].  The 
retrovirus, MPMV, had complete loss of virus release with mutation of the PPPY motif.  The 
PSAP motif acted as an additional L domain to promote efficient viral release but required an 
intact PPPY motif to perform its function implying that in the context of MPMV, the PPPY 
and PSAP motifs are not redundant [258].  Ebola virus matrix protein VP40 is the major 
structural protein and plays a key role in viral assembly and release.  Efficient viral release is 
dependent on the presence of the intact N-terminal of VP40 which contains a PPXY and a 
PSAP motif [259].  The PPXY motif mediates interaction with proteins that contain WW 
domains [260] and Tsg101 interacts with monomeric and oligomeric VP40 through the PSAP 
motif [226].  The overlapping motifs of PPXY and PSAP of Ebola virus VP40 suggest that 
Tsg101 and Nedd4 may interact with VP40 at two different steps during budding and may 
involve different cellular pathways [226].  
The PTAP motif of HIV-1 Gagp6 was found to bind to Tsg101 (tumor susceptibility 
gene 101) in the UEV domain at its N-terminus [204, 240, 248, 261].   Tsg101 is an ESCRT-
I component, a 350 kDa cellular complex essential in the VPS pathway.  Point mutations in 
HIV-1 PTAP motif block virus release at late stages [61, 62] and disrupt binding to Tsg101 
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[240].  Small inhibitory RNA-mediated Tsg101 depletion potently blocks HIV-1 release 
[240].  Furthermore, overexpression of a dominant-negative form of VPS4 inhibits particle 
release of HIV-1 and other enveloped viruses [240] indicating that the VPS machinery is 
involved in the budding of PTAP-encoding retroviruses [240, 261] (Figure 13).   
A second region in HIV-1 Gagp6 has been defined to contribute to viral release and 
interacts with AIP1, a host protein [246, 247].   AIP1 interacts with Tsg101 and CHMP 
proteins of ESCRT-III complex, coupling HIV-1 Gagp6 to the early and late-acting 
endosomal sorting complexes by providing an interaction scaffold.  AIP1 also binds the HIV-
1 Gag via the LRSL Gagp6 sequence and EIAV Gagp9 proteins, indicating it can function 
directly in virus budding [246, 247].  HIV-1 release can be arrested at late stage by deletion 
or mutation of at least 8 different human class E proteins, which function both early (Tsg101, 
Vps28) and late (CHMP2A, CHMP3, CHMP4B, CHMP4C, VPS4A, VPS4B) in the MVB 
pathway [246].  HIV-1 particles package multiple copies of proteins that act in the MVB 
pathway (i.e. Tsg101, Vps28 and AIP1) [246, 247].  The viral release of HIV-1 is dependent 
on a protein network that connects early and late components of MVB biogenesis (Figure 
14). 
Additionally, HIV-1 Gag has been shown to interact directly with the δ subunit of the 
AP-3 complex at an early step in viral particle assembly, in an interaction that is mediated by 
the N-terminal α-helical region of the Gag matrix [262].  AP-3 is an adaptor protein complex 
that mediates sorting of cargo proteins to specific membrane compartments (trans-Golgi 
network and peripheral endosomal compartments) within the cell [263-267].  Disruption of 
this interaction prevents Gag from reaching the MVB compartment and inhibits viral particle 
formation, suggesting that trafficking of Gag to this compartment is part of the normal 
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productive pathway in HIV-1 assembly, even in cell types where particle release takes place 
predominantly at the plasma membrane [262]. 
Collectively, retroviruses and other enveloped viruses seem to interact with a diverse 
set of host proteins, all linked to the endosomal sorting pathway in some manner, to mediate 
viral assembly and release at sites of budding.  These interactions can be complicated and 
may have redundancy, suggesting the overall functional importance these host proteins 
perform in terms of viral assembly/release.   
 
Endosomal Sorting Pathway 
The endosomal sorting pathway controls a variety of cellular processes and is 
involved in the sorting of mono-ubiquitinated proteins into the lumen of the MVB [54, 268].  
Ubiquitinated proteins are recognized by endosomal sorting complexes, taken to the limiting 
endosomal membrane and sorted, resulting in either MVB fusion with the lysosome to 
degrade contents or release of material into the extracellular environment via exosomal 
vesicles [269-271].  Ubiquitination is the covalent attachment of ubiquitin to specific lysine 
residues in target proteins and occurs in three steps mediated sequentially by ubiquitin-
activating (E1), ubiquitin-conjugating (E2) and ubiquitin-protein ligase (E32) enzymes.   
ESCRT-I, composed of Tsg101, Vps28 and Vps37, is a conserved component of the 
endosomal sorting pathway which recognizes the mono-ubiquitinated tag on proteins and 
recruits two other class E protein complexes (ESCRT-II/III) to participate in protein sorting 
and vesicle formation [268, 272, 273].  ESCRT-I recognizes ubiquitinated cargo and requires 
the presumed ubiquitin enzyme 2 variant region (UEV) in Tsg101, implying that MVB 
sorting machinery is regulated by ubiquitin or binding to ubiquitin membrane proteins to 
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direct them into the MVB [274].  Mutation of the Tsg101 UEV-like domain not only 
prevents sorting of ubiquitinated cargo into internal MVB vesicles but also prevents the 
formation of the vesicles themselves.  The recognition of cargo by ESCRT-I activates 
downstream components of the vesicles budding machinery (ESCRT-II/III) [273].  ESCRT-
II is a soluble, stable, heterotrimeric 155 kDa complex and the four structurally related 
components of ESCRT-III are monomeric in the cytosol, associating only when they are 
recruited to membranes.  High levels of ESCRT-II can partially overcome the need for 
ESCRT-I suggesting a sequential assembly of the three ESCRT complexes.  ESCRT-III 
components also recruit another class E protein, Vps4p, an AAA-ATPase, which catalyzes 
the dissociation of the ESCRT machinery at the endosomal membrane [269] (Figure 15).   
More than 50 gene products are involved in vacuolar protein sorting with Vps 
proteins functioning at distinct steps of protein transport [275].  All 17 class E Vps proteins 
are required for the sorting of MVB cargo proteins.  Functional loss of any individual class E 
Vps protein results in a malformed late endosome/MVB known as the “class E 
compartment”, an enlarged aberrant endosome [269].  In vps4 mutant cells, ESCRT-I/II/III 
all accumulate on the class E compartment membranes without dissociating.   
Sorting into MVB vesicles is a highly coordinated event.  The Vps pathway is 
regulated as follows: the binding of ubiquitinated cargo by ESCRT-I leads to the activation 
of ESCRT-II,  ESCRT-II interacts directly with the ESCRT-III Vps20/Snf7 subcomplex to 
promote the assembly of multiple copies of ESCRT-III on the membrane and in the final 
step, the AAA-ATPase Vps4p interacts with the ESCRT-III Vps2/24 subcomplex to catalyze 
the release of the entire machinery from the membrane [272, 275].  Fusion of the limiting 
membrane of the MVB with the lysosomal membrane results in delivery of the luminal MVB 
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vesicles and their contents to the hydrolytic interior of the lysosome, where they are degraded 
[276].  Proteins that are spared this fate are excluded from these inner MVB vesicles and 
remain in the limiting MVB membrane where they can be recycled to the plasma membrane 
or transported to other sites within the cell (Figure 16).   
The sorting of transmembrane proteins into topologically distinct limiting and 
intralumenal membranes may serve two functions; (1) transmembrane proteins in the 
intralumenal membrane are susceptible to degradation by lysosomal hydrolases whereas 
proteins in the limiting membrane are resistant and (2) intralumenal vesicles might represent 
storage vehicles for transmembrane proteins that are to be released from the cell in a 
regulated manner.  In specialized cell types (melanocytes and hematopoietic cells), MVBs 
serve as intermediates in the formation of secretory lysosomes, such as melanosomes, MHC 
II compartments and lytic granules [277].  The formation of these specialized organelles 
requires sorting of specific proteins at the level of MVBs, where upon appropriate stimulus, 
secretory lysosomes fuse with the plasma membrane and all intralumenal vesicles will be 
shed into the extracellular space (as exosomes) or transferred to neighboring cells (Figure 
17).   
 Recent studies have shown that several enveloped RNA viruses reprogram the 
endosomal sorting machinery for their budding processes [278].  Viruses, like HIV-1, do not 
encode their own machinery for viral budding and require a cellular protein function that is 
activated by their late domain membrane-associated structural proteins.  The PTAP motif of 
HIV-1 binds Tsg101 and when Tsg101 is depleted, HIV-1 is unable to bud from the plasma 
membrane, forming stalks of unbudded virions [240].  HIV-1 budding is inhibited by 
dominant-negative Vps4, indicating that the ESCRT machinery is required for completion of 
 26
viral release [279] (Figure 14).  In macrophages, HIV-1 buds into MVBs indicating the virus 
is capable of using the ESCRT machinery at its normal location [280], not solely through 
recruitment of the endosomal machinery to the plasma membrane (Figure 16).   
Viruses not only parasitize the machinery for MVB formation and viral release, they 
also usurp the MVB sorting machinery to subvert immune surveillance.  The Kaposi’s 
sarcoma-associated herpes virus gene product, K3 (KK3) prevents MHC class I antigen 
presentation by downregulating MHC class I from the plasma membrane.  KK3 associates 
with MHC class I molecules, promotes their ubiquitination and once internalized, directs 
them to the late endocytic pathway for degradation by the lysosome in a Tsg101-dependent 
manner [281].  In the case of antigen-presenting cells, exosomes act as vehicles of 
immunomodulation [282, 283] and are important players in intracellular communication 
during the immune response.  B-cell derived exosomes carrying peptide-loaded MHC class II 
can stimulate CD4+ T cells in vitro [284].  Exosomes, from cultured DCs, loaded with tumor-
derived peptides stimulated CTL-mediated anti-tumor responses in vivo [285] and tumor 
cells can secrete exosomes with tumor antigens, which after transfer to the DC, can mediate 
CD8+ T cell dependent anti-tumor effects [286].    
MVBs are also important for the activation of the immune response.  Immature 
dendritic cells (DCs) package and store MHC class II molecules in the luminal vesicles of the 
MVB-like compartments that are known as MHC class II compartments (MIIC).  Upon 
stimulation of the cell by antigen, the luminal MIIC vesicles fuse with the limiting 
membrane, the MHC class II molecules are loaded with antigenic peptide and the MHC class 
II peptide complexes are transported to the plasma membrane for presentation to naïve T 
cells [287].  The antigenic stimulation of DCs can also cause the limiting membranes of 
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MIICs to dock and fuse with the plasma membrane, releasing the luminal vesicles of MIICs 
from the cell.  These secreted vesicles known as exosomes, contain MHC molecules and 
CD86, a co-stimulatory factor for T cells [285].  Exosomes are also secreted by other 
hematopoietic cell types which include immature reticulocytes, B cells and platelets, but their 
exact physiological targets are not yet known (Figure 17). 
The endosomal sorting pathway operates in most cell types and is used to sort and 
transport a wide variety of proteins within the cell.  It makes sense that viruses would usurp 
such a key pathway to facilitate in its replication and to subvert immune recognition. 
 
Role of RhoGTPases in Membrane Trafficking Events 
RhoGTPases play a pivotal role in the dynamic regulation of the actin cytoskeleton 
and, through this, modulate cell morphology, motility and adhesion [120, 288].  In recent 
years, studies in mammalian cells and other organisms have uncovered multiple links 
between RhoGTPases and membrane trafficking events.  Not only can RhoGTPases act 
locally on individual trafficking events, they can act globally to control the spatial 
organization of membrane traffic in response to cues from the extracellular environment.  
Vesicle trafficking events require an active process of either actin disassembly to mediate 
their movement through cortical actin or actin-based motor proteins to drive budding and 
fusion.   
The most clear-cut interface of RhoGTPases with the endocytic trafficking is in the 
process of clathrin-independent internalization from the cell surface.   All clathrin-
independent routes into the cell are driven by actin polymerization and therefore, have 
obligatory requirements for RhoGTPases (Figure 18).   For example, Type II phagocytosis, 
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phagocytes displaying the CR3 complement receptor, recognize particles opsonized with the 
complement iC3b [289].  This morphologically distinct process is dependent on RhoA, but 
not Cdc42 or Rac [290].  The RhoA effector, Rho-associated kinase (ROCK) is required for 
Type II phagocytosis and may contribute to the process of engulfment by regulating the 
actinomyosin contractility [291, 292] and recruitment of the actin nucleating Arp2/3 complex 
[293].  Inhibition of the RhoA-ROCK- myosin-II pathway via inhibitors specifically 
targeting ROCK and myosin-II, caused a decreased accumulation of Arp2/3 complex and F-
actin around bound particles thereby reducing phagocytic engulfment [292].  These finding 
suggest an essential role for RhoA and ROCK in mediating Type II phagocytosis. 
Additionally, there are two distinct classes of clathrin-independent receptor 
endocytosis; one involving GPI-coupled receptor internalization and requiring Cdc42 [294] 
and the second, involving interleukin-2 (IL-2) receptor internalization and requiring RhoA 
[295].  The IL-2 receptor is internalized from lipid rafts [296] in a dynamin-dependent 
fashion [295].  This process is inhibited by expression of dominant-negative RhoA or Rac, 
but is not affected by the constitutively active versions of these GTPases, suggesting roles for 
both Rho and Rac in IL-2 receptor endocytosis. 
Internalized receptors travel through a number of distinct endocytic sub-
compartments where sorting decisions are made to determine whether the receptor is 
recycled to the plasma membrane or targeted to lysosomes for degradation.  Several Rho-
GTPases have been localized to these compartments indicating the actions of Rho-GTPases 
are not confined to the plasma membrane.  RhoD GTPases have been localized to both the 
plasma membrane and early endocytic vesicles [297].  Constitutively active RhoD promotes 
the alignment of early endocytic vesicles with actin filaments by activation of an isoform of 
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Diaphanous (Dia) which leads to the loss of early endocytic motility through a mechanism 
requiring tyrosine kinase c-Src activity [298].   
Receptors following the lysosomal degradation pathway are sorted into MVBs with 
the final step involving fusion of these MVBs with lysosomes, resulting in transfer and 
degradation of cargo.  RhoB and RhoA share about 85% amino acid identity and differ 
primarily in their C-terminal hypervariable region, a crucial determinant of membrane 
targeting [299].  RhoB, unlike RhoA, can target to both the plasma membrane and internal 
membranes [299-302].  RhoB is activated by protein kinase C related kinase 1(PRK1) which 
delays intracellular trafficking of the EGF receptor to lysosomes [301, 303, 304] and blocks 
the transfer of the EGF receptor from the MVB to the lysosome.  However, overexpression 
of wild-type RhoB had no effect on endosome transport suggesting that endogenous RhoB 
only transiently inhibits endocytosis [305].  The RhoB effector, PRK1 may play a key role in 
membrane trafficking.  RhoB targets PRK1 to endosomal membranes and overexpression of 
kinase-inactive PRK1 releases the inhibitory effect of RhoB on the trafficking of internalized 
receptors [306]. 
These findings collectively suggest that RhoGTPases link the actin cytoskeleton with 
endocytic trafficking events at multiple levels as a means to control and regulate these 
processes.  RhoGTPases, because of their roles in actin cytoskeleton and endocytic 
trafficking, are ideally poised to be involved in mediating signaling pathways necessary for 
HIV-1 replication. 
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RhoGTPases and HIV-1 
Rac, Cdc42 and Rho are three members of the Rho family of small GTPases which 
act as molecular switches cycling between an active GTP-bound and inactive GDP-bound 
state.  Activation, in response to extracellular stimuli, is mediated by the Dbl family of GEFs 
while downregulation involves poorly characterized family of GAPs and RhoGDIs [156, 
307].  In their active states, Rho, Rac and Cdc42 interact with a variety of effector proteins to 
elicit cellular responses [121].  Once activated, Rac induces polymerization of monomeric 
actin at the cell periphery to produce a dense meshwork of actin filaments forming extending 
lamellipodia and membrane ruffles [124], Cdc42 stimulates actin polymerization to form 
filopodia [122-124, 137, 138] and Rho mediates integrin-dependent cell adhesion found to 
form focal adhesions and stress fibers [120]. 
Members of the RhoGTPase family also regulate gene transcription.  All three 
GTPases have been reported to stimulate the JNK/SAPK and p38 MAP kinase cascades, the 
transcription factor NF-κB and the transcription factor SRF [125, 126, 128, 140, 141, 144, 
308, 309].  Ectopic expression of Rac effector, hPOSH, leads to activation of the JNK 
pathway and to nuclear translocation of NF-κB, independent of either actin reorganization or 
JNK activation [310] suggesting hPOSH acts as a scaffold protein linking signaling events 
with transcriptional changes.  Additionally, Rho, Rac and Cdc42 can trigger G1 progression 
when introduced into quiescent fibroblasts and are required for serum-induced cell cycle 
progression and Ras-induced cell transformation [128, 311-313].  Stimulation of G1 
progression and cell transformation correlate with the ability of the GTPases to induce 
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cytoskeletal changes and signals may be induced in response to actin polymerization or 
integrin complex assembly [147, 148, 314].   
Despite RhoGTPases being implicated in actin cytoskeletal events, T cell activation, 
vesicle trafficking and a myriad of other cellular processes, little is known about the role 
RhoGTPases may play in HIV-1 replication.  There is increasing evidence supporting key 
roles for RhoGTPases in regulating various steps of HIV-1 replication.  In T cells and 
monocyte-derived myeloid cells, inhibition of myosin light chain kinase (MLCK), through 
the use of wortmannin, an inhibitor of MLCK and MLC phosphorylation, suppressed HIV-1 
release [315].  Wortmannin did not disrupt transport of viral proteins to the plasma 
membrane but rather inhibited budding.  These findings suggest that after localization to sites 
of viral budding, the subsequent actinomyosin interactions participate in the release of viral 
particles from host cells [315].  However, cytochalasin D, an inhibitor that disrupts the 
equilibrium between monomeric and polymeric actin, only partially inhibited HIV-1 viral 
release most likely due to cytochalasin D’s partial depolymerization of actin filaments [315].   
In most HIV-1 infected cells, release occurs as virus buds and pinches off from the 
plasma membrane, although even in cell-types where HIV-1 egress occurs primarily at the 
plasma membrane, Gag assembly can be detected in late endosomes [316].  Analysis of 
MLV- and MPMV-infected cells showed association of Gag with late endosomal membranes 
and subsequent movement to the plasma membrane, the latter requiring a functional vesicular 
transport system [317, 318].  Protein ubiquitination is a major regulator of intracellular 
protein transport and serves as a signal for sorting of proteins from the cell surface or the 
TGN into late endosomes and lysosomes [319-324].   
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A productive HIV-1 infection requires the exploitation of the host protein sorting and 
trafficking pathways.  Ubiquitination is known to be involved in the late steps of the HIV-1 
life cycle [232, 234, 325] therefore it is likely that an E3 ubiquitin ligase activity is involved 
in HIV biogenesis.  The Rac effector, hPOSH, a TGN-associated E3 ubiquitin ligase was 
identified as a critical factor in the sorting of HIV-1 Gag to the plasma membrane [326].  In 
HIV-1 infection, hPOSH functions independently of the viral late domain but acts upstream 
of virus budding at the cell membrane since depletion of hPOSH ablated accumulation of 
particles at the cell surface.  An E3 ligase mutant of hPOSH was unable to restore production 
of VLP in hPOSH-inhibited cells implying that targeting of Gag from the TGN to the plasma 
membrane requires the ubiquitination activity of hPOSH [326]. 
Previously, we had shown that the cytoplasmic tail of the HIV-1 transmembrane 
envelope glycoprotein, gp41c, interacts directly with the carboxy-terminal regulatory domain 
of p115RhoGEF [195], a GEF and activator of RhoA.  Ectopic expression of p115RhoGEF 
or Gα13, which activates p115RhoGEF activity, leads to inhibition of HIV-1 replication via a 
RhoA-dependent mechanism (Figure 11).  The RhoA effector activity inhibiting HIV-1 
replication is genetically separable from its activities in activation of SRF and actin stress 
fiber formation, suggesting RhoA inhibits HIV-1 regulation via a novel effector activity 
Figure 11) [196]. 
To investigate how RhoA signaling pathways modulate HIV-1 replication, we tested 
several RhoA effectors in 293T and human T cells.  We found citron kinase, a Ser/Thr 
kinase, to preferentially enhance virion production of both HIV-1 and MLV, in a late domain 
independent manner.  Depletion of endogenous citron kinase inhibited HIV-1 virion 
production.  The leucine-zipper, Rho-binding and zinc-finger domains, but not the kinase 
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domain, were necessary for the enhancement activity.  Ectopic expression of citron kinase 
led to the formation of cytoplasmic structures containing citron kinase and HIV-1 Gag 
proteins.  Citron kinase enhanced secretion of exosomes and microvesicles that copurified 
with HIV-1 virions.  Even though citron kinase-mediated enhancement of HIV-1 replication 
was HIV-1 late domain independent, an intact late endosomal sorting pathway was 
necessary.   
To more clearly define the role of citron kinase in modulating HIV-1 virion 
production, we wanted to identify possible component(s) of the endosomal sorting pathway 
that may facilitate citron kinase’s role in HIV-1 replication.  We identified a functional 
interaction between citron kinase and Tsg101, a component of the ESCRT-I complex.  The 
kinase activity of citron kinase was necessary and sufficient for the functional interaction 
with Tsg101.  Additionally, the functional interaction was dependent on maintaining the 
integrity of Tsg101’s PTAP-binding region.  Collectively, our findings suggest novel 
mechanisms for regulation of HIV-1 virion release involving citron kinase-mediated 
exocytosis and components of the endosomal sorting pathway. 
 
Concluding Remarks 
HIV-1 is one of the most serious infectious diseases to plague humans.  Despite 
increased knowledge involving the mechanics of HIV-1 infection, we are still a long way 
from fully understanding it.  The HIV-1 genome encodes only ten open reading frames and 
therefore requires use of host pathways to facilitate in the completion of its life cycle.  
Therefore it is necessary to identify host proteins involved in HIV-1 regulation.  RhoGTPases 
are involved in a number of diverse cellular processes, many of which potentially could 
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influence the outcome of HIV-1 infection.  RhoGTPases play key roles in mediating T cell 
activation, regulating the actin cytoskeleton and vesicle transport and in inhibiting/activating 
transcription factors – thus RhoGTPases may link these pathways with HIV-1 replication.   
Our lab previously found that the cytoplasmic tail of the HIV-1 envelope glycoprotein binds 
directly to p115RhoGEF, a guanine nucleotide exchange factor, to inhibit HIV-1 replication.  
This thesis further explores the role of RhoA signaling pathways in regulating HIV-1 
replication. 
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People currently living with HIV-1 in 2005
People who died with AIDS in 2005
Figure 1: UNAIDS/WHO Epidemic Update 2005. (A) At the end of 2005,  
UNAIDS and WHO estimated that 37-45 million people live with HIV-1, with the 
majority of those people living in Sub-Saharan Africa.  (B) An estimated 2.8-3.6 
million people died with AIDS in 2005 according to the 2005 UNAIDS/WHO 
Epidemic Update. 
A
B
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Figure 2: Acute vs. Long-term Infection. HIV-1 is best described as the 
result of two sequentially distinct phases with different pathogenic 
mechanisms.  The first phase; primary infection is characterized by a rapid and 
massive, directly HIV-1 mediated, loss of memory CD4+ T cells (blue line) and 
a high viral load (red line).  The second phase; chronic infection (clinical 
latency) which can last for several years, results in a slow decline in CD4+ T 
cells in the peripheral blood (blue line), leading to increased death rate of T 
cells.  The loss of CD4+ and CD8+ T cells prevents the host from adequately 
fighting opportunistic infections and causes viral titers to increase (red line).
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Figure 3: HIV-1 Envelope Glycoprotein. The envelope glycoprotein is a 
heterodimer composed of the external gp120 noncovalently attached to the 
transmembrane domain, gp41, organized into a trimeric structure.  Gp120 
contains both the CD4-receptor binding site and the coreceptor binding site.  
The coreceptor binding site is not fully exposed until CD4 is bound.  Gp41 
forms pores in the plasma membrane and anchors the gp120 in both virions
and infected cells.  
Sierra S, Kupfer B and Kaiser R.  Basics of the virology of HIV-1 and its 
replication. Journal of Clinical Virology 2005;34:233-44.
 38
Figure 4: Model for HIV-1 Virion Attachment and Entry. The external 
gp120 domain interacts with the CD4 receptor on the cellular plasma 
membrane triggering a conformational change in gp120 which displaces a 
previously hidden region which acts as the coreceptor binding site.  The 
binding of a cellular coreceptor induces additional conformational changes in 
the envelope protein allowing the HR1 and HR2 domains of gp41 to interact 
with each other to form a stable six-helix bundle structure leading to 
membrane fusion and core entry into the target cell.
Sierra S, Kupfer B and Kaiser R.  Basics of the virology of HIV-1 and its 
replication.  Journal of Clinical Virology 2005;34:233-44.
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Figure 5: Schematic of the HIV-1 Genome. HIV-1 is a retrovirus with ten 
open reading frames.  In addition to the four major proteins encoded by all 
retroviruses; Gag, Pro, Pol and Env, HIV-1 also encodes six accessory 
proteins that help regulate and control viral replication.  HIV-1’s major 
structural proteins are encoded by Gag, its major enzymatic activities by Pro 
and Pol and the envelope glycoproteins required for recognition and binding of 
cellular receptors for viral entry are encoded by Env. Tat is critical for 
transcription and Rev plays a major role in the transport of viral RNAs from the 
nucleus to the cytoplasm.  Additionally, Vpu, Vif, Vpr and Nef are accessory 
proteins that are not uniformly required for virus replication.
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Figure 6: The HIV-1 Life Cycle.  The main steps in HIV-1 replication are 
sequentially numbered 1-6.  (1) Virus binds to CD4 and the appropriate 
coreceptor resulting in fusion of the viral envelope with the cellular membrane 
and release of the viral nucleocapsid into the cytoplasm. (2) Following 
uncoating, viral RNA is reverse transcribed by the RT. (3) The resulting dsDNA
migrates into the cell nucleus and is integrated into cellular DNA by the 
integrase. (4) The proviral DNA is transcribed by the cellular RNA polymerase 
II. (5) The mRNAs are translated by the cellular polysomes. (6) Viral proteins 
and genomic RNA are transported to the cellular membrane and assemble.  
Immature virions are released.  Gag polypeptide precursors are processed by 
the viral protease to produce mature infectious viral particles.
Sierra S, Kupfer B and Kaiser R.  Basics of the virology of HIV-1 and its 
replication.  Journal of Clinical Virology 2005;34:233-44.
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Figure 7: Schematic of HIV-1 Gag Polyprotein.  The HIV-1 Gag-Pro-Pol
message is primarily translated to produce the Gag and Gag-Pol polyproteins.  
The Gag polyprotein is a 55 kDa precursor that is proteolytically processed 
during maturation of the virus into six structural proteins (matrix, capsid, 
nuclocapsid, p6 late domain and two spacers; p2 and p1) which rearrange and
produce the mature virion.  A regularly occurring ribosomal -1 frameshift
(occurs 5% of the time) during translation, leads to the expression of the Gag-
Pro-Pol polyprotein that encodes the major enzymatic proteins; protease, 
reverse transcriptase and integrase.
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Figure 8: Diagram of HIV-1 Mature Virion.  Mature virions are spheres of 
100-120 nm in diameter, with a lipid bilayer membrane surrounding the dense 
truncated cone-shaped core that contains the genomic RNA molecules, the 
viral protease, reverse transcriptase, integrase, Vpu, Vif, Vpr and Nef.  The 
principal structural proteins forming the core are matrix (MA) which forms the 
shell associated directly to the inner side of the membrane through the N 
terminus, capsid (CA) with its N-terminal domain assembling into hexameric
rings, nucleocapsid (NC) which has been implicated in the formation and 
stabilization of the genomic RNA dimers and in NC assembly and p6 which is 
the domain required for the late stages of viral assembly, efficient release from 
the cell and internalization of the Vpr protein into the assembled virion.
Sierra S, Kupfer B and Kaiser R.  Basics of the virology of HIV-1 and its 
replication.  Journal of Clinical Virology 2005;34:233-44.
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Figure 9: Schematic of HIV-1 Viral Promoter. The viral core promoter is 
composed of the TATAA box and three Sp1 binding sites.  This region is 
necessary for efficient HIV-1 proviral DNA-mediated basal transcription.  
Immediately upstream of the three Sp1 sites is an enhancer region with two 
inducible NF-κB binding sites and an NFAT site, and although these sites are 
not absolutely necessary for viral replication, they respond to cellular activation 
signals by stimulating LTR activity and increasing the rate of viral production.  
Further upstream is the modulatory region with numerous transcription factor 
binding sites that may increase or decrease transcription. The modulatory
region contains binding sites for NFAT, C/EBP, LEF-1 and ATF/CREB.
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Figure 10: The RhoGTPase Cycle. RhoGTPases cycle between an inactive 
GDP-bound form and an active GTP-bound form. The cycle is tightly regulated 
mainly by guanine exchange factors (GEFs), GTPase activating proteins 
(GAPs) and guanine dissociation inhibitors (GDIs). In their active form, 
RhoGTPases can bind to effector molecules such as kinases and scaffold 
proteins.
Raftopoulou M and Hall A. Cell Migration:Rho GTPases lead the way.
Developmental Biology 2004;265:23-32.  
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Figure 11: p115RhoGEF Links Gα13 to Regulation of RhoA and HIV-1 
Replication. The putative GPCR linking Gα13 and the RhoA-signaling pathway 
trigger a cascade of events to modulate actin cytoskeletal organization (actin
fiber), transcriptional activation (SRF), cell survival and growth.  p115RhoGEF 
contains both a regulator of G protein signaling (RGS) domain which allows 
specific binding to either Gα12 or Gα13, resulting in the activation of their GTPase
activity (negative regulator) and a Dbl homology (DH) domain which acts as a 
guanine nucleotide exchange factor (GEF) to specifically activate the small 
GTPase RhoA (positive regulator).  Both p115RhoGEF and RhoA63L reduced the 
luciferase gene expression (~5-fold) of pNL4.Luc when coexpressed in 293T cells.  
pNL4-3 was cotransfected with vector or different RhoA mutant derivatives 
resulting in a distinct profile.  The RhoA E40W mutant showed efficient inhibition 
of HIV-1 replication despite impaired activity in transformation of NIH3T3 cells, 
SRF activation, and actin stress fiber formation. Furthermore, the RhoA F39L 
mutant, similar to the RhoA E40W mutant in cell transformation, but still with low 
or normal activity in SRF activation and actin stress fiber formation, showed 
significantly reduced inhibition of HIV-1 replication.  Therefore, activation of SRF 
(partially) and actin stress fiber formation by RhoA is neither necessary nor 
sufficient to inhibit HIV-1 replication. These results suggest that the HIV-1 
inhibitory activity of RhoA is genetically separable from its other activities.
Wang L, Zhang H, Solski PA, Hart MJ, Der CJ, Su L. Modulation of HIV-1 
Replication by a Novel RhoA Effector Activity. J Immunol 2000;164:5369-74.
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Figure 12: HIV-1 Late Domain Mutants Show a Novel Phenotype.  There is 
a marked reduction in virion release displayed by L1/s and P10, 11/L mutants.  
The L1/s mutant replaces the N-terminal leucine of p6 and is predicted to 
create truncated capsid precursors that lack p6 entirely.  The P10,11/L 
mutants replaced the two adjacent proline residues within the 5 amino-acid 
stretch of PTAPP.  (A) Numerous particles were evident on outer surface of 
the cell membrane but very few infectious particles left the cell surface.  (B) 
Viral particles produced by L1/s mutant had an immature appearance with a 
thick electron-dense outer shell and an electron-lucent center.  (C) Virus 
remains attached to the cell surface via a thin tether.
Gottlinger HG, Dorfman T, Sodroski JG, Haseltine WA.  Effect of mutations 
affecting the p6 gag protein on human immunodeficiency virus particle release.  
PNAS 1991;88:3195-9.
 47
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HIV-1
Interactions with 
Host ProteinsLocationL domainVirus
Table 1: Most enveloped viruses have L domains to facilitate in viral 
release. The summarizes data regarding the specific L domain sequence 
used by each virus, its location within the virus and known host protein 
interactions.
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Figure 13: Tsg101 Depletion and Vps4 Dominant-Negative Mutants Block 
Virus Budding at a Late Stage. (A) TEM showing the effects on HIV-1 
budding when mutating the Gagp6 PTAP sequence (left), depleting cellular 
Tsg101 (center) or overexpressing the dominant-negative Vps4E228Q protein 
(right). In each case, virus budding was arrested at a late stage, with immature 
particles remaining connected to the plasma membrane via thin membrane 
tethers or to other budding particles forming clusters of interconnected 
particles. (B) TEM showing the effects on MLV budding when mutating the p12 
PPPY motif (left) or overexpressing the dominant-negative Vps4E228Q protein 
(right). These MLV late domain phenotypes are similar to those described for 
HIV-1. 
Garrus JE, von Schewedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang 
HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG and Sundquist WI.  
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 
budding. Cell 2001;107:55-65.
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Figure 14: Model for HIV-1 Late Domain Function. The HIV-1 Gagp6 domain 
forms a ternary complex with host proteins; AIP1 and ESCRT-I component, 
Tsg101, which then recruits CHMP proteins (components of ESCRT-III) directly 
via AIP1 and indirectly via ESCRT-II to form ESCRT-III.  
Strack B, Calistri A, Craig S, Popova E and Gottlinger HG. AIP1/ALIX is a binding 
partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003;114:689-
99. 
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Figure 15: MVB Sorting in Yeast. Yeast Class E Vps protein complexes and 
auxiliary factors that function in protein sorting and vesicle formation during MVB 
biogenesis.  ESCRT-I recognizes ubiquitinated cargo and requires the UEV 
domain of Vps23 (yeast homolog of Tsg101).  The binding of ubiquitinated cargo 
by ESCRT-I leads to activation of ESCRT-II.  ESCRT-II interacts directly with the 
ESCRT-III Vps20/Snf7 subcomplex to promote the assembly of multiple copies of 
ESCRT-III on the membrane.  In the final step, the AAA-ATPase Vps4p interacts 
with the ESCRT-III Vps2/24 subcomplex to catalyze the release of the entire 
machinery from the membrane.
Pornillos O, Garrus JE and Sundquist WI.  Mechanisms of enveloped RNA virus 
budding. TRENDS in Cell Biology 2002:12(12)569-79.
 51
Figure 16: The Endosomal Sorting Pathway, HIV-1 Assembly/Budding and 
Exosome Formation.  HIV-1 Gag proteins are shown in dark blue and protein 
cargos sorted through the Vps pathway are shown in magenta, green and light 
blue.  The process of HIV-1 viral assembly/budding is analogous to the sorting of 
ubiquitinated cargo by the endosomal sorting pathway and formation of the 
multivesicular body.  Sorting of proteins by the endosomal sorting pathway can 
lead to one of three outcomes; (1) the MVB fuses with the lysosome and contents 
are degraded, (2) the MVB fuses with the plasma membrane and contents are 
released as exosomes into the extracellular space or (3) the proteins remaining in 
the intraluminal membrane are recycled to their place of origin.
Pornillos O, Garrus JE and Sundquist WI.  Mechanisms of enveloped RNA virus 
budding. TRENDS in Cell Biology 2002:12(12)569-79.
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Figure 17: Formation and Function of MVEs. Multivesicular endosomes (aka 
MVBs) are formed after invagination of the limiting membrane of the sorting 
endosome. They are versatile and can serve different functions in different cell 
types, such as being precursors for (a) lytic granules in T lymphocytes, (b) MHC 
class II compartments and exosomes in antigen-presenting cells, (c)  melano-
somes in melanocytes, and (d) late MVEs/lysosomes in most nucleated cells. 
Both endocytic and biosynthetic proteins are sorted in and out of MVEs, indicated 
by the arrows. 
Raiborg C, Rusten TE and Stenmark H. Protein sorting into multivesicular
endosomes. Current Opinion in Cell Biology 2003;15:446-55. 
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Figure 18: Diagram Summarizing the Known and Proposed Sites of Action 
of RhoGTPases in Internalization from the Plasma Membrane.  The most 
clear-cut interface of RhoGTPases with the endocytic trafficking is in the process 
of clathrin-independent internalization from the cell surface.  All clathrin-
independent routes into the cell are driven by actin polyermization and therefore 
have obligatory requirements for RhoGTPases.  In type II phagocytosis, 
phagocytes display the CR3 complement receptor, recognizing particles 
opsonized with the complement iC3b – this process is dependent on RhoA but not 
Cdc42 or Rac.  Additionally, RhoA is involved in type II clathrin-independent 
receptor internalization of IL-2.  The IL-2 receptor is internalized from lipid rafts in 
a dynamin-dependent manner – this process is inhibited by expression of 
dominant-negative RhoA or Rac.
Qualmann B and Mellor H. Regulation of endocytic traffic by Rho GTPases.  
Biochem J. 2003;371:233-41.  
 
  
 
 
CHAPTER TWO: 
INHIBITION OF HIV-1 REPLICATION BY RHOA IS MEDIATED BY RHO-
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ABSTRACT: 
 RhoGTPases play essential roles in modulating the actin cytoskeleton, controlling cell 
processes and activation of transcription factors.  Previously, we reported that the 
cytoplasmic tail of the HIV-1 transmembrane envelope glycoprotein gp41 (gp41c) interacts 
directly with the carboxy-terminal regulatory domain of p115RhoGEF, a specific guanine 
nucleotide exchange factor and activator of RhoA.  Binding of gp41c to p115RhoGEF 
inhibits activation of RhoA by p115RhoGEF [195].  Ectopic expression of p115RhoGEF, 
Gα13, which activates p115RhoGEF activity, or constitutively active RhoA leads to 
inhibition of HIV-1 replication.  The RhoA effector activity involved in inhibiting HIV-1 
replication is genetically separable from its other known activities suggesting that RhoA 
inhibits HIV-1 replication via a novel effector activity [196].   
 We found Rho-associated kinase (ROCK), a RhoA effector, to specifically inhibit 
HIV-1 gene expression in T cells.  ROCK overexpression inhibited viral gene expression in a 
dose-dependent manner.  At very low levels of ROCK overexpression, we saw a preferential 
inhibitive effect on HIV-1 virion production (i.e. assembly/release) with a minimal effect on 
viral gene expression, whereas higher levels of ROCK overexpression, significantly inhibited 
HIV-1 gene expression.  A ROCK specific inhibitor, Y27632, counteracted RhoA inhibition 
of HIV-1 gene expression.  Coexpression of ROCK with constitutively active RhoA further 
inhibited viral gene expression than when either ROCK or constitutively active RhoA were 
expressed alone.  Therefore ROCK is the RhoA effector that contributes to RhoA-mediated 
inhibition of HIV-1 gene expression.  Mutations in the second NF-κB and/or the first two 
Sp1 binding sites of the HIV-1 LTR abrogated ROCK-mediated inhibition of HIV-1 gene 
expression.  The mechanism of RhoA-mediated inhibition via ROCK has eluded us.   
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INTRODUCTION: 
The small GTPase family of Rho proteins (RhoA, Rac1 and Cdc42) regulate a variety 
of important cellular processes by cycling between an inactive GDP-bound form and an 
active GTP-bound form [119-121].  RhoGTPases are involved in numerous intracellular 
signaling pathways including actin cytoskeletal reorganization [122-124], activation of 
transcription factors such as serum-response factor [125] or NF-κB [126], and cell cycle 
progression [127, 128].  RhoA’s diverse functions are mediated by its association with RhoA 
effector proteins when in its active form [175].  These include three families of Ser/Thr 
kinases; (1) Rho-associated kinase (ROCK) and other ROCK family kinases, (2) protein 
kinase N and its related kinases and (3) citron kinase.  The conformational changes between 
the GTP and GDP-bound forms of RhoA are restricted primarily to two surface loops, named 
switch regions I and II [176, 177].  Effector proteins utilize these differences to discriminate 
between GTP- and GDP-bound forms.  Using RhoA effector domain mutants, it was 
demonstrated that distinct effectors are involved in RhoA-mediated transformation of 
NIH3T3 cells, SRF activation and actin stress fiber formation [178, 179].   
G protein coupled receptors (GPCRs) play critical roles in facilitating T cells to react 
to external signals ranging from developmental cues to chemotactic molecules.  GPCRs 
transduce signals through their direct interaction with members of the heterotrimeric G 
protein families: Gαi, Gαs, Gαq and Gα12.  The p115RhoGEF protein couples Gα13 signaling 
to RhoA activation.   p115RhoGEF contains both a regulator of G protein signaling (RGS) 
domain which allows specific binding to either Gα12 or Gα13,  resulting in the activation of 
their GTPase activity, and a Dbl homology (DH) domain which acts as a guanine exchange 
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factor to specifically activate the small GTPase RhoA [170-172].  Both p115RhoGEF and 
RhoA have been shown to affect T cell function.  
Although RhoGTPases have been implicated in various steps of T cell activation 
[182, 191, 193], little is known about how RhoGTPases affect HIV-1 replication.  We have 
previously shown that the long cytoplasmic tail of HIV-1 gp41c, interacts directly with the 
carboxy-terminal regulatory domain of p115RhoGEF, a specific guanine nucleotide 
exchange factor and activator of RhoA [195].  Ectopic expression of p115RhoGEF or Gα13, 
which activates p115RhoGEF activity, leads to inhibition of HIV-1 replication via a RhoA-
dependent mechanism.  The RhoA effector activity involved in inhibiting HIV-1 replication 
is genetically separable from its activities in activation of serum response factor and actin 
stress fiber formation [196], suggesting RhoA inhibits HIV-1 regulation via a novel effector 
activity.   
To investigate how RhoA signaling pathways modulate HIV-1 replication, we tested 
several RhoA effectors in human T cells.  We found that Rho-associated kinase (ROCK), a 
RhoA effector, specifically inhibits HIV-1 gene expression in T cells.  At very low levels of 
ROCK overexpression, HIV-1 virion production (i.e. assembly/release) was significantly 
inhibited without a similar effect on viral gene expression.  Ectopic expression of ROCK 
inhibited HIV-1 gene expression in a dose-dependent manner, with high levels of ROCK 
efficiently inhibiting HIV-1 transcription.  A ROCK specific inhibitor, Y27632, counteracted 
RhoA inhibition of HIV-1 gene expression.  Coexpression of wild-type ROCK with 
constitutively active RhoA synergistically inhibited HIV-1 gene expression than when either 
wild-type ROCK or constitutively active RhoA was expressed alone.  These findings suggest 
RhoA signals through ROCK to repress HIV-1 transcription.  Mutations or deletions in the 
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second NF-κB and/or the first two Sp1 binding sites of the HIV-1 LTR abrogated ROCK’s 
ability to inhibit HIV-1 gene expression.  Disruption of either the NF-κB or the Sp1 sites was 
sufficient to abrogate HIV-1 gene repression by ROCK, suggesting that the cooperative 
interaction between NF-κB and Sp1 may be disrupted. 
Our data suggests that ROCK may inhibit HIV-1 gene expression by affecting 
binding to the NF-κB and/or Sp1 sites.  We demonstrated that ROCK does not disrupt 
binding at either the NF-κB or Sp1 sites individually.  However, we have not fully addressed 
whether the cooperative interaction between NF-κB and Sp1 is disrupted.  Alternatively, 
ROCK may recruit an HDAC to interact with NF-κB and/or Sp1 to prevent activation of the 
HIV-1 LTR.  However, ROCK-mediated HIV-1 gene expression was further repressed by an 
HDAC inhibitor.  Another potential mechanism for ROCK-mediated HIV-1 transcriptional 
repression is through phosphorylation, whether direct or indirect, given that the kinase 
activity of ROCK is necessary for its inhibitive effect on HIV-1 gene expression.  Therefore, 
it is critical to identify possible phosphorylation target(s) of ROCK and any phosphorylation 
changes that occur during HIV-1 infection with constitutively active ROCK.   
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Materials and Methods: 
Reagents, plasmids and cell lines 
 The pNL4-3 plasmid encodes the entire HIV-1 genome DNA in pUC18 [327].  The 
pNL4.LucR-E- plasmid was obtained from the National Institutes of Health AIDS Research 
and Reference Reagent Program [328].  ROCK constructs were previously described (Figure 
19E) [329].  The constitutively active RhoA mutants (RhoA63L) were cloned in the pAX142 
mammalian expression vector [330].  Jurkat T cells (kindly provided by G. Crabtree, 
Stanford, CA) were maintained in RPMI 1640 supplemented with 10% fetal bovine serum 
(FBS), penicillin/streptomycin and L-glutamine.  HeLa-MAGI cells (NIH AIDS Research 
and Reference Reagent Program, [331]) were maintained in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 10% FBS, penicillin/streptomycin and L-glutamine. 
 
HIV-1 Production and Replication in Transfected Human Cells 
 Transient production of HIV-1 was performed by transfecting NL4-3 (0.3 μg) with 
vector, wild-type ROCK, ROCKΔ4 or ROCK KDIA (0.6 μg) in Jurkat T cells in 48-well 
plates at 1x105 cells/well with GenePorter (Gene Therapy Systems, San Diego, CA).  At 48 
hours post-transfection, HIV-1 virions in cell supernatant were measured by p24 ELISA or 
RT assays [332] and infectious units were determined by titering the supernatant on HeLa-
CD4-LTR-lacZ cells (MAGI) as described previously [331].   
 To analyze HIV-1 gene expression in transfected cells, pNL4.Luc (0.3 μg) was 
transfected into Jurkat T cells with vector, wild-type ROCK, ROCKΔ4 or ROCK KDIA (0.6 
μg) in Jurkat T cells in 48-well plates with GenePorter (Gene Therapy Systems, San Diego, 
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CA).   Cell extracts were analyzed at 48 hours post-transfection for luciferase activity 
(AutoLumat LB953, EG&G berthold; FluoStar Optima, BMG LabTech). 
 To define the binding site(s) of the HIV-1 LTR necessary for ROCK-mediated 
inhibition of HIV-1 gene expression, Jurkat T cells were cotransfected with HIV-1 LTR-
luciferase constructs (0.12 μg), HIV-1 tat (0.24 μg) and vector, ROCKΔ4 or ROCK KDIA 
(0.6 μg) in a 48-well plate at 1x105 cells/well.  Cells were harvested 48 hours post-
transfection and analyzed for luciferase activity (AutoLumat LB953, EG&G berthold; 
FluoStar Optima, BMG LabTech).   
 For transfections involving the ROCK specific inhibitor (Y26732), Jurkat T cells 
were cotransfected with pNL4.Luc (0.3 μg) and vector, wild-type ROCK or constitutively 
active RhoA (RhoA63L) (0.6 μg) in a 48-well plate at 1x105 cells/well.  At 24 hours post-
transfection, the Y26732 inhibitor was added at a final concentration of either 10 μM or 25 
μM.  Cells were harvested at 48 hours post-transfection and analyzed for luciferase activity 
(AutoLumat LB953, EG&G berthold; FluoStar Optima, BMG LabTech). 
 For transfections involving the use of HDAC1 inhibitor, trichostatin A (TSA), TSA 
was added at 100 ng/mL at 24 hours post-transfection.  Cells were harvested at 48 hours 
post-transfection for analysis. 
 
Western Blotting 
 Transfected Jurkat T cells were lysed and resolved (50-100 μg of total protein) on 
10% SDS-PAGE.  Gels were transferred to PVDF membranes (Amersham Biosciences) and 
blocked with 5% nonfat milk.  The membrane was probed with mouse α-p24 (NIH AIDS 
Research and Reference Reagent Program), a mouse α-Myc (AbCam, Cambridge, MA) and 
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mouse α-actin (Sigma-Aldrich) specific antibodies and visualized using an ECL Kit 
(Amersham Biosciences). 
 
Electrophoretic Mobility Shift Assays 
To prepare the nuclear extract, the collected cell pellets were resuspended in 90 μL of 
CE+NP-40 buffer.  CE+NP-40 buffer is made of 500 μL 1M Hepes pH 7.6, 3 mL 1M KCl, 
100 μL 0.5M EDTA, 50 μL 1M DTT, 45.1 mL dH2O, 0.2% NP-40 and protease inhibitors.  
Cell lysates were incubated on ice for 3 minutes and then spun at 2500 rpm for 4 minutes.  
The supernatant was discarded (cytoplasmic extract).  The nuclear pellet was resuspended in 
90 uL of CE+NP-40 buffer and spun at 2500 rpm for 4 minutes.  The supernatant was again 
discarded.  The pellet is resuspended in 90 μL of NE buffer.  NE buffer is composed of 1 mL 
1M Tris pH 8, 4.2 mL 5M NaCl, 75 μL 1M MgCl2, 40 μL 0.2M EDTA, 12.5 mL 100% 
glycerol and 31.54 mL dH2O.  The nuclear pellet was incubated for 10 minutes at room 
temperature and spun at full speed for 10 minutes.  The supernatant was transferred to a new 
tube (nuclear extract) and protein concentration was determined using the BCA Protein 
Assay Reagent Kit (Pierce, Rockford, IL). 
Sp1 and NF-κB consensus sequence probes were purchased from Santa Cruz 
Biotechnology, Santa Cruz, CA.  The Sp1 consensus oligonucleotide sequence was 
5’ATTCGATCGGGGCGGGGCGAGC 3’, underlined portion represents Sp1 binding site.  
The NF-κB consensus oligonucleotide sequence was 5’AGTTGAGGGGACTTTCCCAGGC 
3’, underlined portion represents NF-κB binding site.  The labeled probes necessary for this 
experiment were prepared as follows; 7.4 μL Sp1/NF-κB consensus oligo, 2 μL PNK buffer, 
5 μL γ32P, 1 μL PNK and 4.6 μL dH2O.  Mix everything together and incubate at 37°C for 1 
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hour.  The mixture is spun through a G25 Sephadex Spin column to purify at 1.6 krpm for 5 
minutes.  The labeled probe was then counted via a scintillation counter. 
The gel was prepared as follows; 7 mL acrylamide, 4 mL TGE (10x TGE = 0.25M 
Tris, 1.9M glycine, 10mM EDTA pH 8.5), 4 mL 50% glycerol, 25 mL dH2O, 300 μL 10% 
APS and 40 μL Temed. 
Reactions were prepared to contain 20-50 μg protein, 50,000 cpm of labeled probe, 
0.05 μg dIdC/reaction, 4 μL 5xbinding buffer (50mM Tris pH 7.6, 50% glycerol, 5mM DTT 
and 2.5mM EDTA).  Cold competitor or non-specific competitor was added at 50 times the 
amount of labeled probe used.  Water, 5xbinding buffer and protein with either cold 
competitor/non-specific competitor were incubated for 20 minutes at RT.  Labeled probe was 
then added and again the mixture was incubated for 20 minutes at RT.  
The gel was run using 1xTGE as running buffer, at 40mA for approximately 2 hours.  
Once the gel was finished running, it was placed on Watman paper, wrapped in seran wrap 
and dried before exposure to film. 
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RESULTS: 
RhoA Specifically Inhibits HIV-1 Gene Expression in T cells by ROCK 
 To identify the novel RhoA effector activity involved in inhibiting HIV-1 replication, 
we tested various RhoA effectors for their effect on HIV-1 viral replication in 293T and 
human T cells.  Ectopic expression of ROCK, a RhoA effector, was shown to inhibit HIV-1 
gene expression (Figure 19A) and HIV-1 viral release (Figure 19B) in Jurkat T cells.  Both 
wild-type ROCK and constitutively active ROCKΔ4 inhibited HIV-1 replication while the 
kinase-dead ROCK showed no effect on HIV-1 gene expression suggesting that the kinase 
activity of ROCK is required for its inhibitive effect on HIV-1 gene expression (Figure 19E).  
Likewise, we demonstrated that cell-associated viral protein expression was inhibited when 
wild-type ROCK and constitutively active ROCKΔ4 were overexpressed (Figure 19C).  We 
further investigated the effect of ROCK on viral protein expression, specifically looking at 
processing of Gag, and found no evidence that ROCK altered Gag processing (data not 
shown).  We conclude ROCK inhibits HIV-1 gene expression. 
 Next, we sought to determine whether ROCK specifically inhibited HIV-1 gene 
expression by using plasmids with promoters other than HIV-1 LTR.  Jurkat T cells were 
cotransfected with either pGK-GFP (housekeeping promoter) or CMV-GFP (viral promoter) 
and vector, constitutively active ROCKΔ4 or kinase-dead ROCK.   We analyzed promoter 
activity by measuring GFP expression.  ROCKΔ4 did not inhibit GFP expression from either 
the pGK or CMV promoters (Figure 19D) suggesting that ROCK specifically inhibits HIV-1 
LTR gene expression. 
 Ectopic expression of ROCK had a dose-dependent effect on HIV-1 viral replication.  
We cotransfected Jurkat T cells with pNL4.Luc or pNL4-3 and increasing amounts of wild-
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type ROCK.  At very low levels of ROCK overexpression (10 ng), there was a significant 
inhibition of HIV-1 viral release but no effect on viral gene expression (Figure 19F, G).  
HIV-1 viral gene expression was inhibited by ROCK overexpression in a dose-dependent 
manner with higher levels of ROCK expression inhibiting gene expression more significantly 
(Figure 19G).   
 To determine if ROCK was the sole RhoA effector involved in repressing HIV-1 
gene expression, we used a ROCK-specific inhibitor, Y27632, to block ROCK activity.  In 
Figure 20A, we cotransfected Jurkat T cells with pNL4.Luc and vector or wild-type ROCK 
and added various concentrations of Y27632 (0 μM, 10 μM or 25 μM), 24 hours post-
transfection.  At 10 μM concentration of Y27632, wild-type ROCK was unable to inhibit 
HIV-1 gene expression.  In Figure 20B, we cotransfected Jurkat T cells with pNL4.Luc and 
vector or constitutively active RhoA (RhoA63L) and added various concentrations of 
Y27632 (0 μM, 10 μM or 25 μM), 24 hours post-transfection.  At both 10 μM and 25 μM 
concentrations of Y27632, RhoA63L was unable to inhibit HIV-1 gene expression to the 
same degree as when no drug was present.  The ROCK inhibitor, Y27632, partially 
counteracts RhoA inhibition of HIV-1 gene expression.   
To further support our finding that RhoA inhibited HIV-1 gene expression through 
activation of ROCK, we found that coexpression of ROCK and RhoA63L inhibited HIV-1 
gene expression more than when expressing either ROCK or RhoA63L alone (Figure 20C).  
We conclude ROCK is the RhoA effector involved in mediating RhoA’s inhibitive effect on 
HIV-1 gene expression. 
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ROCK Inhibits HIV-1 Gene Expression via NF-κB and Sp1 Binding Sites 
To define the binding site(s) of the HIV-1 LTR necessary for ROCK-mediated 
inhibition of HIV-1 gene expression, we used various LTR truncation and deletion mutants.  
First, we cotransfected Jurkat T cells with HIV-1 long-terminal repeat (LTR)-luciferase 
truncation mutants. We found that the NF-κB binding sites are required for ROCK-mediated 
HIV-1 gene repression (Figure 21A).  Deletion of all sites upstream of the TATA box or 
deletion of the three Sp1 sites but maintaining the integrity of the NF-κB sites resulted in 
LTR gene expression at background levels.  Raw data is shown in Figure 22.  A schematic of 
the HIV-1 LTR-luciferase truncation mutants used are shown in Figure 21B.   
Next, we used LTR-linker scanning mutants to more accurately define the NF-
κB/Sp1 binding site region necessary for HIV-1 gene expression by ROCK.  The LTR-linker 
scanning-luciferase mutants were prepared where 18 base pair regions of the wild-type LTR 
were replaced with an NdeI-XhoI-SalI (NXS) polylinker [333].  These linker-scanning 
mutants provide a more accurate assessment of a promoter’s regulatory sequences than does 
deletion analysis, since effects of relatively small substitution mutations are analyzed in the 
spatial context of the remaining wild-type sequences.  The linker-scanning mutants used in 
this analysis are shown and described in Figure 23B, C.  ROCKΔ4 was unable to inhibit 
HIV-1 gene expression when either NF-κB sites or the first two Sp1 sites were altered, but 
was able to inhibit HIV-1 gene expression when the third Sp1 site was altered (Figure 23A).  
Raw data is shown in Figure 24.  We, therefore, conclude that ROCK inhibits HIV-1 gene 
expression by affecting interaction or binding at the NF-κB and the first two Sp1 sites.   
To more closely analyze the NF-κB/NFAT site(s) involved in ROCK-mediated HIV-
1 gene repression, we used HIV-1 LTR constructs with point mutations in the first NF-κB 
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site, the second NF-κB site, the NFAT site or both NF-κB sites (Figure 25B).  When both 
NF-κB sites were mutated, the LTR promoter activity was negligible.  However, when either 
the first NF-κB site or the NFAT site were mutated, constitutively active ROCKΔ4 was able 
to repress HIV-1 gene expression but when the second NF-κB site was mutated, ROCKΔ4 
was unable to inhibit HIV-1 gene expression (Figure 25A).  Raw data is shown in Figure 26. 
Taken together, the results of the HIV-1 LTR mutant analysis demonstrate the 
necessity of the second NF-κB site (Figure 25A) and the first two Sp1 sites (Figure 23A) in 
ROCK-mediated inhibition of HIV-1 gene expression.  Disruption of either NF-κB or Sp1 
was sufficient to abrogate ROCK’s effect on HIV-1 gene expression suggesting that ROCK 
disrupts the cooperative interaction of NF-κB/Sp1 needed to activate the HIV-1 LTR. 
 
Mechanism by which ROCK Mediates HIV-1 Repression 
Although we have yet to elucidate the mechanism by which ROCK inhibits HIV-1 
gene expression, we have several hypotheses.  First, ROCK may disrupt the cooperative 
interaction between NF-κB and Sp1 to inhibit gene activation (Figure 27A) to inhibit HIV-1 
gene activation.  NF-κB and Sp1 sites are often found adjacently in promoter regions, 
including those for HIV-1 [74], intracellular adhesion molecule 1 [99], vascular adhesion 
molecule 1 [100] and granulocyte-macrophage colony-stimulating factor [101].  In the HIV-1 
LTR, the actions of NF-κB and Sp1 are highly cooperative, involving the effects on DNA 
binding of both factors to their adjacent binding sites, leading to increased transcriptional 
control [81].   
If this cooperative interaction is disrupted, most likely indirectly by ROCK, binding 
to one or both the NF-κB and Sp1 sites would be inhibited.  To test this hypothesis, we 
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performed electrophoretic mobility shift assays (EMSAs) attempting to determine whether 
binding to the NF-κB or Sp1 sites was altered in the presence of  ROCK and if any alteration 
correlated with effects on HIV-1 transcription.  The preliminary EMSAs revealed no change 
or perhaps an increase in binding to the NF-κB and Sp1 sites, individually, in the presence of 
constitutively active ROCK (Figure 27B, C).  To fully address whether the cooperative 
interaction between NF-κB and Sp1 is disrupted by ROCK to inhibit HIV-1 gene expression 
we need to perform EMSAs using a probe that contains both the NF-κB and Sp1 sites 
adjacent to one another, as seen in the HIV-1 LTR.   
Second, ROCK may enhance histone deacetylase1 (HDAC1) recruitment for 
interaction with Sp1 at the HIV-1 LTR (Figure 28A).  Sp1 binds the GC-box and activates a 
host of viral and cellular genes [95, 334] and it composed of a several modules including N-
terminal inhibitory domain, Ser/Thr domain, glutamine rich domains which are important for 
transcriptional activation and a zinc-finger DNA binding domain in its C-terminus [95, 334, 
335].  HDACs have been implicated in repression of gene expression by facilitating 
chromatin condensation through the removal of an acetyl group of nucleosomal core histones 
[336-339] and may be involved in cell-cycle regulation, differentiation and development, as 
well as human cancers [340, 341].  Sp1 can be a target for HDAC1-mediated transcriptional 
repression with the interaction between Sp1 and HDAC1 being direct and requiring the C-
terminal zinc-finger domain of Sp1 [101, 340].  In this case, the transcriptional repression did 
not involve the deacetylase activity of HDAC1 and was accomplished by the direct protein-
protein interaction between Sp1 and HDAC1, which interferes with GC-box Sp1 binding. 
We hypothesize that ROCK inhibits HIV-1 gene activation by enhancing recruitment 
of HDAC1 to interact with Sp1 and/or NF-κB.  To test this hypothesis, we added an HDAC1 
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inhibitor, trichostatin A (TSA), to our transfected cells.  Preliminary results revealed that the 
addition of the HDAC1 inhibitor further repressed HIV-1 gene expression with 
overexpression of constitutively active ROCK implying that ROCK does not recruit HDAC1 
to the Sp1 binding site of the HIV-1 LTR to maintain gene repression (Figure 28B), although 
we do not yet know why the addition of TSA led to further repression of the HIV-1 LTR. 
However, it is also possible that ROCK mediates HIV-1 transcription through some 
other mechanism such as phosphorylation.  ROCK is a Ser/Thr kinase, whose kinase activity 
is essential for its ability to inhibit gene expression and Sp1 contains a Ser/Thr region with 
several sites known to be phosphorylated with effects on promoter activity.  ROCK may 
mediate Sp1 phosphorylation thereby affecting Sp1 promoter activity. 
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DISCUSSION: 
 To investigate how RhoA signaling pathways modulate HIV-1 replication, we tested 
several RhoA effectors in human T cells.  We found Rho-associated kinase (ROCK), a RhoA 
effector, to specifically inhibit HIV-1 gene expression in T cells.  Overexpression of wild-
type ROCK at very low levels had a significant inhibitive effect on virion production (i.e. 
assembly/release) without a similar effect on viral gene expression.   Wild-type ROCK 
overexpression inhibited viral transcription in a dose-dependent manner, with the greatest 
transcriptional inhibition at the highest levels of wild-type ROCK overexpression.  A ROCK 
specific inhibitor, Y27632, counteracted RhoA inhibition of HIV-1 gene expression.  
Coexpression of wild-type ROCK with constitutively active RhoA further inhibited viral 
gene expression than when either ROCK or RhoA were expressed alone.  Together, these 
findings suggest RhoA signals via ROCK to inhibit HIV-1 transcription.  Mutation or 
deletion of the second NF-κB and/or the first two Sp1 sites in the HIV-1 LTR abrogated 
transcriptional repression by ROCK. 
HIV-1 latency is a natural consequence of the virus replicating in activated CD4+ T 
cells.  CD4+ T cells are capable of undergoing reversible changes in activation state [8, 342].  
After responding to an antigenic challenge, some activated CD4+ T cells return to a resting 
state and persist as memory cells.  In this state, the cells are not permissive for viral 
replication, however, integration of the viral genome into a host-cell chromosome, guarantees 
viral persistence for the lifespan of the memory T cell [343].  Upon mitogen stimulation, 
infectious virus can be recovered from these cells. 
A major obstacle to HIV-1 eradication is the establishment of a transcriptionally 
silent viral infection in infected resting memory CD4+ T cells [344, 345].  The extremely 
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long half-life of these cells, combined with the tight control of HIV-1 expression, make this 
reservoir ideal to maintain hidden copies of the virus.  The exact mechanism by which HIV-1 
establishes latency is not understood, but several models exist; (1) transcriptional repression 
of the proviral DNA by binding of specific inhibitory DNA binding proteins, (2) 
modification of the chromatin conformation or (3) methylation of the DNA at the 
enhancer/modulatory region of the HIV-1 promoter [75, 346-350].   ROCK may facilitate in 
maintaining a state of viral latency by preventing the transcriptional activation of the HIV-1 
LTR.  
The mechanism by which ROCK mediates HIV-1 transcriptional repression has 
eluded us.  We have several plausible hypotheses.  First, we speculated that ROCK may 
disrupt the cooperative interaction between NF-κB and Sp1 to inhibit gene activation (Figure 
27A) because disruption of either the NF-κB or Sp1 sites, alone, was sufficient to abrogate 
inhibition of HIV-1 gene expression by ROCK.  Our data revealed no change or perhaps an 
increase in binding to the NF-κB and Sp1 sites, individually, in the presence of constitutively 
active ROCKΔ4 (Figure 27B, C).  The role of NF-κB and Sp1 cooperative interaction in 
ROCK-mediated HIV-1 gene expression has not been fully addressed. Additional binding 
studies need to be completed to look at binding to the NF-κB and Sp1 sites together, using a 
probe that contains both sites adjacent to one another as seen in the HIV-1 LTR.  It will also 
be necessary to determine what protein complexes or factors bind to and interact at the NF-
κB and Sp1 sites.   
Second, ROCK may enhance histone deacetylase1 (HDAC1) recruitment for 
interaction with Sp1 at the HIV-1 LTR (Figure 28A).  HDACs have been implicated in 
repressing gene expression by facilitating chromatin condensation [336-339] and to directly 
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interact with Sp1 [101, 340].  Our results revealed that the addition of the HDAC1 inhibitor, 
TSA, further repressed HIV-1 gene expression with overexpression of constitutively active 
ROCK.  This finding suggests that ROCK does not recruit HDAC1 to the Sp1 binding site of 
the HIV-1 LTR to maintain gene repression (Figure 28B), although we do not yet know why 
the addition of TSA led to further repression of the HIV-1 LTR since acetylation is often 
associated with transcriptional activation.  It is possible that a repressor of HIV-1 LTR 
transcription is activated by acetylation.  Again, it is necessary to identify the protein 
complexes or factors associated with the NF-κB and/or Sp1 sites. 
The third and perhaps, most likely, mechanism for ROCK to mediate HIV-1 gene 
repression is through phosphorylation.  ROCK is a Ser/Thr kinase and Sp1 has a Ser/Thr 
region with several sites known to be phosphorylated with effects on promoter activity.  Sp1 
phosphorylation in its N-terminus (Ser131 and Ser59) [340, 351-353] generally augments 
transcription whereas phosphorylation of Sp1 at its C-terminus (i.e. Thr579) correlates with 
Sp1 inactivation [354, 355].  It is possible that transcriptional activation or repression is 
regulated through changes in the interaction between Sp1 and other regulatory factors as a 
result of Sp1 phosphorylation, as opposed to changes in Sp1 site occupancy (Figure 29).  In 
support of this model, the kinase activity of ROCK was necessary for HIV-1 mediated 
repression, suggesting that the ability of ROCK to phosphorylate a currently unknown target 
plays an important role in HIV-1 gene repression.  Additionally, preliminary EMSAs 
revealed little change in DNA binding to either the Sp1 or NF-κB sites in the LTR promoter.  
ROCK may phosphorylate Sp1 to prevent its activation of the HIV-1 LTR. 
It is necessary to identify possible phosphorylation targets modified, either directly or 
indirectly by ROCK, in the context of HIV-1 infection.  Understanding the role of ROCK 
 72
mediated phosphorylation in modulating HIV-1 repression, will hopefully provide, not only 
an increased understanding of how host proteins interact with HIV-1 to mediate replication, 
but also new host targets for the development of anti-HIV-1 therapeutics. 
 73
Acknowledgments: 
We thank Dr. Yi Zhang (UNC-CH) for TSA, Dr. Clark Huang (UNC-CH) for Sp1+ cell 
control for the EMSA; Andrew Elms for technical support; Drs. Ron Swanstrom, Channing 
Der and Blossom Damania (UNC-CH) for helpful discussions.  This work was supported by 
NIH grant (AI/GM 48407 and CA92240).  
 
 74
A B
C D
Figure 19: ROCK Specifically Inhibits HIV-1 Gene Expression. (A-C) Jurkat T 
cells were cotransfected with pNL4.Luc or proviral DNA, NL4-3 and vector, wild-
type ROCK, constitutively active ROCK (Δ4) or kinase dead ROCK.  Supernatants 
and cells were collected 48 hours post-transfection. (A) Effect of ROCK on HIV-1 
viral gene expression.  (B) Effect of ROCK on HIV-1 virion production.  (C) Cell-
associated viral proteins in Jurkat T cells were analyzed using α-p24, α-Myc and 
α-actin antibody.  (D) ROCK inhibition of HIV-1 gene expression is specific to the 
HIV-1 LTR.  Jurkat T cells were cotransfected with retroviral vectors expressing 
pGK-driven GFP or CMV-driven GFP and vector, constitutively active ROCK (Δ4) 
or kinase dead ROCK.  GFP expression was analyzed by FACS.  The percentage 
of live cells and GFP positive cells were similar in all samples. (E) ROCK 
constructs were previously described in Ishizaki et al. 1997.  ROCK has an N-
terminal Ser/Thr kinase domain, a long a-helix region which contains the Rho-
binding domain and at its C-terminus, has a pleckstrin homology and cysteine-rich 
domains. 
E
 75
F G
Figure 19: ROCK Specifically Inhibits HIV-1 Gene Expression. (F, G) 
Dose-dependent response of wild-type ROCK overexpression on HIV-1 virion
production (assembly/release) (F) and gene expression (G).  (F) At low levels 
of wild-type ROCK overexpression, ROCK significantly inhibited HIV-1 virion
release.  Increasing amounts of wild-type ROCK seemed not to have any 
further effect on virion replication.  (G) Dose-dependent response of wild-type 
ROCK overexpression on HIV-1 viral gene expression.  Higher levels of ROCK 
overexpression were needed to see an effect on viral gene expression.
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Figure 20: The ROCK Specific Inhibitor, Y27632, Partially Counteracts 
RhoA Inhibition of HIV-1 Gene Expression.  (A, B) Jurkat T cells were 
cotransfected with pNL4.Luc and vector, wild-type ROCK (A) or constitutively 
active RhoA (RhoA63L) (B).  Inhibitor was added 24 hours post-transfection at 
10 μM or 25 μM concentrations.  HIV-1 gene expression was analyzed by 
luciferase assay at 48 hours post-transfection. Y27632 inhibition of ROCK is 
achieved by competing with ATP for binding to the catalytic site. (C) Co-
expression of wild-type ROCK and constitutively active RhoA further inhibited 
HIV-1 gene expression than when either was expressed alone.  Jurkat T cells 
were cotransfected with pNL4.Luc and vector, wild-type ROCK or ROCK KDIA 
and/or constitutively active RhoA.  Cells were harvested 48 hours post-
transfection and analyzed by luciferase assay.
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Figure 21: ROCK Inhibition of HIV-1 Gene Expression is Dependent on 
the NF-κB Sites in the HIV-1 LTR.  (A) Jurkat T cells were cotransfected with 
various LTR-luciferase constructs and vector, constitutively active ROCK (Δ4) 
or kinase dead ROCK.  HIV-1 gene expression was analyzed by luciferase
assay at 48 hours post-transfection.  Deletion of all sites upstream of TATA 
box or deletion of the three Sp1 sites but maintaining the integrity of NF-κB
sites resulted in gene expression at background levels.  (B) Schematic 
representing LTR deletion constructs used in this experiment.
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Figure 22: Raw Data Demonstrating that ROCK Inhibition of HIV-1 Gene 
Expression is Dependent on the NF-κB Sites in the HIV-1 LTR. Jurkat T 
cells were cotransfected with various LTR-luciferase constructs and vector, 
constitutively active ROCK (Δ4) or kinase dead ROCK.  HIV-1 gene 
expression was analyzed by luciferase assay at 48 hours post-transfection.  
Deletion of all sites upstream of TATA box or deletion of the three Sp1 sites 
but maintaining the integrity of the NF-κB sites resulted in gene expression at 
background levels.  All other LTR-deletion constructs had levels of expression, 
that were above background levels (500 or greater).
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Figure 23: ROCK Inhibits HIV-1 Gene Expression by Affecting 
Interactions at the NF-κB and the First Two Sp1 Sites. (A) ROCK still 
inhibited HIV-1 gene expression when the third Sp1 site was mutated.  Jurkat
T cells were cotransfected with linker-scanning LTR-luciferase mutants and 
vector, constitutively active ROCK (Δ4) or kinase dead ROCK.  HIV-1 gene 
expression was analyzed by luciferase assay at 48 hours post-transfection.  
The LSM -111/-94 NXS disrupts the 5’ proximal NF-κB site, LSM -93/-76 NXS 
disrupts the 3’ proximal NF-κB site and the first 2 bases of the 5’ proximal Sp1 
site, LSM -75/-58 NXS disrupts the 2 5’ proximal Sp1 sites and LSM -57/-40 
NXS disrupts the 3’ proximal Sp1 site (28).  (B) Schematic representing the 
linker scanning mutation constructs used in this experiment. (C) Schematic 
depicting the disruption of Nf-κB and Sp1 sites by linker scanning mutants.  
Blue=NF-κB sites, Red=NFAT site, Green=Sp1 sites and Purple=linker 
scanning sequence.
C
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Figure 24: Raw Data Demonstrating that ROCK Inhibits HIV-1 Gene 
Expression by Affecting Interactions at the NF-κB and the First Two Sp1 
Sites.  Jurkat T cells were cotransfected with linker-scanning LTR-luciferase
mutants and vector, constitutively active ROCK (Δ4) or kinase dead ROCK. 
HIV-1 gene expression was analyzed by luciferase assay at 48 hours post-
transfection.  The LSM -111/-94 NXS disrupts the 5’ proximal NF-κB site, LSM 
-93/-76 NXS disrupts the 3’ proximal NF-κB site and the first 2 bases of the 5’
proximal Sp1 site, LSM -75/-58 NXS disrupts the 2 5’ proximal Sp1 sites and 
LSM -57/-40 NXS disrupts the 3’ proximal Sp1 site (28).  ROCK still inhibited 
HIV-1 gene expression when the third Sp1 site was mutated suggesting it was 
not necessary for ROCK-mediated repression of HIV-1 transcription.  The 
lowest relative light units seen in this experiment were 5000.
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Figure 25: ROCK Inhibits HIV-1 Gene Expression by Affecting 
Interactions at the Second NF-κB Site.  (A) Jurkat T cells were 
cotransfected with point mutant LTR-luciferase constructs and vector, 
constitutively active ROCK (Δ4) or kinase dead ROCK.  HIV-1 gene 
expression was analyzed by luciferase assay at 48 hours post-transfection.  
Deletion of both NF-κB sites resulted in gene expression at background levels 
(HIV-mnκB).  (B) Schematic representing the LTR point mutant constructs 
used in this experiment.  Gray represents the binding site containing a point 
mutation abrogating binding.
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Figure 26: Raw Data Demonstrating that ROCK Inhibits HIV-1 Gene 
Expression by Affecting Interactions at the Second NF-κB Site.  Jurkat T 
cells were cotransfected with point mutant LTR-luciferase constructs and 
vector, constitutively active ROCK (Δ4) or kinase dead ROCK.  HIV-1 gene 
expression was analyzed by luciferase assay at 48 hours post-transfection.  
Deletion of both NF-κB sites resulted in gene expression at background levels 
(HIV-mnκB).  The lowest relative light units seen in this experiment was 800, 
with the majority of conditions being between 1000-8000.
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Figure 27:  Constitutively Active ROCK Did Not Disrupt Binding at Either the 
NF-κB or Sp1 Sites.  (A) We hypothesized that ROCK may disrupt the 
cooperative interaction between NF-κB and Sp1 to inhibit HIV-1 gene expression.  
NF-κB and Sp1 sites are often found adjacently in promoter regions, including 
those for HIV-1, intracellular adhesion molecule 1, vascular adhesion molecule 1 
or granulocyte-macrophage colony-stimulating factor.  In HIV-1 LTR, the actions 
of NF-κB and Sp1 are highly cooperative, involving the effects on DNA binding of 
both factors to their adjacent binding sites, resulting in increased transcriptional 
control.  (B, C) Electrophoretic mobility shift assays using consensus Sp1 (B) and 
NF-κB (C) binding site probes, to determine if constitutively active ROCK 
disrupted/inhibited binding to the Sp1 or NF-κB sites to repress HIV-1 
transcription.
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Figure 28: Further Transcriptional Repression was seen with ROCK in 
the Presence of an HDAC Inhibitor, TSA.  (A) We speculated that since 
ROCK inhibits HIV-1 gene activation, that ROCK enhances recruitment of 
HDACs to interact with Sp1 and/or NF-κB.  Sp1 can be a target for 
HDAC1-mediated transcriptional repression with the interaction between
Sp1 and HDAC1 being direct and requiring the C-terminal domain of Sp1.  
Deacetylation events are involved in maintaining gene repression.  (B) 
ROCK-mediated HIV-1 gene expression is counteracted by HDAC inhibitor, 
trichostatin A (TSA).  Jurkat T cells were transfected with pNL4.Luc and 
wild type ROCK, constitutively active ROCK (Δ4) or kinase dead ROCK.  
TSA was added at 24 hours post-transfection at a concentration of 100 
ng/mL.  HIV-1 gene expression was analyzed at 48 hours.
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Figure 29: Model for ROCK Mediated Phosphorylation Regulating HIV-1 
Repression.  The transcriptional activation/repression of the HIV-1 LTR 
promoter may be regulated through changes in the interaction between Sp1 
and other regulatory factors as a result of Sp1 phosphorylation that may be 
mediated by ROCK.
 
  
 
CHAPTER THREE: 
PERSPECTIVE ON ROLE OF RHO-ASSOCIATED KINASE ON HIV-1 
TRANSCRIPTION 
 
Previously, we reported that the long cytoplasmic tail of the HIV-1 transmembrane 
envelope glycoprotein, gp41c, interacts directly with the carboxy-terminal regulatory domain 
of p115RhoGEF, a guanine nucleotide exchange factor and activator of RhoA [195].  Ectopic 
expression of p115RhoGEF or Gα13, which activates p115RhoGEF activity, leads to 
inhibition of HIV-1 replication in a RhoA-dependent mechanism.  The RhoA effector 
activity inhibiting HIV-1 replication is genetically separable from its other known activities 
[196], suggesting RhoA inhibits HIV-1 regulation via a novel effector activity.   
To investigate how RhoA signaling pathways modulate HIV-1 replication, we tested 
individual RhoA effectors in human T cells.  We found that Rho-associated kinase (ROCK), 
a RhoA effector, to specifically inhibit HIV-1 gene expression in T cells.  At very low levels 
of ROCK overexpression, there was a significant inhibitive effect on HIV-1 virion 
production (i.e. assembly/release) without a similar effect on HIV-1 gene expression.   
Ectopic expression of ROCK inhibited viral transcription in a dose-dependent manner with 
high levels of ROCK efficiently suppressing HIV-1 gene expression.  A ROCK specific 
inhibitor, Y27632, counteracted RhoA inhibition of HIV-1 gene expression.  Coexpression of 
ROCK with constitutively active RhoA further inhibited viral gene expression than when 
either ROCK or constitutively active RhoA were expressed alone, suggesting RhoA signals 
through ROCK to inhibit HIV-1 transcription.  Mutation or deletion of the second NF-κB 
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and/or the first two Sp1 sites in the HIV-1 LTR abrogated ROCK-mediated HIV-1 
transcriptional repression.  Disruption of either NF-κB or Sp1 binding sites was sufficient to 
abrogate ROCK’s effect on HIV-1 gene expression implying that the cooperative interaction 
required for HIV-1 LTR activation is disrupted in some manner by ROCK.  Although we 
have yet to elucidate the mechanism used by ROCK to inhibit HIV-1 transcription, we have 
several hypotheses, which will be discussed below. 
  
Rho-associated Kinase (ROCK) 
Rho-associated kinase (ROCK) is a 160 kDa protein Ser/Thr kinase with several 
distinct domains; an N-terminal kinase domain, a 600 amino acid long coiled-coil region in 
the middle, a pleckstrin homology region and a cysteine-rich zinc-finger like motif in the 
carboxy-terminus [356].  The kinase domain of ROCK has significant sequence homology to 
myotonic dystrophy protein kinase [357, 358].  ROCK binds selectively to the GTP-bound 
form of RhoA and is modestly activated by this binding [358].  ROCK is highly expressed in 
the heart, lung, skeletal muscle, kidney and pancreas and to a lesser extent in the placenta and 
liver, with only trace amounts found in the brain [358].  ROCK regulates cytoskeletal 
organization including stress fiber and focal adhesion formation [329, 356, 359], enhances 
both myosin light chain (MLC) phosphorylation [360] and c-fos SRE gene expression 
downstream of Rho [361] and is involved in cytokinesis [360, 362].   
Phosphorylation of myosin binding subunit (MBS) and MLC by ROCK [121, 360, 
363] leads to an increase in MLC phosphorylation, myosin filament assembly and F-actin 
bundling, thereby enhancing stress fibers.  ROCK promotes formation of stress fibers and 
focal adhesion complexes, which are dependent on both the kinase domain and kinase 
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activity [359].  ROCK also phosphorylates LIM kinase and adducin.  LIM kinase 
phosphorylates the actin depolymerizing protein, cofilin, inhibiting its function [364].  The 
inhibition of cofilin stabilizes actin filament arrays such as stress fibers and cell cortex and 
phosphorylation of adducin by ROCK increases its binding to F-actin [365].  The ROCK 
specific inhibitor, Y-27632, did not prevent the activation of SRF, transcription of c-fos or 
cell cycle re-entry following serum stimulation, although repeated treatment with Y-27632, 
substantially disrupted the actin fiber network but did not affect the growth rate [366].   
Both RhoA and ROCK are localized to cleavage furrows, participating in cytokinesis.  
ROCK can directly phosphorylate MLC in vitro [360] and in vivo [362].  At the same time, 
ROCK inhibits myosin phosphatase by phosphorylating the MBS of myosin phosphatase, 
blocking the turnover of MLC phosphorylation.  Both activities lead to an increase in MLC 
phosphorylation.  ROCK can take the place of MLC kinase (MLCK) directly 
phosphorylating the MLC and enhancing myosin activation [360].  ROCK specific inhibitor, 
Y-27632, does not effectively block cytokinesis suggesting there is another RhoA effector 
molecule that is a Rho target in cytokinesis.   
 
Latency and Transcriptional Silencing 
In infected individuals, viral production is a dynamic process involving continuous 
rounds of infection of CD4+ T lymphocytes with rapid turnover of both free virus and virus-
producing cells that have a half-life of 1–2 days [10, 12].  HIV-1 latency is a natural 
consequence of the virus replicating in activated CD4+ T cells, cells which are capable of 
undergoing reversible changes in activation state [8, 342].  After responding to an antigenic 
challenge, some activated CD4+ T cells return to a resting state and persist as memory cells.  
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In this state, the cells are not permissive for viral replication, however, integration of the viral 
genome into a host-cell chromosome guarantees viral persistence for the lifespan of the 
memory T cell [343].  Upon mitogen stimulation, infectious virus can be recovered from 
these cells.  The lifespan of these cells is long because they provide the cellular basis for 
immunologic memory. 
A major obstacle to HIV-1 eradication is the establishment of a transcriptionally 
silent viral infection in infected resting memory CD4+ T cells [344, 345].  The extremely 
long half-life of these cells, combined with the tight control of HIV-1 expression, make this 
reservoir ideal to maintain hidden copies of the virus.  The exact mechanism by which HIV-1 
establishes latency is not completely understood, but several models exist; (1) transcriptional 
repression of the proviral DNA by binding of specific inhibitory DNA binding proteins, (2) 
modification of the chromatin conformation or (3) methylation of the DNA at the 
enhancer/modulatory region of the HIV-1 promoter [46, 75, 346-350].   
Two key host transcription factors are sequestered in the cytoplasm of resting T cells, 
NF-κB and NFAT.  Both NF-κB and NFAT are only recruited to the nucleus following 
cellular activation by TCR engagement or cytokine signaling, thereby linking HIV-1 gene 
expression to the activation state of the host cell.  Although nuclear forms of NF-κB and 
NFAT are clearly involved in upregulation of HIV-1 gene expression following T cell 
activation, their role in a resting cell when they are located in the cytoplasm, is still unclear.  
The differential localization of NF-κB and NFAT in resting and activated CD4+ T cells may 
be important in the maintenance of latent HIV-1 infection.  ROCK may facilitate in 
maintaining a state of latency by preventing activation of transcription from the HIV-1 LTR 
by acting at the NF-κB and/or Sp1 sites.   
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Mechanisms by which ROCK May Mediate HIV-1 Repression 
First, ROCK could disrupt the cooperative interaction between NF-κB and Sp1 to 
inhibit gene activation (Figure 27A).  In the HIV-1 LTR, the actions of NF-κB and Sp1 are 
highly cooperative, involving the effects on DNA binding of both factors to their adjacent 
binding sites, resulting in increased transcriptional control [81].  If this cooperative 
interaction is disrupted, most likely indirectly, by ROCK then HIV-1 transcription would be 
inhibited.  Our data revealed that there was no change or perhaps an increase in binding to 
the NF-κB and Sp1 sites, individually, in the presence of constitutively active ROCK (Figure 
27B, C).   Additional binding studies need to be completed to look at the cooperative binding 
of the NF-κB and Sp1 sites by using a longer primer to encompass both sites.  The LTR 
deletion/mutation analysis suggests that disruption of either the NF-κB or Sp1 sites abrogated 
ROCK-mediated inhibition of HIV-1 gene expression, which may ultimately be due to a 
disruption of the cooperative interaction between the NF-κB and Sp1 sites.  ROCK may still 
inhibit activation of the promoter without affecting binding to either site or the slight increase 
in binding that we saw in our EMSAs could be due to recruitment of a transcriptional 
repressor.  
Second, ROCK may inhibit HIV-1 gene activation by enhancing HDAC1 (histone 
deacetylase 1) recruitment for interaction with Sp1 and/or NF-κB (Figure 28A).  Sp1 has 
been shown to directly interact, through its zinc-finger domain, with HDAC1 [340].  In this 
case, the resulting transcriptional repression did not involve the deacetylase activity of 
HDAC1 but was accomplished by direct protein-protein interactions between Sp1 and 
HDAC1, which interferes with GC-box Sp1 binding.  Surprisingly, the addition of an 
HDAC1 inhibitor further repressed HIV-1 gene expression (Figure 28B).  One possible 
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explanation for this unexpected result is that an unidentified repressor involved in controlling 
HIV-1 transcription through interaction with Sp1 and/or NF-κB is activated by acetylation 
and its activation promotes transcriptional repression – although that is probably unlikely 
since acetylation typically enhances transcription.  Identification of protein complexes or 
factors associated with the NF-κB and/or Sp1 binding sites should be completed.   
Third, ROCK could affect the state of histone or DNA methylation to prevent NF-κB 
and/or Sp1 from promoting transcription.  DNA methylation is a component of a multilevel 
control mechanism through which the expression of eukaryotic genes can be regulated.  
Typically, there is an inverse relationship between gene methylation and gene expression.  
DNA methylation in the regulatory regions of genes plays a role in silencing of genes either 
by directly inhibiting interaction of transcriptional factors with their regulatory sequences or 
by attracting methylated DNA-binding proteins, which then recruit HDACs and histone 
methyltransferases, resulting in inactive chromatin structure [367].  DNA methylation is 
catalyzed by DNA methyltransferases (DNMTs) which transfer the methyl moiety from the 
methyl donor S-adenosylmethionine to the fifth position on the cytosine ring [368].  DNMT1 
(DNA methyltransferase I) catalyzes the post-replication methylation of DNA and is 
responsible for maintaining the DNA methylation pattern during embryonic development and 
cell division [369, 370].   
DNA methylation is known to suppress Sp1 responsive genes by attracting 
methylated DNA-binding proteins to suppress their activation [371-373].   DNMT1 interacts 
with HDAC1 [374] and HDAC2 [375] as well as histone methyltransferases [376] suggesting 
that DNMT1 silences gene expression by recruiting chromatin-modifying enzymes.  
Knockdown of DNMT1, in lung carcinoma and 293T cells, activated Sp1 response elements 
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without an increase in either Sp1 or Sp3 protein levels or occupancy of the Sp1 elements 
within these proteins suggesting that DNMT1 is acting either directly or indirectly on 
proteins interacting with Sp1 or Sp3 and modulating their trans-activation activity [367].  The 
regulation of Sp1 responsive elements by DNMT1 is separate from the known epigenetic 
mechanisms of DNA methylation, histone acetylation or histone methylation because 
DNMT1 can regulate Sp1 responsiveness in the absence of DNA methylation and acetylation 
is unaffected by DNMT1 knockdown [367]. 
Analysis of the EMSAs previously completed demonstrated that constitutively active 
ROCK minimally enhanced binding at the NF-κB or Sp1 binding sites, implying that the 
effect on HIV-1 LTR transcription by ROCK may be by an indirect mechanism.  ROCK may 
recruit a DNA methyltransferase to prevent activation of the HIV-1 LTR by Sp1 or in some 
other way, modulates methylation of the chromatin to prevent transcription.  To determine if 
methylation is important for ROCK to maintain HIV-1 transcriptional repression, we could 
add a methylation inhibitor, 5-azacytidine, to our transfected cells.  5-azacytidine inhibits the 
catalytic activity of DNMT1 and would determine how the DNA methylation-dependent 
roles of DNMT1 contribute to ROCK-mediated HIV-1 repression.  RNAi knockdown of 
DNMT1 [377] would allow us to address the possible DNA methylation-independent 
regulatory functions of DNMT1 in ROCK-mediated inhibition of HIV-1 gene expression.  In 
both cases, the effect on HIV-1 gene expression, in the context of wild-type and 
constitutively active ROCK overexpression, could be evaluated. 
The last and perhaps, most likely, mechanism for ROCK to mediate HIV-1 gene 
expression is through phosphorylation.  ROCK is a Ser/Thr kinase and Sp1 has a Ser/Thr 
region with several sites known to be phosphorylated with effects on promoter activity.  The 
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first protein kinase to be identified to phosphorylate Sp1 was DNA-dependent protein kinase 
(DNA-PK) [378].  Sp1 phosphorylation is predominantly seen in the N-terminal 610 amino 
acids of Sp1 and is found primarily on Ser residues, with only about 5% of the 
phosphorylation occurring on Thr residues [378].  In Jurkat and HeLa cells, expression of 
viral tat was linked to increased Sp1 phosphorylation at Ser131 [351].  While phosphorylation 
of Ser59 increased DNA binding implying that the C-terminal region is not the only area in 
Sp1 responsible for DNA binding and that changes in the very N-terminal region could affect 
DNA binding either directly or indirectly [340, 352, 353].  Phosphorylation of Thr579 (in the 
second zinc-finger in the DNA binding domain) is essential for CK-II mediated inhibition of 
binding to a consensus Sp1 binding site [354].   
Sp1 phosphorylation in its N-terminus (Ser131 and Ser59) [340, 351-353] generally 
augments transcription whereas phosphorylation of Sp1 at its C-terminus (i.e. Thr579) 
correlates with Sp1 inactivation [354, 355].  Furthermore, it is possible that transcriptional 
activation/repression is regulated through changes in the interaction between Sp1 and other 
regulatory factors as a result of Sp1 phosphorylation (Figure 29).  In support of this model, 
the kinase activity of ROCK was necessary for HIV-1 mediated repression, suggesting that 
the ability of ROCK to phosphorylate a currently unidentified target plays an important role 
in HIV-1 gene repression.  Additionally, preliminary EMSAs revealed little change in DNA 
binding to either the Sp1 or NF-κB sites in the HIV-1 LTR promoter.  It is necessary to 
identify possible phosphorylation targets modified, either directly or indirectly by ROCK, in 
the context of HIV-1 infection, in order to have a more complete understanding of how 
ROCK inhibits HIV-1 gene expression. 
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Understanding the role of ROCK in modulating HIV-1 repression, will hopefully 
provide, not only an increased understanding of how host proteins interact with HIV-1 to 
mediate replication, but also new host targets for the development of anti-HIV-1 therapeutics. 
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ABSTRACT:  
RhoGTPases play important roles in the regulation of protein transport and membrane 
recycling.  Little is known, however, about how RhoGTPases affect HIV-1 virion production, 
which is dependent on the endosomal sorting pathway.  We report that ectopic expression of 
citron kinase, a RhoA effector, preferentially enhances HIV-1 virion production.  Depletion 
of endogenous citron kinase inhibits HIV-1 viral production.  Citron N, which lacks the 
kinase domain, also enhances HIV-1 virion production.  Additionally, the leucine-zipper, 
Rho-binding and zinc-finger domains are necessary for the enhancement activity.  Citron 
kinase also enhances murine leukemia viral production and the HIV-1 late domain is not 
required for the citron kinase-mediated enhancement activity.  Ectopic expression of citron 
kinase leads to the formation of cytoplasmic structures containing citron kinase and HIV-1 
Gag proteins.  Citron kinase and HIV-1 cooperatively enhance late endosome and lysosome 
compartments.  Finally, citron kinase enhances secretion of exosomes or microvesicles that 
copurify with HIV-1 virions.  We conclude that citron kinase enhances HIV-1 viral 
production by stimulating exocytic secretion.  Collectively, our findings suggest a new 
mechanism of HIV-1 virion release involving citron kinase-mediated exocytosis and may 
have important implications for developing novel HIV-1 therapeutics. 
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INTRODUCTION: 
 HIV-1 replication is modulated by a number of cellular signaling pathways regulated 
by both host and viral factors [379].  HIV-1 assembly and release occur in a series of 
essential steps mediated by the viral Gag precursor protein, Pr55Gag [20, 47].  HIV-1 Gag is 
organized into four distinct regions: matrix; capsid; nucleocapsid and late domain.  The late 
(L) domain catalyzes the pinching off and detachment of virus particles from the cell surface 
and each other [47].  The L domain is a highly conserved Pro-rich motif found in enveloped 
viruses.  There are three classes of tetrapeptide motifs; PT/SAP [61, 62], PPXY [217-219] 
and YPXL [220].  In the case of HIV-1, the L domain is encoded by a small peptide motif, 
Pro-Thr/Ser-Ala-Pro (PTAP) in the C-terminal, p6 domain of Pr55Gag.  The L domains of 
retroviruses, despite differences in amino acid sequence and location within their respective 
viral structural proteins, are functionally interchangeable, suggesting commonality of 
function, perhaps as docking sites for host proteins [222, 234, 243].  Mutations in the PTAP 
motif of p6 or deletion of the p6 domain produced a striking defect in the production of virus 
particles where viral particles remain tethered to each other and the plasma membrane [61, 
62] thereby identifying the p6 domain as playing a critical role in HIV-1 budding. 
Viruses like HIV-1 do not encode their own machinery for viral budding and 
therefore must usurp existing cellular pathways to facilitate viral release.  The PTAP motif of 
HIV-1 Gagp6 was found to bind to the ubiquitin enzyme 2 variant (UEV) domain of Tsg101 
[204, 240, 248, 261].   Tsg101 is a component of the endosomal sorting complex required for 
transport (ESCRT-I), a 350 kDa cellular complex essential in the vacuolar protein sorting 
(VPS) pathway.  Point mutations in HIV-1 PTAP motif block virus release at late stages [61, 
62] and disrupt binding to Tsg101 [240].  Small inhibitory RNA-mediated Tsg101 depletion 
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in T cells potently blocks HIV-1 release resulting in the virus forming stalks of tethered virus 
at the plasma membrane [240].  Additionally, overexpression of the dominant-negative form 
of VPS4, an ESCRT recycling factor, inhibits particle release of HIV-1 and other enveloped 
viruses, such as MLV [240].   Additionally, a second region of HIV-1 Gagp6 has been defined 
to contribute to viral release and interacts with AIP1, a host protein [246, 247].  AIP1 
interacts with Tsg101 and CHMP proteins of ESCRT-III complex, coupling HIV-1 Gagp6 to 
the early and late-acting endosomal sorting complexes and binds directly to HIV-1 Gagp6 
LRSL [246, 247].  Taken together, these data suggest that the VPS machinery and perhaps 
other host factors are involved in the facilitating the budding of retroviruses. 
The endosomal sorting pathway controls a variety of cellular processes and plays a 
role in the sorting of ubiquitinated cargo proteins into the lumen of the multivesicular bodies 
(MVB) [54, 268].  Ubiquitinated proteins are recognized on the limiting endosomal 
membrane and sorted resulting in either MVB fusion with the lysosome to degrade contents 
or release of material into the extracellular environment via exosomal vesicles [269-271]. 
ESCRT-I, composed of Tsg101, Vps28 and Vps37, recognize the ubiquitinated protein cargo 
and recruit two more class E protein cargos (ESCRT-II/III) that participate in protein sorting 
and vesicle formation [272, 273, 327].  HIV-1 may bind Tsg101 and AIP1 to gain access to 
downstream machinery involved in catalyzing MVB vesicle budding, a mechanism 
topologically similar to viral budding from the plasma membrane.  
RhoGTPases play a pivotal role in the dynamic regulation of actin cytoskeleton [122-
124] and through this, control cell morphology [127, 128], motility, adhesion and activation 
of transcription factors such as NF-κB [126] and serum response factor [125].  Although 
RhoGTPases have been implicated in various steps of T cell activation [182, 191, 193], little 
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is known about how RhoGTPases affect HIV-1 replication.  We have previously shown that 
the cytoplasmic tail of the transmembrane glycoprotein, gp41c, interacts directly with the 
carboxy-terminus of p115RhoGEF [195], a guanine nucleotide exchange factor and activator 
of RhoA.  Activation of p115RhoGEF leads to inhibition of HIV-1 replication in a RhoA-
dependent manner [196].  The RhoA effectors involved in modulating HIV-1 replication are 
not defined.   
To investigate how RhoA signaling pathways modulate HIV-1 replication, we tested 
several RhoA effectors in 293T and human T cells.  We determined that citron kinase, a 
Ser/Thr kinase, enhances both HIV-1 replication and the exocytosis pathway.  Ectopic 
expression of citron kinase preferentially enhanced HIV-1 virion production.  Knock-down 
of citron kinase by shRNA reduced HIV-1 viral production.  Citron kinase enhanced murine 
leukemia viral production, as well as viral production with a GagΔp6 construct suggesting 
that citron kinase mediates viral production independently of the viral late domain.  Citron 
kinase induced intracellular compartments and colocalized with Gag in these compartments.  
Citron kinase and HIV-1 cooperatively enhanced late endosome and lysosome 
compartments.  Furthermore, citron kinase enhanced secretion of exosomes and 
microvesicles that copurified with HIV-1 virions.  
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Materials and Methods: 
Reagents, plasmids and cell lines 
The pNL4-3 plasmid encodes the entire HIV-1 genome DNA in pUC18 [327].  The 
pNL4.Luc.R-E- plasmid was obtained from the National Institutes of Health (NIH) AIDS 
Research and Reference Reagent Program [328].  The pNL4GFP plasmid encodes Gag, Pol, 
tat and rev and was kindly provided by Dr. Dan Littman, NYU, NY, NY.  pCAG (vector), 
pCAG/citron kinase, pCAG/citronΔ1 plasmids were previously reported [380].  All citron 
truncation mutants were generated by PCR of the citron N template with an N-terminal Myc-
tag added and inserted into a retroviral vector, pHSCG [331].  The control 
(pSUPER.Retro.Puro, OligoEngine, Seattle, WA) and citron short-hairpin constructs (cit A, 
cit B and cit C) were a kind gift from Dr. Alan Hall, University College London, London, 
UK.  Gag and GagΔp6 constructs were a kind gift from Dr. Paul Bieniasz, Aaron Diamond 
AIDS Research Center, NY, NY [381] and GagGFP was a kind gift from Dr. Marilyn Resh, 
Sloan-Kettering Institute, NY, NY. 
293T, HeLa and HeLa-MAGI cells (NIH AIDS Research and Reference Reagent 
Program; [331]) were maintained in Dulbecco modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin and L-glutamine.  
Jurkat T cells were maintained in RPMI 1640 supplemented with 10% FBS, 
penicillin/streptomycin and L-glutamine.  NIH-3T3 cells were maintained in DMEM 
supplemented with 10% FBS, penicillin/streptomycin and L-glutamine.  
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HIV-1 Production and Replication in Transfected Human Cells 
 Transient production of HIV-1 was performed by transfecting NL4-3 (0.1 μg) with 
pCAG, pCAG/citron kinase, pCAG/citronΔ1 or citron truncation plasmids (0.2 μg) in 293T 
cells in 48-well plates at 2.5x104 cells/well using Effectene (Qiagen, Santa Clarita, CA) or 
NL4-3 (0.3 μg) with pCAG, pCAG/citron kinase, pCAG/citronΔ1 or citron truncation 
plasmids (0.6 μg) in Jurkat T cells in 48-well plates at 4x105 cells/well using GenePorter 
(Gene Therapy Systems, San Diego, CA).  At 48 hours post-transfection, HIV-1 virions in 
cell supernatant were measured by p24 or RT assays [332] and infectious units were 
determined by titering the supernatant on HeLa-CD4-LTR-lacZ cells (MAGI) as described 
previously [331].   
 To analyze HIV-1 gene expression in transfected cells, pNL4.Luc (0.1 μg) was 
cotransfected into 2.5x104 293T cells/well together with pCAG, pCAG/citron kinase, 
pCAG/citronΔ1 or citron truncation plasmids (0.2 μg) or pNL4.Luc (0.3 μg) was 
cotransfected into 4x105 Jurkat T cells/well with pCAG, pCAG/citron kinase, 
pCAG/citronΔ1 or citron truncation plasmids (0.6 μg).  Cell extracts were analyzed at 48 
hours after transfection for luciferase activity (AutoLumat LB953, EG&G berthold; FluoStar 
Optima, BMG LabTech).  In some experiments, we used pGag, pGagΔp6 or pNL4GFP, in 
place of pNL4-3 or pNL4.Luc.   
  
Western Blotting 
Transfected 293T or Jurkat T cells were lysed and resolved (50-100 μg of total 
protein) on a 10% SDS-PAGE.  Gels were transferred to PVDF membranes (Amersham 
Biosciences) and blocked with 5% nonfat milk. The membrane was probed with mouse α-
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p24 (NIH AIDS Research and Reference Reagent Program), mouse α-Myc (AbCam, 
Cambridge, MA), rabbit α-citron (a kind gift from Dr. Lola Reid, UNC-CH, as described in 
[382], mouse α-actin (Sigma-Aldrich), mouse α-tubulin, mouse α-hsc70 (BD Biosciences), 
mouse α-LAMP1 (Santa Cruz) or mouse α-CD82 (BD Biosciences) specific antibodies and 
visualized using an ECL Kit (Amersham Biosciences).   
 
shRNA Knockdown of Citron Kinase 
 The citron kinase short-hairpin RNA (shRNA) and control constructs are in the 
pSUPER.Retro.Puro vector from OligoEngine.  The citron kinase shRNA constructs target 
different regions of citron kinase.   Cit A RNA targets the C-terminus of citron kinase 
beginning at base pair 6085, Cit B and Cit C RNA target the N-terminus of citron kinase 
beginning at base pair 359 and 244 respectively (Figure 31A).  For experiments in 293T 
cells, 293T cells were plated in a 24-well plate at 5x104 cells/well and transfected with 0.4 μg 
control or citron targeted shRNA constructs using Effectene.  Twenty-four hours later, 
another transfection was performed with 0.1 μg pNL4GFP and 0.2 μg control or citron 
targeted shRNA constructs.  Three days after the second transfection, supernatants and cells 
were harvested for further analysis.  For experiments in Jurkat T cells, 0.3 μg of pNL4GFP 
and 0.6 μg of control or citron targeted shRNA constructs were transfected via GenePorter 
into 4x105 cells/well.  Supernatants and cells were harvested at 48 hours post-transfection for 
further analysis. 
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MLV Production and Replication in Transfected Human Cells 
293T cells were plated in a 6-well plate at 4x105 cells/well and transfected with 2 μg 
HSCG, 1.5 μg VSV-G-env, 1.5 μg MLV Gag-Pol and 2 μg vector or citron kinase DNA 
using the calcium phosphate transfection method as described previously [383, 384].  
Retrovirus was harvested 48 hours after transfection.  Virus was titered by seeding NIH-3T3 
cells at 5x104 cells/well in a 24-well plate, adding serial dilution of virus and counting GFP-
positive cells 48 hours after infection on the Guava EasyCyte (Guava Technologies). 
 
Confocal Microscopy 
 293T cells were plated on coverslips at 1x105 cells/well in a 24-well plate and 
transfected as described previously (Effectene, Qiagen).  For the GagGFP confocal 
experiments, we used 0.2 μg of GagGFP, 0.02 μg vector, 0.4 μg vector or citron kinase and 
for the samples with wild-type Gag – 0.2 μg of GagGFP, 0.02 μg of Gag and 0.4 μg vector or 
citron kinase were used in the transfections.  At 48 hours post-transfection, cells were fixed 
with 4% paraformaldehyde for 15 minutes at 4°C, washed once with cold 1xPBS, 
permeabilized with ice cold methanol for 30 seconds, washed once with cold 1xPBS, washed 
three times with Quench Buffer (1% milk, 150 mM NaOAc pH7, 1xPBS),  washed three 
times with wash buffer (1% milk, 1xPBS), incubated with primary antibody for 1 hour at 
room temperature, washed three times with wash buffer, incubated with secondary antibody 
for 1 hour at room temperature, washed five times with wash buffer and mounted on slide 
with PVD.   The primary antibody used was chicken α-Myc (Molecular Probes) at 1:1000 
dilution.  The secondary antibody used was α-chicken-Cy5 (Molecular Probes) at 1:200 
dilution. 
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For LysoTracker experiment, cells were incubated with 60 μM LysoTracker 
(Molecular Probes) for 90 minutes then fixed with 4% paraformaldehyde 48 hours post-
transfection.  Images were collected using Olympus confocal microscope and software.  
FACS 
 Each sample (~4x105 cells) that had been incubated with 60 μM LysoTracker 
(Molecular Probes) for 90 minutes were washed in PBS with 2% FBS and stained with 
7AAD (1 μL/mL) for 15 minutes on ice, then rinsed and resuspended in PBS with 2% FBS.  
Cells were analyzed using FACScan (Becton Dickinson).  
 
Purification of Exosomal/Microvesicles/HIV-1 Virions 
 Transfections were performed as described previously (Effectene, Qiagen), except in 
100 mm dishes using 1x106 cells/plate of 293T cells or 5x105 cells/plate of HeLa cells.  The 
FBS added to the DMEM media used to culture the cells was depleted of exosomes or 
microvesicles by spinning at 100,000xg overnight at 4°C.   Ten mL of supernatant were 
collected 48 hours post-transfection.  The exosome purification protocol is similar to those 
described previously [385, 386].  At the time of collection, supernatants were spun at 3000 
rpm for 10 minutes to remove cells and large cell debris.  Supernatants were then added to 
Beckman Ultra Clear Centrifuges (11x89 mm) with 2 mL 25% sucrose.  Tubes were spun in 
the Beckman L7 Ultracentrifuge at 100,000xg for 2 hours at 4°C.  Supernatant was discarded 
and exosomal pellet was resuspended in 1% Triton X-100 and loaded onto a 10% SDS-
PAGE gel.   
 105
RESULTS: 
Citron Kinase Preferentially Enhances HIV-1 Viral Replication 
 To investigate how RhoA signaling pathways modulate viral replication, we tested 
various RhoA effectors for their effect on HIV-1 viral replication in 293T and human T cells.  
Ectopic expression of citron kinase (citron-K), a RhoA effector involved in cytokinesis [387] 
and membrane vesicle transport [388-390], was shown to preferentially enhance HIV-1 viral 
production without significantly affecting HIV-1 gene expression in 293T (Figure 30A-D), 
Jurkat T (Figure 30E-G) and HeLa cells (data not shown).  Both viral infectious virions 
(Figure 30A, E) and total virions (virion-associated RT activity or p24, Figure 30B and data 
not shown) demonstrated a similar enhancement (7-to 15-fold) while expression of HIV-1 
reporter gene (Figure 30C, F) and cell-associated viral proteins (Figure 30D, G) showed 
minimal enhancement (<2.5-fold in 293T cells and no change in Jurkat T cells).  The C-
terminal truncation mutant of citron kinase, citronΔ1, did not enhance HIV-1 production.  We 
conclude that citron kinase preferentially enhances HIV-1 virion production with minimal 
effect on HIV-1 gene expression and that activity depends on the C-terminal domains of 
citron kinase. 
To evaluate a role for endogenous citron kinase in HIV-1 virion production, we 
depleted endogenous citron kinase from 293T and Jurkat T cells using shRNA constructs that 
targeted various regions of citron kinase (Figure 31A).  293T cells were transfected twice, 
first with control or citron targeted shRNA constructs only and 24 hours later cells were 
cotransfected with citron targeted shRNA constructs and pNL4GFP.  Supernatant and cells 
were harvested 72 hours after the second transfection and analyzed.  We saw efficient 
knockdown of citron kinase protein (65-90%, Figure 31B) and a 75-85% reduction in viral 
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production by all three constructs as determined by p24 ELISA (Figure 31C).  HIV-1 gene 
expression, as measured by cell-associated Gag was not affected by depletion of citron kinase 
(Figure 31B).  Jurkat T cells were also cotransfected with pNL4GFP and the citron-specific 
shRNA or control constructs.  Supernatants and cells were collected 48 hours post-
transfection.  Virion production was inhibited by 60% in citron kinase depleted cells 
compared with the control (Figure 31D).  The inhibition of viral particle release correlated 
with reduction in expression of endogenous citron kinase (Figure 31E).  Therefore, citron 
kinase is required for efficient HIV-1 virion production. 
 
Leucine-Zipper, RBD and Zinc-finger but Not Kinase, PH, SH3 or PDZ, Domains of Citron 
Kinase are Necessary for Enhancing HIV-1 Virion Production 
 Deletion mutants were generated to map the domain(s) of citron kinase involved in 
the enhancement of HIV-1 viral production.  Citron N, a naturally occurring splice variant of 
citron kinase lacking the N-terminal kinase domain, showed similar enhancement activity as 
citron kinase, indicating that the kinase domain was dispensable (Figure 32A).  Next, we 
made a series of C-terminal truncations in the citron N backbone.  The PH, SH3 and PDZ 
domains were not required for the activity.  The zinc finger motif of citron was found to be 
necessary for enhancement of viral production because deletion of the zinc finger domain 
from citron N (CNΔZnF) abolished its ability to enhance virion production (Figure 32A).  
The zinc-finger domain alone was unable to enhance virion production (Figure 32A).  
Further deletion of the N-terminal α-helix demonstrated that a portion of the domain with 
two copies of the leucine zipper motif and the Rho-binding domain, in addition to the zinc-
finger domain were sufficient for citron kinase-mediated viral enhancement (Figure 32A).  A 
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schematic of our findings on the effect of citron mutants on virion production is shown 
(Figure 32B).  A western blot with anti-Myc antibody showed that all citron truncation 
mutant proteins were efficiently expressed to similar levels as citron kinase or citron N 
(Figure 33A, B).   
 
Citron Kinase Enhances MLV Release and Enhancement of HIV-1 VLP Production Is 
Independent of the Late Domain 
To determine if citron kinase enhancement of virion production is HIV-1 specific, we 
evaluated whether citron kinase was able to enhance murine leukemia virus (MLV) 
production.  Citron kinase enhanced MLV virion production to comparable levels as HIV-1 
(Figure 34A) suggesting that citron kinase has a general enhancement activity on retroviral 
production.   
The late domain is an important component for retroviral release [61, 62].  It has been 
shown that HIV-1 viral release is dependent on the unique HIV-1 late domain to interact with 
the endosomal sorting protein TSG101 and subsequently the endosomal sorting pathway.  
Release of MLV, which contains a different late domain tetrapeptide sequence (PPPY) than 
HIV-1 (PTAP), is unaffected by depletion of Tsg101 [240].   To determine the role of HIV-1 
late domain in citron kinase-mediated virion production, we transfected 293T cells with Gag 
or GagΔp6 constructs [381].  The GagΔp6 construct lacks the entire late domain, including 
the PTAP tetrapeptide sequence.  GagΔp6 significantly inhibited virion production compared 
to full-length Gag (Figure 34B).  Citron kinase enhanced VLP production to the same degree 
with or without the late domain present (5-7 fold, Figure 34B, C).  Our results demonstrate 
that citron kinase enhances HIV-1 virion production independent of the viral late domain.   
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Citron Kinase Induces the Formation of Intracellular Compartments and Colocalizes with 
HIV-1 Gag 
 To define a possible mechanism by which citron kinase enhances HIV-1 viral 
production, we evaluated by confocal microscopy the subcellular localization of citron kinase 
and HIV-1 Gag in 293T cells.  Citron kinase localized to dense protein aggregates that 
accumulated in the cytoplasm (data not shown, previously described in [391]).  When 
GagGFP was expressed alone or GagGFP/Gag were coexpressed in 293T cells (Figure 35A, 
C), Gag exhibited cytoplasmic and plasma membrane localization, the primary site for HIV-1 
release.  However, when GagGFP or GagGFP/Gag were coexpressed with citron kinase, Gag 
localized to the same dense protein aggregates that expressed citron kinase (Figure 35B, D).  
Thus citron kinase relocalized Gag to these citron kinase-induced intracellular structures that 
could be mediating enhancement of viral production by exploiting an unused or little used 
intracellular pathway. 
   
Citron Kinase Enhances HIV-1 Viral Production by Promoting Exocytosis 
 Next, we determined the effect of citron kinase on the late endosomal and lysosomal 
compartments during HIV-1 replication since all retroviruses are dependent on the late 
endosomal sorting pathway for productive release.  Cells were cotransfected with citron 
kinase and/or pNL4-3 and labeled with LysoTracker, a dye that marks compartments of low 
internal pH (i.e. late endosomes and lysosomes).  Citron kinase or HIV-1 alone showed no 
significant effect on these compartments (Figure 36A-C).  Citron kinase and HIV-1, 
however, cooperatively enhanced the late endosomal and lysosomal compartments (Figure 
36D).  The results from confocal microscopy were supported by FACS analysis of the 
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LysoTracker signal (Figure 36E).  These findings suggest that citron kinase interacts with 
HIV-1 to enhance activity of the late endosomal sorting pathway to promote HIV-1 virion 
production.   
 The endosomal sorting pathway is crucial for a number of key biological processes.  
Once a protein enters the endosomal sorting pathway, there are three outcomes: (1) 
internalized receptor/cargo can be recycled to the cell surface; (2) the MVB fuses with the 
lysosome to degrade its contents or (3) the MVB can be directed to the plasma membrane 
where its contents are released via an exocytic pathway.  We, therefore, hypothesized that 
citron kinase modulates HIV-1 virion production and the MVB sorting pathway by 
promoting late endosome trafficking to secretion by the exocytic pathway.  To address this, 
we purified exosomes secreted from cells transfected with HIV-1 proviral DNA in the 
presence and absence of citron kinase.  Our results indicate that citron kinase, alone and with 
HIV-1, enhanced the secretion of microvesicles with exosomal markers (i.e. hsc70, CD82 
and LAMP-1), as well as HIV-1 virions, in HeLa (Figure 37A) and 293T cells (Figure 37C).  
There was no enhancement of intracellular exosomal markers in the presence of citron kinase 
and/or HIV-1 (Figure 37B, D).  Interestingly, citron kinase and HIV-1 seemed to 
cooperatively enhance secretion of microvesicles or exosomes by evaluating levels of hsc70, 
LAMP-1 and CD82.  We conclude that citron kinase enhances HIV-1 virion production by 
enhancing the release of exosome/microvesicle-like virions via the exocytic pathway.  
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DISCUSSION: 
We investigated the role of the RhoA effector, citron kinase, in modulating HIV-1 
replication.  Ectopic expression of citron kinase and the kinase-deficient splice variant citron 
N preferentially enhanced HIV-1 virion production.  Knock-down of endogenous citron 
kinase by shRNA inhibited HIV-1 virion production, demonstrating a relevant and important 
role for endogenous citron kinase in viral budding.  Citron kinase also enhanced MLV 
production and the HIV-1 late domain was not required for the enhancement.  Citron kinase 
forms cytoplasmic structures [391] and when both HIV-1 Gag and citron kinase are co-
expressed, Gag is colocalized to these citron kinase-induced cytoplasmic structures.  Further 
analysis of the endosomal sorting pathway indicated that citron kinase, together with HIV-1, 
enhanced the size and intensity of late endosomes and lysosomes. We demonstrated that 
production of exosomes and HIV-1 virions were both enhanced by citron kinase.  These 
results suggest citron kinase is involved in the exocytic pathway.  HIV-1 interacts 
functionally with citron kinase and this pathway to cooperatively enhance HIV-1 virion 
production. 
There are two endogenous forms of citron, the kinase form (citron-K) and the 
nonkinase form (citron N).  Citron kinase, a 240 kDa protein, is ubiquitously expressed in 
most cell-types with cell-cycle dependent cellular localization [380].  RhoA colocalizes with 
citron kinase in the cell cortex during ana- and telophase and both are enriched in the 
cleavage furrow and midbody during telophase [387].  The Rho-binding domain of citron 
kinase is essential for localization to the cleavage furrow and midbody.  Citron kinase 
modulates the contractile motion required for separation of the two daughter cells during 
cytokinesis.  Full-length citron kinase and the kinase domain alone phosphorylated regulatory 
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light chain (MLC) of myosin II at both Ser19 and Thr18 during cytokinesis [392].  It is feasible 
that citron kinase enhances virion budding from host cells in a similar process as cytokinesis.  
However, our observation that the kinase domain is not required to enhance HIV-1 virion 
production argues against this mechanism. 
The nonkinase form, citron N, is a splice variant of citron kinase and a brain-specific 
Rho-binding protein [393].  There is a molecular association between citron N and the post-
synaptic scaffold protein, PSD-95/SAP-90, a member of the membrane-associated guanylate 
kinase protein family (MAGUK) [394, 395].  This interaction involves signaling pathways 
essential for neural plasticity and postsynaptic signal transduction events [394, 395].  Actin 
polymerization and cytoskeleton are regulated by RhoGTPases and are essential for the 
organization and dynamics of membrane organelles such as endosomes and the Golgi 
complex [388-390].  Citron N is enriched and associated with the Golgi apparatus of 
hippocampal neurons in culture [396].  Suppression of citron N or expression of a mutant 
lacking Rho-binding activity leads to dispersion of the Golgi apparatus [396] suggesting that 
citron N functions as a scaffolding molecule on Golgi membranes, organizing Rho-mediated 
actin polymerization locally by assembling the actin polymerizing complexes together 
(ROCK II and profilin-IIa) [396].  Therefore, citron N may play a role in organization of the 
endosomal sorting pathway and regulation of the actin cytoskeleton to facilitate exosome and 
virion release.  We analyzed monomeric and polymerizing actin in cells transfected with 
citron kinase and/or HIV-1, neither monomeric nor polymerizing actin appear to be altered 
by citron kinase and/or HIV-1 (Figure 38). 
We determined that the region of citron kinase necessary for enhancement of virion 
production contained the leucine-zipper, the Rho-binding domain and the zinc-finger 
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domains.  It has been speculated that the leucine-zipper domain may be a scaffold for 
multimeric structures functioning through conformational changes and interactions with 
additional partners [393].  The zinc-finger (C6H2) in citron kinase is believed to bind lipid 
second messengers or to recruit additional proteins [393].  Taken together, citron kinase may 
enhance virion production by binding or recruiting other cellular (perhaps endosomal sorting 
proteins) or viral components to facilitate viral release. 
RhoGTPases play a central role in the dynamic regulation of the actin cytoskeleton 
and through this, control cell morphology, motility and adhesion [120, 288].  RhoGTPases 
act locally to control individual trafficking events, but also act globally to control the spatial 
organization of membrane traffic, in response to cues from the extracellular environment.  In 
addition to interacting with the endocytic pathway to modulate clathrin-independent 
internalization from the cell surface [294, 295].  RhoGTPases are involved in mediating 
trafficking/sorting decisions at a number of distinct endocytic subcompartments.  For 
example, RhoD is localized to both the plasma membrane and early endocytic vesicles, 
resulting in activation of an isoform of Diaphanous and tyrosine kinase c-Src [297].  RhoB, 
which is highly homologous to RhoA, is localized to the plasma membrane and the bounding 
membrane of MVBs [300, 302] and is activated by internalized epidermal growth factor 
receptors as they enter the late endosomal compartment [303].  These findings suggest that 
RhoGTPases interface the actin cytoskeleton with endocytic trafficking events. 
Recent evidence has shown that Tsg101, a component of ESCRT-1, binds specifically 
to the late domain of HIV-1 Gag to promote viral release [204, 240, 261].  Small inhibitory 
RNA-mediated depletion of Tsg101 potently blocked HIV-1 release but not MLV release 
[240].  We showed that citron kinase enhanced virion production of MLV.  Citron kinase 
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also enhanced VLP production of HIV-1 GagΔp6, which lacks the late domain.  Therefore, 
this citron kinase activity probably affects a step of HIV-1 viral release that is distinct from 
the Tsg101-dependent step.  Dominant-negative mutants of Vps4 inhibited viral release of 
both HIV-1 and MLV indicating the essential role of the late endosomal pathway in 
mediating retroviral release [240].   Coexpression of dominant-negative Vps4 mutants 
completely blocked HIV-1 virion production in the absence or presence of citron kinase 
(Figure 39).  Therefore, citron kinase enhanced virion production that is still dependent on 
the late endosomal sorting pathway. 
HIV-1 can bud from both the plasma membrane and internal endosomal membranes 
[197, 240, 247, 280, 381, 386, 397, 398].  Citron kinase may either recruit late endosomal 
factors to the plasma membrane or promote utilization of the endosomal pathway for viral 
production.  Cells transfected with both citron kinase and HIV-1 lead to larger LysoTracker 
compartments with increased intensity of signal compared to cells transfected with HIV-1 or 
citron kinase alone.  Based on the localization of citron kinase and colocalization of Gag, it is 
likely that citron kinase promotes the late steps of the endosomal sorting pathway for viral 
production.   
HIV-1 virions share similar characteristics with exocytosed microvesicles or 
exosomes [386, 399].  They are similar in size and contain exosome-specific markers, as well 
as common cellular membrane proteins.  Although exosome production occurs more 
prominently in macrophages, B cells and dendritic cells, recent evidence indicates that the 
exosomal pathway operates in most blood cell types, including T cells [283].  Our data 
support a model where citron kinase is involved in modulating the exosomal secretion 
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pathway and HIV-1 interacts with citron kinase, directly or indirectly, to further enhance 
exosome and HIV-1 virion production.   
Remarkably, citron kinase -/- mice are viable, although they grow at slower rates, are 
severely ataxic and die before adulthood as a consequence of fatal seizures [400].  Since 
knock-down of endogenous citron kinase expression or activity in T cells inhibited viral 
production, the interactions between citron kinase and HIV-1 may provide new host targets 
(citron kinase and the exosomal pathway) for the development of anti-HIV-1 therapeutics.  In 
addition to affecting HIV-1 virion production, the altered release of exosomes may also have 
significant immunological consequences as exosomes have been shown to function as APCs 
to interact with T cells [283, 385, 386, 399]. 
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ADDITIONAL FINDINGS OF INTEREST:  
In addition to the findings discussed above, we performed studies in primary T cells.  
We looked at citron kinase levels in unstimulated and stimulated primary blood mononuclear 
cells (PBMCs) to elucidate the role of endogenous citron kinase in HIV-1 replication.  
Unstimulated PBMCs were transfected by Amaxa with pNL4GFP or GFP control vector.  
PBMCs were stimulated with PHA at 24 hours post-transfection and treated with IL-2 at 48 
hours post-transfection.  Supernatants and cells were harvested at day five.  First, activation 
of PBMCs induced citron kinase expression.  Second, in activated PBMCs, citron kinase 
expression was further induced by HIV-1 (Figure 40).  We have seen this induction or 
enhancement of citron kinase expression with HIV-1 infection in several cell types besides 
primary cells including 293T, HeLa and Jurkat T cells (data not shown).   
Although many proteins are only expressed when cells are activated, the induction of 
citron kinase, due to its increased expression in proliferating cells and role in enhancing 
exocytosis, even in the absence of HIV-1 infection, may be a means for the virus to usurp a 
necessary cellular component to facilitate its replicative capacity.  The further induction of 
citron kinase with HIV-1 infection could be the result of the virus stabilizing its expression 
(i.e. preventing degradation), perhaps this is accomplished by citron kinase recruitment to a 
complex (i.e. with Tsg101 and other endosomal sorting complexes) where it cannot be 
readily dissociated and turned over.  These findings may have important implications for our 
understanding of HIV-1 infection and in designing HIV-1 therapeutics.   
To further address the relevance of citron kinase in HIV-1 infection, it would be of 
interest to look at whether citron kinase expression is upregulated in HIV-1 positive patients.  
For this experiment, there would have to be a blood sample from either before infection or 
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before seroconversion.   In a longitudinal study, we would have the opportunity to evaluate 
an individual through the various phases of HIV-1 infection, perhaps citron kinase expression 
correlates with phases of higher viral loads.   
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Figure 30: Citron Kinase Preferentially Enhances HIV-1 Virion Production.  
(A, B) 293T cells were cotransfected with proviral DNA NL4-3 and vector, citron 
kinase or citronΔ1.  Supernatant was harvested at 48 hours post-transfection to 
determine infectious units/mL (A) or virion-associated RT activity (B).  (C, D) 293T 
cells were cotransfected with pNL4.Luc and vector, citron kinase or citronΔ1.  
Cells were harvested at 48 hours post-transfection to determine luciferase activity 
(C).  (D) Cell-associated viral Gag proteins, Myc-tagged citron kinase and actin in 
293T cells were analyzed using α-p24, α-Myc and α-actin antibodies, 
respectively.  Error bars are standard deviation of duplicate samples and at least 
3 independent experiments are performed. **=p value<0.005.
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Figure 30: Citron Kinase Preferentially Enhances HIV-1 Virion Production. 
(E, F) Jurkat T cells were cotransfected with pNL4-3 (E) or pNL4.Luc (F) and 
vector, citron kinase or citronΔ1.  Supernatants and cells were harvested at 48 
hours post-transfection to determine infectious units/mL (E) or luciferase activity 
(F).  (G) Cell-associated viral Gag proteins (p55) and actin in Jurkat T cells were 
analyzed using α-p24 and α-actin antibodies.  Error bars are standard deviation of 
duplicate samples and at least 3 independent experiments are performed. *=p 
value<0.05.
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Figure 31: Depletion of Endogenous Citron Kinase Inhibits HIV-1 Virion
Production.  (A) All citron kinase shRNA constructs were made in the 
pSUPER.Retro.Puro vector.  The start site base pairs are from the beginning of 
the coding sequence.  Italics = target sequence, Underline = hairpin.  (B, C)  
Knock-down of endogenous citron kinase using citron shRNA constructs in 293T 
cells inhibited HIV-1 viral production.  293T cells were transfected with citron 
shRNA or control plasmid constructs, 24 hours later, cells were cotransfected with 
pNL4GFP and citron shRNA or control plasmid constructs.  Supernatant and cells 
were collected 48 hours after the second transfection and analyzed for cell-
associated gene expression of citron kinase, p24 and actin (B) and relative HIV-1 
virion production in the supernatant (p24 pg/mL) (C).  (D, E)  Knock-down of 
endogenous citron kinase in T cells inhibited HIV-1 viral production.  Jurkat T cells 
were transfected with pNL4GFP and citron shRNA or control plasmid constructs.  
Supernatant and cells were collected at 48 hours post-transfection.  The effect of 
citron kinase knock-down on HIV-1 viral production in the supernatant was 
measured by p24 ELISA (D).  *=p value<0.05. Cells were lysed and analyze with 
α-citron and α-actin antibodies (E). 
A
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Figure 32: Leucine Zipper, Rho-binding Domain and Zinc-finger Motifs, 
but Not the Kinase Domain, were Necessary for Citron Kinase to 
Enhance HIV-1 Viral Release.  (A) 293T cells were cotransfected with pNL4-3 
and citron truncation constructs.  Supernatants and cells were collected at 48 
hours for infectious unit assays.  Graph depicts fold enhancement of infectious 
units by various citron truncations compared to vector control. *=p value<0.05.  
(B) Schematic diagram of the citron kinase constructs and of results shown in 
(A).  + = enhancement of viral release.
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Figure 33: Protein Expression of Citron Kinase Mutants.  (A, B) 
Expression of citron constructs was verified by analyzing cell-associated 
proteins with α-Myc, α-p24 and α-actin antibodies.  All citron constructs are 
Myc-tagged on the N-terminus.
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Figure 34: Citron Kinase also Enhanced Release of MLV and HIV-1 
GagΔp6 (A) MLV virus-like particle production was similarly enhanced by 
citron kinase.  293T cells were cotransfected with MLV Gag-Pol, VSV-G-env
and HSCG (an MLV-based retroviral vector expressing GFP) with citron kinase
or control vector.  Supernatant was collected at 48 hours post-transfection and 
titered for GFP expression on 3T3 cells to determine infectious units/mL.  (B, 
C)  Citron kinase enhancement of virion production is late domain 
independent.  293T cells were cotransfected with Gag or GagΔp6 and vector 
or citron kinase.  Supernatant and cells were collected 48 hours post-
transfection for analysis.  (B) Citron kinase enhances virion production of both 
HIV-1 Gag and GagΔp6.   Virion production of GagΔp6 alone is significantly 
reduced compared to Gag but is enhanced by citron kinase. (C) Citron kinase
similarly enhances virion production of HIV-1 Gag, GagΔp6 and NL4-3.  
Shown is relative enhancement of virion production of Gag, GagΔp6 and NL4-
3 from two independent experiments. **=p value<0.005, *=p value<0.05.
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Figure 35: Citron Kinase and Gag Colocalize to Citron Kinase Induced 
Cytoplasmic Compartments.  (A, C) 293T cells were transfected with 
GagGFP or GagGFP/Gag in a 10:1 ratio and protein localization was 
determined by confocal microscopy.  GagGFP localizes primarily to the 
plasma membrane in the absence of exogenous citron kinase.  (B, D) 293T 
cells were cotransfected with GagGFP or GagGFP/Gag combination and 
citron kinase.  The localization of GagGFP is altered in the presence of citron 
kinase.  Instead of localizing to the plasma membrane, GagGFP localized 
intracellularly with citron kinase into “citron induced cytoplasmic
compartments”. Bar represents 17.5 μm.
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Figure 36: Citron Kinase and HIV-1 Cooperatively Enhance Late Endosomal
and Lysosomal Compartments.  293T cells were transfected with pNL4-3 and 
vector or citron kinase.  Cells were incubated with 60 μM LysoTracker for 90 
minutes before fixation at ~48 hours post-transfection.  (A-D) Images of 
LysoTracker signals were collected via confocal microscopy.  N= nucleus.  Bar 
represents 7 μm.  (E) Relative LysoTracker signals of 293T cells were measured 
by FACS analysis (average of four independent experiments).  **=p value<0.005. 
E
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Figure 37: Citron Kinase Enhances the Exocytic Pathway.  (A, B) HeLa
cells or (C, D) 293T cells were cotransfected with pNL4-3 and vector or citron 
kinase.  Supernatant and cells were collected 48 hours post-transfection for 
analysis.  The microvesicles and virion pellets in the supernatant were purified 
and analyzed for late endosomal/exosomal markers and HIV-1 Gag p24 (A, 
C).  Exosomal markers analyzed include hsc70, LAMP-1 and CD82.  Cell-
associated proteins were analyzed for late endosomal/exosomal markers (B, 
D).
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Figure 38: Citron Kinase and/or HIV-1 Does Not Alter Monomeric or 
Polymerizing Actin.  293T cells were transfected with proviral DNA, pNL4-3 
and vector or citron kinase.  Cells were fixed, permeabilized and stained with 
(A, B) phalloidin to analyze polymerizing actin or (C, D)  mouse α-actin to 
analyze monomeric actin.  Bar represents 17.5 μm.
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Figure 39: Citron Kinase Requires an Intact Late Endosomal Sorting 
Pathway to Enhance HIV-1 Virion Production.  (A, B, C) 293T cells were 
cotransfected with pNL4-3 and vector or citron kinase and/or Vps4EQ.  
Supernatant and cells were collected 48 hours post-transfection for analysis. (A, 
B) Supernatants were analyzed for viral production by p24 ELISA. Raw data is 
shown in (A) and fold enhancement is shown in (B).  (C) Cell-associated proteins 
were analyzed for Vps4 expression (mouse α-GFP) and intracellular p24 
expression.   
A
B
C
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Figure 40:  Endogenous Citron Kinase Expression is Induced by T Cell 
Activation and Further Induced by HIV-1 Infection. (A, B) Primary blood 
mononuclear cells were Amaxa treated with NL4GFP, stimulated with PHA 24 
hrs post-transfection, IL-2 was added 48 hrs post-transfection and cells were 
collected at day 5.  Cells were lysed and analyzed for citron kinase expression 
(A).  (B) Fold enhancement of citron kinase expression compared to actin in 
stimulated PBMCs.
A
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ABSTRACT: 
 RhoGTPases play crucial roles in modulating the actin cytoskeleton, controlling cell 
processes and activating transcription factors.  Previously, we showed that the cytoplasmic 
tail of the HIV-1 envelope glycoprotein, gp41c, interacted directly with the carboxy-terminus 
of p115RhoGEF, an activator of RhoA, to inhibit HIV-1 replication via a RhoA-dependent 
mechanism.  Recently, we identified citron kinase, a RhoA effector, to preferentially enhance 
HIV-1 replication by promoting exocytosis.  This enhancement was HIV-1 late domain 
independent and required an intact late endosomal sorting pathway.  In this study, we wanted 
to identify possible component(s) of the endosomal sorting pathway that may facilitate citron 
kinase’s role in mediating HIV-1 virion production.   
We identified a functional interaction between citron kinase and Tsg101, a 
component of the ESCRT-I complex, that inhibited HIV-1 virion production.  The kinase 
activity of citron kinase was necessary and sufficient to mediate the functional interaction 
between citron kinase and Tsg101.  Disruption of the PTAP-binding region of Tsg101 
(Tsg101 TYN-) prevented citron kinase and Tsg101 from functionally interacting.  
Immunoprecipitation studies indicated that when citron kinase and Tsg101 functionally 
interact, the Tsg101-Gagp6 interaction was undisrupted suggesting a requirement for the 
Tsg101-Gagp6 interaction.  
Taking these findings and those previously described (Chapter 4) suggest a disparate 
role for citron kinase; one involving its protein-protein interaction domains to enhance HIV-1 
production by promoting exocytosis and the other, involving the kinase activity of citron 
kinase which functionally interacts with Tsg101 to inhibit HIV-1 virion production. 
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INTRODUCTION:  
RhoGTPases play pivotal roles in the dynamic regulation of actin cytoskeleton [122-
124] and through this, control cell morphology [127, 128] and activation of transcription 
factors such as serum response factor [125] and NF-κB [126].  Although RhoGTPases have 
been implicated in various steps of T cell activation [182, 191, 193], little is known about 
how RhoGTPases affect HIV-1 replication.  We have previously shown that the cytoplasmic 
tail of the HIV-1 envelope glycoprotein, gp41c, interacts directly with the carboxy-terminus 
of p115RhoGEF [195], a guanine nucleotide exchange factor and activator of RhoA.  
Activation of p115RhoGEF leads to inhibition of HIV-1 replication in a RhoA-dependent 
manner [195].  The RhoA effector activity inhibiting HIV-1 replication is genetically 
separable from its other known activities, suggesting RhoA inhibits HIV-1 replication by a 
novel effector activity [196].  We found citron kinase, a RhoA effector, to preferentially 
enhance HIV-1 replication by promoting exocytosis (manuscript under review, Chapter 4). 
There are two endogenous forms of citron that result from differential splicing [391, 
393]; the kinase form (citron-K) and the nonkinase form (citron N).  Citron kinase is a 240 
kDa Ser/Thr kinase resembling the ROCK family of proteins in its overall domain structure 
[401].  Citron kinase is ubiquitously expressed in most tissues and cell-types with a cell-cycle 
dependent localization and plays a key role in cytokinesis [380, 387].   The nonkinase form, 
citron N, is a splice variant of citron kinase and a brain-specific Rho-binding protein [393].  
It has been suggested that citron N functions as a scaffolding molecule on Golgi membranes, 
organizing Rho-mediated actin polymerization locally by assembling the actin polymerizing 
complexes together (ROCK II and profilin-IIa) [396].  Actin polymerization and cytoskeletal 
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rearrangements are regulated by RhoGTPases and are essential for the organization and 
dynamics of membrane organelles such as endosomes and the Golgi complex [388-390].   
HIV-1 replication is modulated by a number of cellular signaling pathways regulated 
by both host and viral factors [379].  HIV-1 assembly and release occur in a series of 
essential steps mediated by the viral Gag precursor protein, Pr55Gag [20, 47].  The late (L) 
domain catalyzes the pinching off and detachment of virus particles from the cell surface and 
each other [47].  In the case of HIV-1, the L domain is encoded by a small peptide motif, 
Pro-Thr-Ala-Pro (PTAP) in the C-terminal, p6 domain of Pr55Gag.  The L domains of 
retroviruses, despite differences in amino acid sequence and location within their respective 
viral structural proteins, are functionally interchangeable, suggesting a commonality of 
function, perhaps as docking sites for host proteins [222, 234, 243].   
Viruses like HIV-1 do not encode their own machinery for viral budding and 
therefore must usurp existing cellular pathways to facilitate viral release.  The PTAP motif of 
HIV-1 Gagp6 was found to bind to the ubiquitin enzyme 2 variant (UEV) domain of Tsg101 
[204, 240, 248, 261].  Tsg101, a component of the endosomal sorting complex required for 
transport (ESCRT-I), is a 350 kDa cellular complex essential in the vacuolar protein sorting 
(VPS) pathway.  Point mutations in HIV-1 PTAP motif block virus release at late stages [61, 
62] and disrupt binding to Tsg101 [240].  Small inhibitory RNA-mediated Tsg101 depletion 
in T cells potently blocks HIV-1 release resulting in the virus forming stalks of tethered virus 
at the plasma membrane [240].  Additionally, overexpression of the dominant-negative form 
of VPS4, an ESCRT recycling factor, inhibits particle release of HIV-1 and other enveloped 
viruses, such as MLV [240] indicating the importance of a functional endosomal sorting 
pathway in mediating HIV-1 viral release.    
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The endosomal sorting pathway controls a variety of cellular processes and functions 
in the sorting of ubiquitinated cargo proteins into the lumen of multivesicular bodies (MVB) 
[54, 268].  Ubiquitinated proteins are recognized on the limiting endosomal membrane and 
sorted resulting in either MVB fusion with the lysosome to degrade contents or release of 
material into the extracellular environment via exosomal vesicles [269-271].  ESCRT-I, 
composed of Tsg101, Vps28 and Vps37, recognizes the ubiquitinated protein cargo and 
recruits two more class E protein cargos (ESCRT-II/III) that participate in protein sorting and 
vesicle formation [272, 273, 327].  HIV-1 may bind Tsg101 and other host proteins to gain 
access to the downstream machinery involved in catalyzing MVB vesicle budding, a 
mechanism topologically similar to viral budding from the plasma membrane.  
Previously, we found citron kinase to preferentially enhance virion production of both 
HIV-1 and MLV, in a late domain independent manner.  The kinase domain of citron kinase 
was not necessary for this enhancement activity.  Citron kinase enhanced secretion of 
exosomes and microvesicles that copurified with HIV-1 virions.  However, citron kinase was 
unable to enhance HIV-1 virion production when a dominant-negative Vps4 mutant was 
expressed indicating that a functional late endosomal sorting pathway was required for citron 
kinase to enhance HIV-1 virion production.   
To more clearly understand the role of citron kinase in modulating HIV-1 virion 
production, we wanted to identify possible component(s) of the endosomal sorting pathway 
that may interact with citron kinase to help facilitate its role in enhancing HIV-1 virion 
production.  In this study, we identified a functional interaction between citron kinase and 
Tsg101.  The kinase activity of citron kinase was necessary and sufficient to mediate the 
functional interaction with Tsg101.  Disruption of the PTAP-binding region of Tsg101 
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(Tsg101 TYN-) abrogated the functional interaction between citron kinase and Tsg101.  
Immunoprecipitation studies indicated that when citron kinase and Tsg101 functionally 
interact, the Tsg101-Gagp6 interaction was undisrupted whereas under conditions where 
citron kinase enhanced HIV-1 virion production, the Tsg101-Gagp6 interaction was reduced.  
This data, in conjunction with the inability of the Tsg101 TYN- mutant to maintain a 
functional interaction with citron kinase, suggests that the Tsg101-Gagp6 interaction is 
required for the functional interaction between citron kinase and Tsg101.  Our findings 
demonstrate that (1) the kinase activity of citron kinase is necessary and sufficient to mediate 
the functional interaction with Tsg101 and (2) the functional interaction between citron 
kinase and Tsg101 requires the PTAP-binding region of Tsg101 to remain intact.
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Materials and Methods: 
Reagents, plasmids and cell lines 
The pNL4-3 plasmid encodes the entire HIV-1 genome DNA in pUC18 [327].  The 
pNL4.Luc.R-E- plasmid was obtained from the National Institutes of Health (NIH) AIDS 
Research and Reference Reagent Program [328].  pCAG (vector), pCAG/citron kinase, 
pCAG/citronΔ1, CRIK SK, CRIK SKKD and CRIK KD plasmids were previously reported 
[380, 391].  Citron N was generated by PCR with an N-terminal Myc-tag added and inserted 
into a retroviral vector, pHSCG [331].  Tsg101-FLAG was a kind gift from Dr. Wes 
Sundquist (University of Utah, Salt Lake City, Utah).  TsgF and TsgF TYN- constructs were 
a kind gift from Dr. Paul Bieniasz (Aaron Diamond AIDS Research Center, NY, NY).    
293T and HeLa-MAGI cells (NIH AIDS Research and Reference Reagent Program; 
[331]) were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), penicillin/streptomycin and L-glutamine.   
 
HIV-1 Production and Replication in Transfected Human Cells 
 Transient production of HIV-1 was performed by transfecting NL4-3 (0.1 μg) with 
vector, citron-K or other citron mutant (0.2 μg) and Tsg101-FLAG, TsgF, TsgF TYN- or 
vector (0.05 μg) in 293T cells in 48-well plates at 2.5x104 cells/well using Effectene 
transfection reagent (Qiagen, Santa Clarita, CA).  At 48 hours post-transfection, HIV-1 
virions in cell supernatant were measured by infectious units, determined by titering the 
supernatant on HeLa-CD4-LTR-lacZ cells (MAGI) as described previously [331].    
 For the Tsg101-FLAG titration experiment, 293T cells were cotransfected with NL4-
3 (0.1 μg) and increasing amounts of Tsg101-FLAG (0.01 μg-0.2 μg), with vector being 
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added to keep the total DNA transfected in each case at 0.3 μg in 48-well plates at 2.5x104 
cells/well using Effectene transfection reagent (Qiagen, Santa Clarita, CA).  At 48 hours 
post-transfection, HIV-1 virions in cell supernatant were measured by infectious units as 
described previously [331].  
 For the citron kinase titration experiment, 293T cells were cotransfected with NL4-3 
(0.05 μg) and increasing amounts of citron-K (0.01 μg-0.5 μg), with vector being added to 
keep the total DNA transfected in each case at 0.6 μg in 24-well plates at 5x104 cells/well 
using Effectene transfection reagents (Qiagen, Santa Clarita, CA).  At 48 hours post-
transfection, HIV-1 virions in cell supernatant were measured by p24 ELISA assay.  
 
Western Blotting 
Transfected 293T were lysed and resolved (50-100 μg of total protein) on a 10% 
SDS-PAGE.  Gels were transferred to PVDF membranes (Amersham Biosciences) and 
blocked with 5% nonfat milk. The membrane was probed with mouse α-p24 (NIH AIDS 
Research and Reference Reagent Program), mouse α-Myc (AbCam, Cambridge, MA), 
mouse α-actin (Sigma-Aldrich), rabbit α-citron [382] specific antibodies and visualized 
using an ECL Kit (Amersham Biosciences).   
 
Immunoprecipitations 
 Transfections were performed as described previously (Effectene, Qiagen), except in 
100 mm dishes using 1x106 cells/plate of 293T cells and cells were transfected with 1 μg 
pNL4-3, 2 μg vector or citron-K and 0.5 μg TsgFLAG or vector.  At 48 hours post-
transfection, supernatants and cells were collected for analysis.   Cells were lysed in a buffer 
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containing 0.1% Triton X-100, 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 50 mM NaF, 1mM 
Na3VO4) with protease inhibitors (0.1 mM each PMSF, aprotinin, leupeptin and pepstatin) at 
4oC for 1 hour, followed by 10 minutes centrifugation in a microcentrifuge (10,000xg) at 
4oC.  Lysates were quantitated using BCA Protein Assay Reagent Kit (Pierce, Rockford, IL).  
One mg protein/sample was pre-cleared using 15 μL CL-4B beads, rotated at 4oC for 30 
minutes and microcentrifuged at 3000xg for 3 minutes.  Supernatant was removed to new 
tube where 3 μg mouse α-Tsg101 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was 
added to each sample and incubated overnight at 4oC with rocking.  Proteins were incubated 
using pre-washed protein A beads (15 μL/tube, Pierce, Rockford, IL), rotated at 4oC for 1 
hour, washed 5 times with lysis buffer.  Bound proteins were eluted by boiling in sodium 
dodecyl sulfate (SDS) sample buffer.  Both whole cell lysates (50 μg) and the Tsg101-bound 
fraction were analyzed by Western blotting (described above) with immunoblot detection 
with rabbit α-p24 (NIH AIDS Research and Reference Reagent Program) or rabbit α-citron 
[382] antibodies.   
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RESULTS: 
Citron Kinase and Tsg101 Functionally Interact 
 Previously, we found that ectopic expression of citron kinase preferentially enhanced 
HIV-1 virion production and although, this activity required an intact endosomal sorting 
pathway, it was late domain independent.  To further evaluate the role of citron kinase and its 
effect on virion production, we wanted to identify component(s) of the endosomal sorting 
pathway that may facilitate citron kinase in mediating HIV-1 virion production.  We 
transfected Tsg101 and citron kinase, individually and in combination, in 293T cells.  Tsg101 
overexpression exhibited a dose-dependent response on HIV-1 virion replication; at low 
levels it enhanced virion production (2-fold) but at higher levels, Tsg101 inhibited virion 
production (Figure 41A) which is in agreement with previous findings [251].  The stability 
and expression of intracellular Gag was unaffected by Tsg101 overexpression, even at high 
levels (Figure 41B) indicating that Tsg101 affected a step of the viral life cycle downstream 
of HIV-1 gene expression.  Overexpression of citron kinase enhanced HIV-1 virion 
production in a dose-dependent manner (Figure 41C) however, at higher levels was unable to 
enhance virion production.  Intracellular Gag levels were unaffected by citron kinase 
overexpression (Figure 41D).  Although ectopic expression of either citron kinase or Tag101 
enhanced HIV-1 virion production, coexpression of citron kinase and Tsg101 inhibited HIV-
1 replication (Figure 41E) with intracellular Gag levels remaining unaltered (Figure 41F).  
These findings indicate that citron kinase and Tsg101 functionally interaction. 
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Kinase Activity of Citron Is Necessary and Sufficient for Functional Interaction with Tsg101 
Truncation/deletion mutants were used to evaluate the domain(s) of citron kinase 
important for the functional interaction with Tsg101.  Citron N, a truncation lacking the N-
terminal Ser/Thr kinase domain and a naturally occurring splice variant of citron kinase, 
showed no functional interaction with Tsg101 (Figure 42A).  CitronΔ1, a C-terminally 
truncated citron kinase mutant, demonstrated functional interaction with Tsg101 (Figure 
42A) suggesting an important role for the kinase domain of citron in the functional 
interaction of citron kinase with Tsg101.   
To further characterize the role of citron’s kinase domain in the interaction with 
Tsg101, we used a kinase-dead citron construct (citron KD), the kinase domain alone (citron 
SK) and a kinase-dead kinase domain construct (citron SKKD) (Figure 42B).  The kinase 
domain alone was capable of functional interaction with Tsg101, however, the kinase-dead 
kinase domain demonstrated no functional interaction with Tsg101 (Figure 42A) indicating 
that the activity of the kinase domain is necessary for the functional interaction with Tsg101.  
The kinase-dead mutant in the context of wild-type citron kinase yielded a similar loss of 
functional interaction with Tsg101, as the kinase-dead kinase domain, further supporting the 
finding that the activity of the kinase domain is necessary and sufficient to mediate the 
functional interaction of citron kinase and Tsg101. 
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Functional Interaction of Tsg101 with Citron Kinase is Disrupted with Mutation of Tsg101’s 
PTAP-binding Region 
 After mapping the region of citron kinase necessary for the functional interaction with 
Tsg101, we wanted to determine the domain(s) of Tsg101 involved.  Mutation of the PTAP-
binding region of Tsg101 (Tsg101 TYN-) leads to the disruption of not only the Tsg101-
Gagp6 interaction but also interaction of Tsg101 with AIP1, another ESCRT protein and 
prevents homodimerization of Tsg101.  Disruption of the PTAP-binding region inhibited the 
ability of Tsg101 to functionally interact with citron kinase (Figure 43A).  Citron kinase, 
alone, was able to enhance HIV-1 virion production (Figure 43A) and this enhancement was 
not inhibited by exogenous Tsg101 TYN- mutant.  Previously, we found that citron kinase 
enhanced HIV-1 virion production independently of the HIV-1 viral late domain (manuscript 
under review, Chapter 4).  These findings suggest that binding of proteins to the PTAP-
binding region of Tsg101 is inhibitory to the ability of citron kinase to enhance HIV-1 virion 
production and may be due to the disruption of the Tsg101-Gagp6 interaction.  Additionally, 
citron mutants such as citronΔ1, which do not enhance HIV-1 viral release in the absence of 
exogenous Tsg101 but do functionally interact with Tsg101, did not demonstrate any 
functional interaction with the Tsg101 TYN- mutant suggesting that citron kinase can 
enhance HIV-1 virion production independently of the Tsg101-Gagp6 interaction.  However, 
the functional interaction of citron kinase with Tsg101 is dependent on the Tsg101-Gagp6 
interaction because if that interaction is disrupted with the Tsg101 TYN- mutant, there is no 
functional interaction seen between citron kinase and Tsg101. 
Our results demonstrate that the functional interaction between Tsg101 and citron 
kinase is dependent on the integrity of the PTAP-binding region of Tsg101.  To investigate 
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whether citron kinase affects the Tsg101-Gagp6 interaction, we immunoprecipitated Tsg101 
from cell lysates containing HIV-1, citron-K and exogenous Tsg101 with mouse α-Tsg101 
antibody (Santa Cruz) comparing the amount of Gag associated with Tsg101 under each 
condition.  Under conditions where citron kinase enhanced HIV-1 virion production (no 
exogenous Tsg101), citron kinase reduced the interaction of Tsg101 with HIV-1 Gag (Figure 
43C) indicating citron kinase either inhibits the Tsg101-Gagp6 interaction or promotes the 
dissociation of Tsg101 and HIV-1 Gag to complete viral release.  When both Tsg101 and 
citron kinase were overexpressed and HIV-1 virion production was inhibited, there was no 
change in the Tsg101-Gagp6 interaction (Figure 43C), suggesting that Tsg101-Gagp6 
interaction is necessary for the functional interaction of citron kinase and Tsg101.  Additional 
immunoprecipitation studies need to be completed looking at the effect of a Tgs101 mutant 
defective in Gagp6 binding (Tsg101 TYN-) with various citron kinase constructs including the 
kinase domain alone (citron SK) and the kinase-dead citron kinase (citron KD) on the 
Tsg101-Gagp6 interaction. 
We further mapped the domain(s) of Tsg101 that were important for the functional 
interaction with citron kinase.  The N-terminal region of Tsg101 is involved in mediating 
interactions with other proteins such as HIV-1 Gagp6 and AIP1 and in homodimerization 
[204, 240, 246-248, 402] whereas the C-terminal region of Tsg101 mediates interactions with 
other components of the ESCRT-I complex, most notably Vps28 [381].  The results of 
further domain mapping of Tsg101 were inconclusive (Figure 44), probably due to the 
multiple roles of the each region of Tsg101.    
Collectively, our results suggest that the ability of citron kinase to enhance HIV-1 
virion production is a late domain independent function whereas the functional interaction of 
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Tsg101 and citron kinase which inhibits HIV-1 virion production is a late domain dependent 
function.   
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DISCUSSION: 
Citron kinase was previously found to preferentially enhance HIV-1 virion production 
by promoting exocytosis.  Despite this enhancement by citron kinase being HIV-1 late 
domain independent, it required an intact late endosomal sorting pathway.  In this report, we 
wanted to identify possible component(s) of the endosomal sorting pathway that may 
facilitate citron kinase in mediating HIV-1 virion production.  We identified a functional 
interaction between citron kinase and Tsg101 that required the kinase activity of citron 
kinase and the PTAP-binding region of Tsg101 suggesting a possible HIV-1 Gag late domain 
dependent function. 
Rho family proteins have been implicated in cell shape regulation, cell adhesion, cell 
division and for effects on actin structures, most notably, stress fibers [122-128].  These 
proteins are regulated by nucleotide binding, with the GDP-bound form being inactive and 
the GTP-bound form being active.  When Rho family proteins are activated, they are able to 
interact with downstream effector proteins, such as citron kinase. 
There are two endogenous forms of citron resulting from differential splicing [391, 
393]; the kinase form (citron-K) and the nonkinase form (citron N).  Citron kinase and citron 
N interact with GTP-bound forms of Rho and Rac1, but not Cdc42 [393].  Citron kinase is a 
240 kDa Ser/Thr kinase resembling the ROCK family of proteins in its overall domain 
structure.  The kinase domain of citron has ~50% sequence identity to the sequences of 
ROCK, myotonic dystrophy protein kinase and the Cdc42 effector known as MRCK or GEK 
[401, 403].  Citron kinase is ubiquitously expressed in most tissues and cell-types with cell-
cycle dependent subcellular localization [380, 387].  The Rho-binding domain of citron 
kinase is essential for localization to the cleavage furrow and midbody [380] where citron 
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kinase modulates the contractile motion required for the separation of the two daughter cells 
during cytokinesis [380, 387].  Kinase active mutants of citron caused abnormal contractions 
during cytokinesis but a kinase-dead citron mutant abrogated the abnormal contractile 
movements observed with a C-terminal citron truncation mutant.  These findings suggest that 
the kinase domain of citron plays an important role in mediating cytokinesis [380].   
Full-length citron kinase and the kinase domain alone phosphorylated regulatory light 
chain (MLC) of myosin II at both Ser19 and Thr18 during cytokinesis [392].   MLC is 
currently the only known phosphorylation target for citron kinase.  Unlike ROCK, which also 
phosphorylates MLC, citron kinase does not phosphorylate the myosin binding subunit of 
myosin phosphatase and therefore, does not prevent turnover of MLC phosphorylation [392].  
Expression of the kinase domain of citron increased MLC di-phosphorylation and this di-
phosphorylation restored stress fiber assembly even when ROCK was inhibited with a 
specific inhibitor.  Both mono- and di-phosphorylated MLC were found in cleavage furrows, 
but di-phosphorylated MLC had a more constrained localization than did mono-
phosphorylated MLC [392].  
The functional interaction between citron kinase and Tsg101 was dependent on the 
kinase activity of citron kinase, because when it was deleted (citron N) or a point mutation 
was made to abrogate kinase activity (citron KD) in citron kinase, no functional interaction 
was observed.  The kinase domain alone maintained a functional interaction with Tsg101 
while the kinase-dead kinase domain mutant lost its ability to functionally interact with 
Tsg101, suggesting that the activity of the kinase domain is necessary and sufficient for 
mediating the functional interaction with Tsg101.  It is unlikely that Tsg101 is a direct 
phosphorylation target for citron kinase since there is no evidence that Tsg101 or its yeast 
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homologue, Vps23, are phosphorylated.  Citron kinase may phosphorylate another protein 
that is in the endosomal sorting pathway.   
In T cells and monocyte-derived myeloid cells, inhibition of myosin light chain 
kinase (MLCK), through the use of wortmannin, an inhibitor of MLCK leading to inhibition 
of MLC phosphorylation, suppressed HIV-1 release [315].  Wortmannin did not disrupt the 
transport of viral components to the plasma membrane, but rather inhibited budding only, 
since even at high levels of wortmannin, viral components were seen with myosin at sites of 
viral budding.  These findings suggest that after localization to sites of viral budding, the 
subsequent actin-myosin interactions participate in the release of viral particles from host 
cells [315].   MLC is the only identified phosphorylation target for citron kinase.  It is 
unlikely that phosphorylation of MLC by citron kinase plays a role in the functional 
interaction of citron kinase with Tsg101 and subsequent inhibition of HIV-1 viral production.  
The aforementioned study found that inhibition of MLC phosphorylation suppressed HIV-1 
release [315], whereas we found citron kinase phosphorylation to be necessary for inhibition, 
which may correlate with an increase in MLC phosphorylation. 
Tyrosine phosphorylation is the most prevalent phosphorylation event in regulating 
various aspects of endosomal trafficking.  Coordinated phosphorylation and 
dephosphorylation events are often necessary to mediate association of proteins and to 
facilitate vesicle transport [404].  Protein kinase activity is important in endocytosis.  When 
protein kinase C βII (PKCβII) was mutated to be deficient in phosphorylation, it specifically 
blocked EGF receptor trafficking and degradation without affecting transferrin receptor 
recycling [405], perhaps by forming a nonfunctional late endosome.  Also, Hrs, a hepatocyte 
growth factor-regulated tyrosine kinase substrate and interacting protein of Tsg101, is 
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phosphorylated by binding of a variety of growth factors and cytokines to their receptors, as a 
means of coordinating endosomal receptor sorting and signaling.  Hrs phosphorylation was 
prevented when endocytosis was inhibited [406].  Collectively, these findings indicate the 
importance of phosphorylation events in regulation of the endosomal sorting pathway. 
Additionally, a second region of HIV-1 Gagp6 has been defined to contribute to viral 
release and interacts with AIP1, a host protein [246, 247].  AIP1/Alix is an adaptor protein 
that interacts with Tsg101 and CHMP proteins of ESCRT-III complex, coupling HIV-1 
Gagp6 to the early and late-acting endosomal sorting complexes and binds directly to HIV-1 
Gagp6 LRSL [246, 247].  The Tyr319 of Alix binds to Src’s SH2 domain leading to AIP1/Alix 
phosphorylation at the C-terminal tyrosine rich region by Src [407].  Phosphorylation of 
AIP1/Alix causes translocation from the membrane and cytoskeleton to the cytoplasm and a 
reduction in its interaction with binding partners [408-410].  Src antagonizes the effects of 
Alix phosphorylation of its C-terminus, leading to disruption of interaction with target 
proteins, negatively regulating its biological function [407].   
Even though the majority of these known interactions linking phosphorylation with 
trafficking events involve tyrosine phosphorylation, it does not preclude a role for a Ser/Thr 
kinase in regulation.  It is possible that citron kinase phosphorylates AIP1/Alix, a known 
component in linking early and late endosomal sorting complexes to HIV-1, thereby 
inhibiting its function in binding to Tsg101, Gag or CHMP proteins and ability to act as a 
scaffold protein, leading to inhibition of HIV-1 virion production.  Alternatively, citron 
kinase may phosphorylate an intermediary protein which then phosphorylates AIP1/Alix or 
there may be an unidentified phosphorylation target for citron kinase.  We have yet to 
identify a potential downstream phosphorylation target for citron kinase.  Elucidation of a 
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phosphorylation target would shed light on how citron kinase and Tsg101 interact to mediate 
HIV-1 virion production.   
This paper suggests a disparate role for citron kinase in regulating HIV-1 virion 
replication (Figure 45).  Previously, we identified citron kinase to preferentially enhance 
HIV-1 virion production by promoting exocytic secretion.  The enhancement of HIV-1 virion 
production by citron kinase required the leucine zipper, the Rho-binding and zinc-finger 
domains but not the kinase domain and was late domain independent.  This activity of citron 
kinase is most likely due to it acting as a scaffolding molecule, linking host proteins to the 
endosomal sorting pathway.  In this paper, we found that the kinase activity of citron was 
necessary and sufficient to mediate the functional interaction with Tsg101 and required 
Tsg101’s PTAP-binding region to be intact, suggesting a potential HIV-1 Gag late domain 
dependent function.  This activity is significantly different from the role citron kinase plays 
in enhancing exocytic release and may be involved in mediating interaction with additional 
host factors through regulation of phosphorylation or by activating an already associated 
factor.  Studies on how these two distinct functions of citron kinase are regulated during 
HIV-1 infection are underway. 
These findings imply an increasing complexity in the interactions of HIV-1 viral 
proteins with host proteins and host proteins with each other to modulate viral release.  The 
interactions between citron kinase and the endosomal sorting pathway in regulation of HIV-1 
viral release may provide new host targets for the development of anti-HIV-1 therapeutics. 
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Figure 41: Citron Kinase and ESCRT-I Component, Tsg101, Functionally 
Interact.  (A, B) Dose dependent response of Tsg101 expression on HIV-1 virion
production.  293T cells were cotransfected with increasing amounts of Tsg101-
FLAG and constant amount of NL4-3.  Supernatants and cells were collected 48 
hours post-transfection for analysis by measuring infectious virion production (A) 
and cell-associated protein expression (B).  (C, D) Dose dependent response of 
citron kinase expression on HIV-1 virionl production.  293T cells were 
cotransfected with increasing amounts of citron kinase and constant amount of 
NL4-3.  Supernatants and cells were collected 48 hours post-transfection for 
analysis by measuring infectious virion production (C) and cell-associated protein 
expression (D).  (E, F) Under conditions where expression of Tsg101 and citron 
kinase individually enhanced HIV-1 virion production, overexpression, in 
combination, negatively affected HIV-1 virion production.  293T cells were 
cotransfected with Tsg101-FLAG, citron kinase and/or NL4-3.  Supernatants and 
cells were collected 48 hours post-transfection for analysis by measuring 
infectious virion production (E) and cell-associated protein expression (F).  **=p 
value<0.005 and *=p value<0.05.
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Figure 42: The Kinase Activity of Citron is Necessary and Sufficient for 
the Functional Interaction with Tsg101.  (A) 293T cells were cotransfected
with NL4-3, Tsg101-FLAG and vector, citron kinase or various citron truncation 
constructs.  Supernatants were collected at 48 hours post-transfection and 
infectious virion production measured.  (B) Schematic of citron kinase
constructs used in this experiment. **=p value<0.005 and *=p value<0.05.
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Figure 43: The Functional Interaction of Tsg101 and Citron Kinase is 
Disrupted with Mutation of the PTAP-binding Region. (A) 293T cells were 
cotransfected with vector, citron kinase or various citron truncation mutants, 
NL4-3 and either wild-type Tsg101 or Tsg101 with a mutated Gagp6 binding 
site, Tsg101 TYN-.  Supernatants were collected at 48 hours post-transfection
and analyzed.  (B) Schematic of Tsg101 constructs used in this experiment.  
**=p value<0.005, *=p value<0.05.  (C) 293T cells were cotransfected with 
pNL4-3 and vector or citron kinase and/or Tsg101.  Supernatant and cells 
were collected 48 hours post-transfection for analysis.  Cells were lysed and 
immunoprecipitated with mouse α-Tsg101.  Immunoprecipitated complexes 
(left panel, 1 mg protein immunoprecipitated) and whole cell lysate (right panel, 
50 μg whole cell lysate) were analyzed by western blot with mouse α-p24 and 
mouse α-tubulin antibodies.
C
B
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Figure 44: The PTAP-binding Region of Tsg101 is Important for Its 
Functional Interaction with Citron Kinase.  293T cells were cotransfected
with vector, citron kinase or citronΔ1, NL4-3 and either wild-type Tsg101 or 
Tsg101deletion mutants (described in Goila-Gaur et al. 2003).  Supernatants 
were collected at 48 hours post-transfection and analyzed by infectious unit 
assay.
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Figure 45: Model for the Disparate Role of Citron Kinase in Regulating 
HIV-1 Virion Production.  HIV-1 replication is dynamically regulated by citron 
kinase.  On the left side, citron N enhances HIV-1 viral replication, is late 
domain independent and requires the leucine zipper, Rho-binding and zinc-
finger domains for its enhancement activity.  On the right, the citron kinase
domain inhibits HIV-1 viral replication by functionally interacting with Tsg101 
which requires the kinase activity of citron and is late domain dependent.
 
  
 
 
CHAPTER SIX: 
PERSPECTIVE ON THE ROLE OF CITRON KINASE IN HIV-1 REPLICATION 
 
Previously, we reported that the long cytoplasmic tail of the HIV-1 transmembrane 
envelope glycoprotein, gp41c, interacts directly with the carboxy-terminal regulatory domain 
of p115RhoGEF, a guanine nucleotide exchange factor and activator of RhoA [195].  Ectopic 
expression of p115RhoGEF or Gα13, which activates p115RhoGEF activity, leads to 
inhibition of HIV-1 replication in a RhoA-dependent mechanism.  The RhoA effector 
activity inhibiting HIV-1 replication is genetically separable from its activities in activation 
of SRF and actin stress fiber formation [196], suggesting RhoA inhibits HIV-1 regulation via 
a novel effector activity.  To investigate how RhoA signaling pathways modulate HIV-1 
replication, we tested individual RhoA effectors in 293T and human T cells.   
We demonstrated that ectopic expression of citron kinase and citron N preferentially 
enhanced HIV-1 virion release without significantly affecting HIV-1 gene expression in 
293T and Jurkat T cells.  Depletion of endogenous citron kinase inhibits HIV-1 virion 
production.  Additionally, the leucine-zipper, Rho-binding and zinc-finger domains, but not 
the kinase domain, were necessary for the enhancement activity.  Citron kinase also enhances 
MLV virion production and the enhancement activity is late domain independent.  Ectopic 
expression of citron kinase leads to the formation of cytoplasmic structures containing citron 
kinase and HIV-1 Gag proteins.  Citron kinase and HIV-1 cooperatively enhance late 
endosome and lysosome compartments.  Finally, citron kinase enhances secretion of 
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exosomes or microvesicles that copurify with HIV-1 virions.  We conclude that citron kinase 
enhances HIV-1 virion production by stimulating exocytosis.  Collectively, our findings 
suggest a novel mechanism of HIV-1 virion release that is late domain independent and 
involves citron kinase-mediated exocytosis.   
 Citron kinase mediated enhancement of virion production is dependent on an intact 
late endosomal sorting pathway therefore we wanted to identify possible endosomal sorting 
pathway components that may facilitate citron kinase in enhancing HIV-1 virion production.  
Although ectopic expression of either citron kinase or Tsg101 enhanced HIV-1 virion 
production, coexpression of citron kinase and Tsg101 inhibited HIV-1 replication.  The 
kinase activity of citron kinase was necessary and sufficient for the functional interaction.  
We have yet to identify a potential phosphorylation target for citron kinase.  Disruption of the 
PTAP-binding region of Tsg101 (Tsg101 TYN-) prevented citron kinase and Tsg101 from 
functionally interacting suggesting a potential role for the Tsg101-Gagp6 interaction in 
mediating the functional interaction with citron kinase.  Immunoprecipitation studies 
indicated that when citron kinase and Tsg101 functionally interact, the Tsg101-Gagp6 
interaction was undisrupted.  This data, in conjunction with the inability of the Tsg101 TYN- 
mutant to maintain a functional interaction with citron kinase, suggests that the Tsg101-
Gagp6 interaction is required for the functional interaction between citron kinase and Tsg101.   
 
Citron Kinase 
There are two endogenous forms of citron; the kinase form (citron-K) [380] and the 
nonkinase form (citron N) [393].  Citron kinase is a 240 kDa Ser/Thr kinase resembling the 
ROCK family of proteins in its overall domain structure [356, 358, 411].  The kinase domain 
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of citron has ~50% sequence identity to the sequences of ROCK and myotonic dystrophy 
protein kinase and the Cdc42 effector known as MRCK or GEK [401, 403].   Citron kinase 
and citron N interact with GTP-bound forms of Rho and Rac1, but not Cdc42 [393].  Activity 
of citron kinase is stimulated by activated RhoA and has been implicated in the control of 
cytokinesis downstream of Rho [380, 387] and in the di-phosphorylation of myosin light 
chain (MLC) [392].  Citron kinase is ubiquitously expressed in most tissues and cell-types 
with cell-cycle dependent subcellular localization [380, 387].   
RhoA colocalizes with citron kinase in the cell cortex during ana- and telophase and 
both are enriched in the cleavage furrow and midbody during telophase [387].  The Rho-
binding domain of citron kinase is essential for localization to the cleavage furrow and 
midbody [380] where citron kinase modulates the contractile motion required for the 
separation of the two daughter cells during cytokinesis [380, 387].  Kinase active mutants of 
citron caused abnormal contractions during cytokinesis but a kinase-dead citron mutant 
abrogated the abnormal contractile movements observed with a C-terminal citron truncation 
mutant.  These findings suggest that the kinase domain of citron plays an important role in 
mediating cytokinesis, specifically contractile movements [380].   
Full-length citron kinase and the kinase domain alone phosphorylated the regulatory 
light chain (MLC) of myosin II at both Ser19 and Thr18 during cytokinesis [392].   MLC is 
currently the only known phosphorylation target for citron kinase.  Unlike ROCK, which also 
phosphorylates MLC, citron kinase does not phosphorylate the myosin binding subunit of 
myosin phosphatase and therefore, permits turnover of MLC phosphorylation [392].  
Expression of the kinase domain increased MLC di-phosphorylation which was able to 
restore stress fiber assembly even when ROCK was inhibited with a specific inhibitor.  
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Although both mono- and di-phosphorylated MLC were found in cleavage furrows, di-
phosphorylated MLC showed more constrained localization than did mono-phosphorylated 
MLC [392].  
The nonkinase form, citron N, is a splice variant of citron kinase and a brain-specific 
Rho-binding protein [393].  There is a molecular association between citron N and the post-
synaptic scaffold protein, PSD-95/SAP-90, a member of the membrane-associated guanylate 
kinase protein family (MAGUK) [394, 395].  This interaction involves signaling pathways 
essential for neural plasticity and postsynaptic signal transduction events [394, 395].  Actin 
polymerization and cytoskeleton are regulated by RhoGTPases and are essential for the 
organization and dynamics of membrane organelles such as endosomes and the Golgi 
complex [388-390].  Citron N is enriched and associated with the Golgi apparatus of 
hippocampal neurons in culture [396].  Suppression of citron N or expression of a mutant 
lacking Rho-binding activity leads to dispersion of the Golgi apparatus [396] suggesting that 
citron N functions as a scaffolding molecule on Golgi membranes, organizing Rho-mediated 
actin polymerization locally by assembling the actin polymerizing complexes together 
(ROCK II and profilin-IIa) [396].   
 
Possibilities for Localization to the Endosomal Pathway 
In our studies, we found that (1) citron kinase relocalized HIV-1 Gag from the plasma 
membrane into cytoplasmic structures, where citron kinase also localized (Figure 36) and (2) 
citron kinase stimulated the exocytic pathway (Figure 38), consequently enhancing HIV-1 
virion production.  This is of interest because in other cell types such as macrophages, HIV-1 
buds almost exclusively into MVBs and is released into the extracellular environment when 
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the MVB fuses with the plasma membrane [280, 386, 399]; although this mechanism of viral 
release is rarely seen in cell types such as T cells.  Citron kinase may divert HIV-1 from 
release at the plasma membrane to release by the exocytic pathway, perhaps because it is a 
more efficient viral release process or promote exploitation of an unused or little used 
pathway in most cell types as a means to enhance virion production.  The subcellular 
localization of citron kinase and HIV-1 Gag implies that viral release occurs predominantly 
into intracellular compartments, most likely of endosomal origin, instead of at the plasma 
membrane.  In T cells, HIV-1 buds primarily from the plasma membrane, although its 
endosomal sorting pathway (exocytic pathway) is operational, suggesting that some factor, 
whether viral or host, prefers the plasma membrane as the site of budding.  Neither is 
mutually exclusive and citron kinase-mediated enhancement is probably the result of both.   
One unanswered question is what causes citron kinase to localize to compartments of 
the endosomal sorting pathway/intracellular origin?  In an initial paper describing citron 
kinase, the authors demonstrated that the Rho-binding region of citron kinase was necessary 
for localization to the cleavage furrow and midbody [380].  Deletion of the Rho-binding 
domain led to an increasingly cytosolic pattern of expression.  One possibility is that citron 
kinase is activated by RhoB.   
Higher vertebrates have 3 RhoGTPases, RhoA, RhoB and RhoC which share 85% 
amino acid sequence identity with most of the sequence divergence being at the C-terminus.  
The C-terminus of Rho family GTPases is essential for correct localization of the proteins.  
RhoA plays a key role in the regulation of actinomyosin contractility and demonstrates 
predominantly membrane localization.  RhoB which is localized primarily on endosomes has 
been shown to regulate cytokine trafficking and cell survival while RhoC is more important 
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in cell locomotion.  In addition, these three Rho isoforms have very different expression 
profiles [412], although they are expressed in most tissues, expression levels varied 
significantly depending on tissue type.   
RhoA, RhoB and RhoC are post-translationally modified by prenylation of a 
conserved C-terminal cysteine followed by methylation and proteolytic removal of the last 
three amino acids [413].  Prenylation of Rho proteins appears to be important for their 
stability, as inhibitors of enzymes that synthesize prenyl groups induce a decrease in RhoA or 
RhoB protein levels and their function [414].  The length of the prenyl group differs between 
Rho proteins; RhoB can be prenylated either with a 15-carbon farnesyl or a 20-carbon 
geranylgeranyl group, whereas RhoA and RhoC are only geranylgeranylated.  This 
difference is reflected in their localization because when RhoB is only geranylgeranylated, it 
shows a predominant membrane localization [415].   
There is a small degree of sequence divergence in and around the Switch I region (the 
region necessary for effector interaction) between RhoA, RhoB and RhoC, suggesting there 
could be differences in their affinities for regulators or effector proteins.  Protein interaction 
studies suggest that ROCK and citron kinase have a higher affinity for RhoC compared to 
either RhoA or RhoB, however the VFSKD sequence in Switch I, essential for binding 
PRKs, ROCK and citron kinase [416, 417], is identical in RhoA, RhoB and RhoC with PRK, 
ROCK and citron kinase binding to all three isoforms of Rho.   
 RhoGTPases are critical regulators of actin dynamics and have been involved in the 
control of endocytosis.  RhoB has been localized to the cytoplasmic face of endosomal 
membranes [300, 302] suggesting a role in endosomal trafficking regulation.  Once activated 
by PRK1, RhoB delays the transport of internalized EGF-receptor to lysosomes [301] and 
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promotes, with Dia1, the polymerization of an actin coat around endosomes and their 
association to subcortical actin cables effectively inhibits further endosomal transport [305].  
Overexpression of wild-type RhoB had no effect on endosome transport, suggesting that 
endogenous RhoB transiently inhibits endocytosis under the regulation of the GTPase cycle.  
Dia1 and PRK1 may cooperate in regulating endosomal trafficking downstream of RhoB 
because a dominant-negative Dia1 reversed the inhibition of EGFR degradation caused by 
activated RhoB [305].   
 Citron kinase may be activated by RhoB, instead of RhoA, causing it to localize to 
the endosomal sorting pathway and once localized there, may interact with other 
components/complexes of the endosomal sorting pathway to promote exocytosis.  RhoB 
seems to only transiently inhibit endocytosis trafficking; rhoB transcripts have a half-life of 
about 30 minutes, significantly shorter than either rhoA or rhoC transcripts [418] therefore it 
is plausible that citron kinase transiently interacts with RhoB localize to the late endosome 
and to come into close proximity with additional binding partners.  To determine if citron 
kinase is activated by RhoB to promote exocytosis and HIV-1 virion production, we can 
perform a series of transfections with citron kinase, constitutively active RhoA and 
dominant-negative RhoB or citron kinase, constitutively active RhoB and dominant-negative 
RhoA.  Analysis of HIV-1 virion production under each condition and immunofluorescence 
to determine localization of citron kinase under each condition may shed light on what 
induces citron kinase to localize to the endosomal sorting pathway.   
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Citron Kinase May Act as a Scaffolding Molecule 
We identified a portion of the leucine zipper, the Rho-binding and zinc-finger 
domains to be necessary for citron kinase to enhance HIV-1 virion production (Figure 32).  
Citron kinase promoted secretion of microvesicles and virions from the exocytic pathway 
(Figure 37).  The domains of citron kinase necessary of enhancement are often associated 
with protein-protein interactions and the endosomal/exocytic pathway involves coordinated 
interactions with a number of complexes to complete its sorting processes, suggesting that 
citron kinase is a scaffolding molecule.   
Citron kinase may act as a scaffold for a multimeric structure functioning through 
conformational changes induced by Rho binding and interactions with additional partners via 
the leucine zipper and zinc-finger domains.  The presence of several leucine zippers is 
consistent with such a model and coiled-coil regions usually serve as dimerization domains, 
suggesting that native citron is a dimer [393].  Rho binding may partially open this structure, 
causing a major conformational change in citron dimer thereby affecting the properties of the 
scaffold, as is established for myosin [419].  Additionally, the zinc-finger domain which 
consists of six cysteines and two histidines, is not a classical zinc-finger and is thought to 
bind to lipid second messengers [393, 420].   
An attractive model for the enhancement of HIV-1 virion production by citron kinase 
is that citron kinase acts as a scaffold, linking components of the endosomal sorting pathway 
together.  It is unlikely that citron kinase binds directly to HIV-1 Gag since citron kinase can, 
in the absence of a viral infection, promote secretion of microvesicles and exosomes.  It is 
much more likely that citron kinase binds to cellular factors, recruiting them to the site(s) of 
viral release.  Depletion of endogenous citron kinase inhibits virion production implying that 
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citron kinase is necessary for a productive viral infection (Figure 31).  Additionally, in 
primary T cells, there was an induction of endogenous citron kinase expression with HIV-1 
infection (Figure 40).   
Tsg101 interacts with a number of proteins via its UEV domain by binding the PTAP 
sequences of Hrs, Tsg101 itself, AIP1 and HIV-1 Gagp6 [204, 240, 248, 261, 421-424].  
Tsg101 is also thought to multimerize thereby allowing it to interact with several different 
proteins via the same UEV region [247].  AIP1 was identified to act as a scaffolding 
molecule linking complexes that act early (Tsg101/ESCRT-I) and late (CHMP/ESCRT-III) 
to the endosomal sorting pathway [247].  Additionally, it was found that mutations disrupting 
the Tsg101-Gagp6 interaction inhibited HIV-1 release to a greater extent than mutations 
disrupting the AIP1-Gagp6 interaction [247].  One of the primary purposes of both Tsg101 
and AIP1 in interacting with HIV-1 Gagp6 is to act as scaffolds to recruit additional 
components and complexes to facilitate in viral egress. 
It is commonly believed that the Tsg101-Gagp6 interaction is required for efficient 
viral release and that disruption of this interaction, either by depletion of Tsg101 or 
mutations removing the HIV-1 late domain, inhibits viral release.  We found citron kinase to 
enhance HIV-1 virion production even when the PTAP-binding region of Tsg101 is disrupted 
– a novel and unprecedented finding (Figure 35).  Citron kinase enhanced virion production 
of not only MLV, which uses the PY- late domain and is Tsg101 independent, but also 
GagΔp6, a Gag mutant which completely lacks the viral late domain.  Collectively, these 
findings indicate that citron kinase’s ability to enhance HIV-1 virion production is 
independent of the Tsg101-Gagp6 interaction, although it does not rule out the necessity of 
Tsg101 to recruit other components of the ESCRT complexes.  
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Citron kinase enhances virion production in a manner capable of circumventing the 
Tsg101-Gagp6 interaction, suggesting that citron kinase acts a scaffold to recruit the 
necessary factors for viral release.  If citron kinase is acting as a scaffolding molecule, it is 
necessary to identify possible proteins that it interacts with directly.  It has already been 
found, via yeast two-hybrid, that citron kinase binds to Tsg101 (W. Sundquist, personal 
communication), making citron kinase likely to interact with other components of the 
endosomal sorting pathway.   
 
Phosphorylation Target(s) for Citron Kinase 
We identified a functional interaction between citron kinase and Tsg101 which was 
dependent on (1) the kinase activity of citron and (2) the PTAP-binding region of Tsg101.  
We have not identified a potential phosphorylation target for citron kinase.  Currently, the 
only known phosphorylation target for citron kinase is MLC.  MLC can also be 
phosphorylated by myosin light chain kinase (MLCK) and ROCK.  It was found that in T 
cells and monocyte-derived myeloid cells, inhibition of MLCK by wortmannin, an inhibitor 
of MLCK which inhibits MLC phosphorylation, suppressed HIV-1 release [315].  Even at 
high levels of wortmannin, viral components localized with myosin at sites of viral budding 
implying that wortmannin did not disrupt transport of viral proteins to the plasma membrane 
but rather inhibited budding.  These findings suggest that after localization to the plasma 
membrane, release of viral particles is dependent on the subsequent actinomyosin 
interactions at the cell surface [315].   It is unlikely that phosphorylation of MLC by citron 
kinase plays a role in the functional interaction of citron kinase and Tsg101 or the subsequent 
inhibition of HIV-1 virion production.  The previous study found that inhibition of MLC 
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phosphorylation suppressed HIV-1 release [315], whereas we found citron kinase 
phosphorylation to be necessary for inhibition, which may correlate with an increase in MLC 
phosphorylation. 
Tyrosine phosphorylation is the most prevalent phosphorylation event in regulating 
various aspects of endosomal trafficking.  Two cellular events normally follow binding of a 
growth factor to its cell surface receptor; the receptor transmits an intracellular signal, 
typically initiating a phosphorylation cascade and it becomes internalized by endocytosis.  
Following endocytosis, the receptor–ligand complex is delivered to an early endosome, from 
which it may be recycled back to the plasma membrane or transported further along the 
endocytic pathway to lysosomes for degradation [425].  Coordinated phosphorylation and 
dephosphorylation events are often necessary to mediate association of proteins and to 
facilitate vesicle transport [404].   
Protein kinase activity plays an important role in endocytosis.  Among such kinases, 
the protein kinase C (PKC) superfamily is responsible for diverse regulatory roles in many 
cellular processes [426, 427].  PKC inhibition has been shown to affect endocytosis [428] 
with normal trafficking of EGF requiring PKCβII activity. When protein kinase C βII 
(PKCβII) was mutated to a phosphorylation deficient form, it specifically blocked EGF 
receptor trafficking and degradation without affecting transferrin receptor recycling [405].  
PKCβII may be a specific regulator of late endosome function with defective PKCβII 
phosphorylation leading to a nonfunctional late endosome. 
Also, Hrs, a hepatocyte growth factor-regulated tyrosine kinase substrate and 
interacting protein of Tsg101, is phosphorylated by binding of a variety of growth factors and 
cytokines to their receptors [406].  Since Hrs is localized to endosomes and has been 
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implicated in the regulation of signal transduction as well as membrane trafficking, it is 
regarded as a potential coordinator of endosomal receptor sorting and signaling.  Although 
the functional consequence of Hrs phosphorylation is not known, it may be of significance 
that Hrs phosphorylation is prevented when endocytosis is inhibited [429]. 
Additionally, PACS-1 (phosphofurin acidic cluster sorting protein-1) is a sorting 
connector that links furin to the AP-1 clathrin adaptor and is required for localization of furin 
to the TGN [430, 431].  The phosphorylation state of PACS1 acidic cluster regulates the 
ability of PACS-1 to bind to and sort cargo proteins to the TGN.  Disruption of PACS-1 
phosphorylation by a Ser278 to Ala substitution results in an interfering mutant that inhibits 
the PACS-1-directed endosome to TGN sorting suggesting a coordination of signaling events 
to regulate transport within the TGN/endosomal system through the phosphorylation state of 
both cargo and sorting machinery [432].   Collectively, these findings indicate the importance 
of phosphorylation events in regulation of the endosomal sorting pathway. 
A second region of HIV-1 Gagp6 has been defined to contribute to viral release and it 
interacts with AIP1, a host protein [246, 247].  AIP1/Alix is an adaptor protein involved in 
regulating the function of receptor and cytoskeleton-associated tyrosine kinases.  AIP1 
interacts with Tsg101 and CHMP proteins of ESCRT-III complex, coupling HIV-1 Gagp6 to 
the early and late-acting endosomal sorting complexes and binds directly to HIV-1 Gagp6 
LRSL [246, 247].  The Tyr319 of Alix binds to Src’s SH2 domain leading to AIP1/Alix 
phosphorylation at the C-terminal tyrosine rich region by Src [407].  Phosphorylation of 
AIP1/Alix causes translocation from the membrane and cytoskeleton to the cytoplasm and a 
reduction in its interaction with binding partners SETA/CIN85 [408], EGF [409] and Pyk2 
[410].  Src antagonizes the effects of Alix phosphorylation of its C-terminus, leading to 
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disruption of interaction with target proteins, negatively regulating its biological function 
[407].   
Despite the majority of known interactions linking phosphorylation with trafficking 
events involve tyrosine phosphorylation; it does not preclude a role for a Ser/Thr kinase in 
regulation.  It is unlikely that citron kinase phosphorylates Tsg101 since there is no evidence 
to indicate that either Tsg101 or its yeast homologue, Vsp23, was phosphorylated.  However, 
the functional and/or physical (W. Sundquist, personal communication) may be necessary to 
recruit citron kinase to a complex where it phosphorylates another component, such as 
AIP1/Alix.  It is possible that citron kinase phosphorylates AIP1/Alix, a known component in 
linking early and late endosomal sorting complexes to HIV-1, thereby inhibiting its function 
in binding to Tsg101, Gag or CHMP proteins and ability to act as a scaffold protein, leading 
to inhibition of HIV-1 virion production.  Alternatively, citron kinase may phosphorylate an 
intermediary protein which then phosphorylates AIP1/Alix (or another component of the 
ESCRT network) or there may be an unidentified phosphorylation target for citron kinase. 
Elucidation of a phosphorylation target for citron kinase could potentially explain the 
mechanism of how citron kinase and Tsg101 interact to mediate HIV-1 virion production.  
These findings imply an increasing complexity in the interactions of HIV-1 viral proteins 
with host proteins and host proteins with each other to modulate viral release.   
 
The Disparate Roles of Citron Kinase in Mediating HIV-1 Replication 
An interesting finding is the disparate role that citron kinase appears to play in 
regulating HIV-1 replication (Figure 45).  Previously, we identified citron kinase to 
preferentially enhance HIV-1 virion production by promoting exocytosis.  The enhancement 
 168
activity of citron kinase required a portion of the leucine zipper, the Rho-binding and zinc-
finger domains but not the kinase domain.  Citron kinase may act as a scaffold, linking host 
proteins of the endosomal sorting and exocytic pathways.  Additionally, the kinase activity of 
citron, although not necessary for its enhancement activity, was necessary and sufficient to 
mediate the functional interaction with Tsg101.   Additionally, if the PTAP-binding region of 
Tsg101 was disrupted, citron kinase and Tsg101 no longer functionally interacted to inhibit 
HIV-1 virion production.  Disruption of Tsg101’s PTAP-binding region prevents interaction 
with Gagp6, AIP1, another component of the ESCRT pathway and homodimerization.  The 
functional interaction between citron kinase and Tsg101 may be involved in mediating 
interactions with additional host factors through phosphorylation regulation or activation of 
an already associated factor or to promote the Tsg101-Gagp6 interaction.  The two activities 
of citron kinase involved in mediating HIV-1 virion production are distinct and independent 
of one another. 
 In the context of wild-type citron kinase, both activities are able to function, therefore 
how are these seemingly opposing functions balanced, not only by the cell but by the virus?  
One possibility is that these two activities are temporally regulated, with the enhancement 
activity of citron kinase occurring first.  At early time points in HIV-1 infection, citron kinase 
would be acting as a scaffolding molecule, linking components of the endosomal sorting 
pathway to facilitate exocytic secretion of microvesicles and HIV-1 viral particles.  The peak 
of citron kinase-mediated enhancement of virion production occurs at about 32-40 hours 
post-transfection (Figure 46).  After that point, citron kinase loses its ability to enhance virion 
production and at later time points (greater than 48 hours post-transfection), appears to 
slightly inhibit virion production.  This inhibition at later time points may be due to 
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functional interaction of citron kinase with Tsg101 and a phosphorylation event that 
facilitates in slowing down viral release, perhaps as a means of keeping virion production 
under control.  Citron kinase may enhance viral secretion so significantly, that the cell 
becomes overwhelmed and/or overworked.  Both the cell and the virus ideally strive to 
maintain a balance between virion production and health of the cell.  If virion production 
outpaces the ability of the cell to translate a necessary protein, production would be inhibited. 
 The second possibility involves the protein levels/accumulation of citron kinase.  
Citron kinase has a very slow turnover rate, as implied from our time course experiment 
(Figure 46) – we see an increased accumulation of citron kinase protein over time.  At late 
time points (48 hours post-transfection), we saw high levels of citron kinase overexpression 
and a slight inhibitive effect on virion production (Figure 41C-D, Figure 46).  When 
analyzing the dose-dependent response of citron kinase overexpression on HIV-1 virion 
production, we found that citron kinase protein levels were increased proportionately to the 
amount of citron kinase transfected (Figure 41D).  At very high level of citron kinase 
expression, virion production was not enhanced (Figure 41C).  These findings suggest that 
high levels of citron kinase are inhibitory to its enhancement activity.   Additionally, when 
we coexpress Tsg101 and citron kinase, we see an upregulation of citron kinase expression, 
compared to when an equal amount of citron kinase is transfected in the absence of 
exogenous Tsg101 (Figure 41F).  Again, this suggests that high levels of citron kinase are 
inhibitory to its enhancement activity.  Perhaps citron kinase is upregulated to control virion 
production or because the phosphorylation activity of citron kinase requires higher protein 
expression levels.   
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 Regardless, it is possible that citron kinase’s two distinct functions are temporally 
regulated and are ultimately controlled by the amount of citron kinase that has accumulated 
within the cell.  Further analysis will have to be completed to determine if this is, in fact, a 
correct mechanism. 
 
  
 
 
 
CHAPTER SEVEN: 
PERSPECTIVE ON RHOA ACTIVITIES AND HIV-1 REGULATION 
 
The HIV-1 life cycle involves regulation on many levels by both viral and host 
factors.  The cellular changes essential for a productive HIV-1 viral infection require 
coordinated regulation of processes such as membrane trafficking, actin cytoskeleton, and 
activation of transcription.  RhoGTPases are critical regulators of actin dynamics and have 
been linked to control of various endocytic pathways.  Additionally, the Rho family of 
proteins have been implicated in cell shape regulation, cell adhesion, cell division and actin 
cytoskeleton reorganization, most notably the formation of stress fibers [122-128].  
RhoGTPases are known to be involved in a diverse array of cellular processes and are poised 
to be used by the virus to facilitate its replicative cycle.   
We identified two RhoA effectors, ROCK and citron kinase to be involved in 
regulation of HIV-1 replication.  Although we have yet to identify the mechanisms used by 
these two effectors, we have linked RhoA signaling pathways to regulate more than one step 
in the HIV-1 life cycle.  ROCK specifically inhibited HIV-1 gene expression in T cells.  A 
ROCK specific inhibitor, Y27632, counteracted RhoA inhibition of HIV-1 gene expression 
suggesting that RhoA signals through ROCK to regulate HIV-1 replication.  Citron kinase, 
however, preferentially enhanced HIV-1 virion production by promoting exocytosis.  This 
activity was found to be HIV-1 late domain independent, but still required an intact late 
endosomal sorting pathway.  Additionally, we found a functional interaction between citron 
kinase and Tsg101 that inhibited HIV-1 virion production.  The kinase activity of citron 
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kinase was necessary and sufficient for this interaction.  Disruption of the PTAP-binding 
region of Tsg101, using a Tsg101 mutant that is defective in Gagp6 binding, interaction with 
AIP1 and homodimerization, abrogated the functional interaction between citron kinase and 
Tsg101.  
It is interesting that two different RhoA effectors effect HIV-1 replication in two 
distinct fashions.  A primary function of RhoA signaling pathways is to regulate the actin 
cytoskeleton.  ROCK promotes the formation of stress fibers and focal adhesion complexes, 
which are dependent on both the kinase domain and kinase activity [359].   A kinase-
defective mutant was unable to induce focal adhesions and stress fibers [329].   
In our study, the kinase-defective ROCK mutant did not affect HIV-1 gene 
expression (Figure 19A, B), suggesting a role for its kinase activity in mediating HIV-1 
replication.  One possibility for why ROCK inhibits HIV-1 viral release at very low levels 
may be due to the disruption of the actin cytoskeleton.  The actin cytoskeleton is an 
important component in the regulation of vesicle transport.  In the case of constitutively 
active ROCK there is an induction of stress fiber formation that results in thicker bundles 
than when ROCK is not ectopically expressed.  These thicker stress fiber bundles could 
inhibit vesicle or protein transport from the nucleus or other cytoplasmic compartment to the 
plasma membrane where viral budding is believed to occur in T cells.  The addition of a 
ROCK specific inhibitor, Y27632, abrogated RhoA-mediated inhibition of HIV-1 gene 
expression through ROCK (Figure 20).  The inhibitor, Y27632, has been shown to prevent 
stress fiber bundling and focal adhesion assembly [329, 359, 366, 433]. The loss of RhoA-
mediated inhibition of HIV-1 gene expression when a ROCK specific inhibitor is added, 
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suggests that the integrity of the actin cytoskeleton is an important component of HIV-1 
replication modulation.   
Citron N, a naturally occurring splice variant lacking the N-terminal Ser/Thr kinase 
domain, is enriched and associated with the Golgi apparatus of hippocampal neurons in 
culture [396].  Suppression of citron N led to the dispersion of the Golgi apparatus [396] 
suggesting that citron N functions as a scaffolding molecule on Golgi membranes, organizing 
Rho-mediated actin polymerization locally by assembling the actin polymerizing complexes 
together (ROCK II and profilin-IIa) [396].  Therefore, citron N may play a role in 
organization of the endosomal sorting pathway and regulation of the actin cytoskeleton to 
facilitate exosome and virion release.    
Additionally, when we added an actin depolymerizing agent, latrunculin B, in cells 
overexpressing citron kinase, we were able to prevent the enhancement of virion production 
by citron kinase (Figure 47).  Latrunculin B induces shortened and thicker stress fiber 
bundles to form that inhibit vesicle transport.  We believe that citron kinase enhances HIV-1 
virion production by promoting exocytosis therefore it is not surprising that disrupting actin 
cytoskeleton and inhibition of vesicle transport would prevent citron kinase from enhancing 
viral production since actin plays a key role in controlling vesicle transport.  This finding also 
suggests that citron kinase uses a novel pathway (because latrunculin B did not disrupt viral 
release in the absence of citron kinase overexpression) – one that is not used or seldom used 
in 293T cells, perhaps using components of the endosomal sorting pathway in their native 
location instead of at the plasma membrane.  It is equally possible that the addition of 
latrunculin B prevents citron kinase from organizing Rho-mediated actin polymerization 
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locally or inhibits the ability of citron kinase to function as a scaffolding molecule, thereby 
abrogating the enhancement of HIV-1 production by citron kinase. 
Despite two very distinct functions for ROCK and citron kinase in regulating HIV-1 
replication, it is likely that these functions are linked through regulation of the actin 
cytoskeleton by RhoA.  Understanding the mechanisms RhoA signaling pathways employ to 
modulate HIV-1 replication will most likely link to its ability to regulate the actin 
cytoskeleton and will provide an increasingly clear picture of the complex viral and host 
protein interactions necessary to have a productive viral infection.   
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Figure 46:  HIV-1 Virion Production Over Time in the Presence of Citron 
Kinase. (A, B) 293T cells were cotransfected with pNL4-3 (0.1 μg) and vector 
or citron kinase (0.2 μg) in a 48-well plate at 2.5x104 cells/well.  Supernatants 
and cells were collected at various time points post-transfection to analyze 
viral production by p24 ELISA (A) and cell-associated protens (B) by α-citron 
and α-p24 antibodies.
A
B
 176
Figure 47:  Disruption of the Actin Cytoskeleton with Latrunculin B 
Inhibitor Prevented Citron Kinase from Enhancing Virion Production.  
293T cells were cotransfected with pNL4-3 (0.1 μg) and vector or citron kinase
(0.2 μg) in a 48-well plate at 2.5x104 cells/well.  Various amounts of latrunculin
B, an inhibitor of actin polymerizion and disrupter of microfilament 
organization, was added at 0μM, 0.1μM, 1μM or 10μM at 36 hours post-
transfection.  Supernatants were collected at 40 hours post-transfection and 
analyzed for viral production by p24 ELISA.
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